minocycline profile

Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	54675783
CHEMBL ID	1434
CHEMBL ID	69484
CHEBI ID	50694
SCHEMBL ID	4042
SCHEMBL ID	24315
SCHEMBL ID	16681149
MeSH ID	M0013912

Synonym
AB00053501-03
CHEMBL1434
MIY ,
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
lactoferrin b & minocycline
lactoferrin h & minocycline
KBIO1_000450
DIVK1C_000450
brn 3077644
minociclina [inn-spanish]
hsdb 3130
minocyclinum [inn-latin]
tri-minocycline
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s-(4alpha,4aalpha,5aalpha,12aalpha))-
cl 59806
4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
SPECTRUM_000967
BSPBIO_002035
NCGC00178854-01
D05045
SMP1_000191
minocycline (usan/inn)
PRESTWICK2_000315
IDI1_000450
minociclina
CHEBI:50694 ,
minociclinum
minocin (hydrochloride)
vectrin (hydrochloride)
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
nsc141993
minocline
10118-90-8
C07225
minocycline
7-dimethylamino-6-demethyl-6-deoxytetracycline
DB01017
minocyclin
minocin
minomycin
nsc-141993
mino
KBIOSS_001447
KBIO3_001535
KBIOGR_000583
KBIO2_001447
KBIO2_006583
KBIO2_004015
SPBIO_002529
SPECTRUM3_000508
SPBIO_000974
PRESTWICK1_000315
PRESTWICK0_000315
NINDS_000450
SPECTRUM4_000062
SPECTRUM2_001047
SPECTRUM5_001293
BCBCMAP01_000027
dynacin
LMPK07000002
HMS2090D03
ksc-12-231b
KUC106429N
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2- carboxamide
NCGC00188954-01
NCGC00183044-01
borymycin
unii-fyy3r43wgo
fyy3r43wgo ,
minocyn
minoz
minocycline [usan:inn:ban]
dtxcid9025033
tox21_113643
dtxsid1045033 ,
cas-10118-90-8
DYKFCLLONBREIL-KVUCHLLUSA-N
minocyclinum
AKOS015969674
BCP9000928
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.))-
tigecycline impurity c [ep impurity]
minocycline [mi]
minocycline [hsdb]
minocycline [who-dd]
minocycline [vandf]
minocycline [usan]
minocycline [inn]
minocycline [mart.]
AM20090714
SCHEMBL4042
SCHEMBL24315
J-500789
(2e,4s,4ar,5as,12ar)-2-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4h-tetracene-1,3 ,12-trione
AC-30184
AB00053501_05
AB00053501_04
SCHEMBL16681149
sr-05000001675
SR-05000001675-3
bdbm50103599
SBI-0051449.P003
(4s,4as,5ar,12as)4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide;(4s,4as,5ar,12as)4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-car
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-
NCGC00178854-02
Q415336
(minocycline)
cl-59806
gtpl10831
cl59806
D78303
(4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
CHEMBL69484
HY-17412A
CS-0009521
EN300-7481098

Excerpt	Reference	Relevance
" The MIC values of tri-minocycline proved to be very low and the LD50 values very high, their separation covering more than 3 orders of magnitude."	( Tri-minocycline: a minocycline complex for parenteral use. I. Antibacterial activity and toxicity data. Joó, I; Kahán, IL; Pusztai, R; Szepesy, GL, 1978)	0.26
" Reported adverse experiences to the minocycline were greater in the 200 mg a day group."	( Gingival crevicular fluid concentration and side effects of minocycline: a comparison of two dose regimens. Ellen, RP; Freeman, E; Lazarus, RH; Song, M; Thompson, G; Weinberg, SE, 1992)	0.28
" No adverse reactions were observed during the trial period."	( Evaluation of the long-term efficacy and safety of locally-applied minocycline in adult periodontitis patients. de Graaff, J; Mantel, MS; Timmerman, MF; van der Velden, U; van der Weijden, GA; van Steenbergen, TJ, 1996)	0.29
" The proportion of adverse events was lowest in group 1 (14%) and highest in groups 3 and 4 (25%)."	( Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Caspi, D; Elkayam, O; Segal, R; Yaron, M; Zhukovsky, G, 1997)	0.3
"Because minocycline can cause serious adverse events including hypersensitivity syndrome reaction (HSR), serum sicknesslike reaction (SSLR), and drug-induced lupus, a follow-up study based on a retrospective review of our Drug Safety Clinic and the Health Protection Branch databases and a literature review was conducted to determine if similar rare events are associated with tetracycline and doxycycline."	( Comparative safety of tetracycline, minocycline, and doxycycline. Knowles, SR; Shapiro, LE; Shear, NH, 1997)	0.3
" We theorize that minocycline metabolism may account for the increased frequency of serious adverse events with this drug."	( Comparative safety of tetracycline, minocycline, and doxycycline. Knowles, SR; Shapiro, LE; Shear, NH, 1997)	0.3
" Currently much attention is being paid in the Dutch and international literature to the safety of minocycline, after several reports on serious adverse events."	( [Side effects of minocycline in the treatment of acne vulgaris]. Bastiaens, MT; Hoefnagel, JJ; Mattie, H; van Leeuwen, RL, 1997)	0.3
"1% of minocycline recipients experienced treatment-related adverse events, the majority of which were mild in nature."	( A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Alirezai, M; Belaïch, S; Grosshans, E; Meynadier, J; Thomas, L, )	0.13
" Specific objectives were to compare the efficacy of minocycline with other drug treatments for acne and to collate information on the incidence of adverse drug reactions."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li Wan Po, A; Newton, J; Popescu, C, 2000)	0.31
" Major outcome measures used in the trials included lesion counts, acne grades/severity scores, doctors' and patients' global assessments, adverse drug reactions and drop out rates."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li Wan Po, A; Newton, J; Popescu, C, 2000)	0.31
" Differences in the way adverse drug reactions were identified could have accounted for the wide variation between studies in numbers of events reported."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li Wan Po, A; Newton, J; Popescu, C, 2000)	0.31
"Although potentially significant adverse reactions and drug interactions have been reported in association with erythromycin, oral tetracyclines, and trimethoprim-sulfamethoxazole, overall these agents are associated with excellent safety profiles, especially considering their widespread use over many years."	( Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Del Rosso, JQ, 2000)	0.31
" Regarding safety, the majority of the adverse effects of zinc gluconate and of minocycline concerned the gastrointestinal system and were moderate (5 dropouts with zinc gluconate and 4 with minocycline)."	( Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Alirezai, M; Amblard, P; Auffret, N; Beylot, C; Bodokh, I; Chivot, M; Daniel, F; Dreno, B; Humbert, P; Meynadier, J; Moyse, D; Poli, F, 2001)	0.31
"CSF from patients with motor neurone disease (MND) has been reported to be toxic to cultured primary neurones."	( Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Andersen, PM; Goldsteins, G; Koistinaho, J; Marklund, SL; Oja, SS; Tikka, TM; Vartiainen, NE, 2002)	0.31
" Specific objectives were to compare the efficacy of minocycline with other drug treatments for acne and to collate information on the incidence of adverse drug reactions."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li, WA; Newton, J; Popescu, C, 2003)	0.32
" Major outcome measures used in the trials included lesion counts, acne grades/severity scores, doctors' and patients' global assessments, adverse drug reactions and drop out rates."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li, WA; Newton, J; Popescu, C, 2003)	0.32
" Differences in the way adverse drug reactions were identified could have accounted for the wide variation between studies in numbers of events reported."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li, WA; Newton, J; Popescu, C, 2003)	0.32
" Similarly the relative risk of adverse drug reactions could not be ascertained reliably and no recommendations can be made concerning the appropriate dose that should be used."	( Minocycline for acne vulgaris: efficacy and safety. Eady, EA; Garner, SE; Li, WA; Newton, J; Popescu, C, 2003)	0.32
" We investigated whether minocycline would protect against toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that selectively destroys nigrostriatal dopaminergic (DA) neurons and produces a clinical state similar to Parkinson's disease (PD) in rodents and primates."	( Minocycline enhances MPTP toxicity to dopaminergic neurons. Albers, DS; Beal, MF; Browne, SE; Chirichigno, JW; Gregorio, J; Joh, TH; Lorenzl, S; Shimizu, Y; Shin, DH; Sugama, S; Yang, L, 2003)	0.32
" Nausea and vomiting were the most common adverse events."	( Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Ellis-Grosse, EJ; Green, SL; Klein, SR; Loh, E; Postier, RG, 2004)	0.32
" In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients."	( Minocycline safety and tolerability in Huntington disease. , 2004)	0.32
"Minocycline has been shown to exert neuroprotection against a wide variety of toxic insults both in vitro and in vivo."	( In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-d-aspartate. Aguirre, N; Goñi-Allo, B; Jordán, J; Ramos, M, 2005)	0.33
" Adverse events were similar, with increased nausea and vomiting in the tigecycline group and increased rash and elevated hepatic aminotransferase levels in the vancomycin-aztreonam group."	( The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Babinchak, T; Dartois, N; Ellis-Grosse, EJ; Loh, E; Rose, G, 2005)	0.33
"719]) were the most frequently reported adverse events."	( The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Babinchak, T; Dartois, N; Ellis-Grosse, E; Loh, E; Rose, GM, 2005)	0.33
" Safety was assessed by physical examination, laboratory analyses, and adverse event reporting."	( Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Campos, ME; Curcio, D; Ellis-Grosse, E; Embil, JM; Loh, E; Penn, RL; Rose, G; Sacchidanand, S, 2005)	0.33
" Frequency of adverse events was similar between groups, although patients receiving tigecycline had higher incidence of nausea, vomiting, dyspepsia, and anorexia, while increased ALT/SGPT, pruritus, and rash occurred significantly more often in V + A-treated patients."	( Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Campos, ME; Curcio, D; Ellis-Grosse, E; Embil, JM; Loh, E; Penn, RL; Rose, G; Sacchidanand, S, 2005)	0.33
"435]) were the most frequently reported adverse events."	( A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. Babinchak, T; Campos, M; Ellis-Grosse, EJ; Loh, E; Oliva, ME; Pasternak, J; Rekha, A; Rose, GM; Yellin, A, 2005)	0.33
" Safety was assessed by physical examination, laboratory results, and adverse event reporting."	( Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Breedt, J; Dartois, N; Ellis-Grosse, EJ; Gardovskis, J; Gioud-Paquet, M; Loh, E; Maritz, FJ; Ross, DP; Teras, J; Vaasna, T, 2005)	0.33
" q12h) in adults is safe and generally well tolerated for up to 11."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. Rello, J, 2005)	0.33
"Scientific literature published between 1966 and August 2003 was searched using the MEDLINE, EMBASE, and Biosis databases (search terms: minocycline or doxycycline, each paired with adverse reaction, adverse event, and side effect, and doxycycline or minocycline with the limits English language, human, and clinical trials)."	( Safety of doxycycline and minocycline: a systematic review. Leyden, JJ; Smith, K, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" The percentage of subjects reporting acute vestibular adverse events (AVAEs) was comparable between those receiving the ER-minocycline 1-mg/kg dose and placebo (approximately 10% of subjects in each group) for both the individual studies and the pooled population."	( Safety and efficacy of a new extended-release formulation of minocycline. Dinehart, S; Fleischer, AB; Plott, RT; Stough, D, 2006)	0.33
"In a number of adverse drug reactions leading to hepatotoxicity drug metabolism is thought to be involved by generation of reactive metabolites from nontoxic drugs."	( Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. Badolo, L; Dalgaard, L; Dubois, J; Hansen, SH; Otto, M, 2008)	0.35
"Tigecycline is safe and effective in hospitalized patients with serious infection caused by MRSA."	( Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Babinchak, T; Beuran, M; Bochan, M; Cooper, CA; Dartois, N; Dimov, R; Dukart, G; Ellis-Grosse, EJ; Fichev, G; Florescu, I; Gandjini, H; Razbadauskas, A, 2008)	0.35
" Most commonly reported treatment emergent adverse events for tigecycline and imipenem/cilastatin were nausea (14."	( The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. Babinchak, T; Castaing, N; Cooper, A; Dartois, N; De Vane, N; Fomin, P; Koalov, S; Tellado, J, 2008)	0.35
" Safety was assessed by physical examination, laboratory results and adverse event reporting."	( Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. Cooper, A; Dartois, N; Dukart, G; Gardovskis, J; Jouve, S; Kupcs, U; Pupelis, G; Teras, J; Vaasna, T, 2008)	0.35
" Computed tomography revealed interstitial lung fibrosis which was attributed to the toxic effects of nitrofurantoin (50 mg/d) that the patient used for approximately one year for recurrent urinary tract infection."	( [Unwanted side effects of antibacterials--a diagnostic challenge]. Fux, R; Gleiter, CH; Mörike, K, 2008)	0.35
" Nausea, vomiting, and diarrhoea were the most frequently reported adverse events."	( Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. Calistru, PI; Castaing, N; Chernyak, V; Cooper, CA; Dartois, N; Gandjini, H; Milutinovic, S; Strausz, J; Tanaseanu, C; Zolubas, M, 2009)	0.35
"(1) In mid-2008 the French National Pharmacovigilance Committee examined spontaneous reports of adverse effects observed during tetracycline therapy; (2) When sales figures are taken into account, reports were more frequent with minocycline than with doxycycline."	( Fewer adverse effects with doxycycline than with minocycline. , 2009)	0.35
"Tigecycline was generally safe and well tolerated in the treatment of secondary bacteremia associated with cSSSI, cIAI, and CAP; cure rates were similar to comparative standard therapies."	( Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Babinchak, T; Cooper, A; Dukart, G; Gardiner, D, 2010)	0.36
" The most common treatment-emergent adverse events in healthy volunteers were nausea (56."	( Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. Baird-Bellaire, SJ; Böhmer, GM; Buecheler, R; Gleiter, CH; Korth-Bradley, JM; Morgan, MY; Patat, AA; Troy, SM, 2011)	0.37
" Minocycline has been safe and well tolerated in the clinical trials conducted to date."	( Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Fagan, SC; Hess, DC, 2010)	0.36
" Minocycline has been safe and well tolerated in clinical trials."	( Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Fagan, SC; Hess, DC, 2010)	0.36
" The overall incidence of treatment-emergent adverse events was 80."	( Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. Bi, J; Chen, X; Chen, Z; Cooper, A; Leng, X; Li, R; Liu, D; Ma, X; Maroko, R; Quan, Z; Wei, J; Wu, J; Wu, Z; Yan, L; Yu, Y; Zhang, Y, 2010)	0.36
" We surveyed 50 patients with fragile X syndrome who received minocycline for at least 2 weeks and found that the most common reported side effect is gastrointestinal difficulty, including loss of appetite."	( Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Chonchaiya, W; Ethell, IM; Faradz, SM; Hagerman, RJ; Nguyen, DV; Rivera, SM; Schneider, A; Utari, A, 2010)	0.36
"Tigecycline monotherapy is a safe and effective therapy for cSSSIs in geographically distinct populations in Asia."	( Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. Aradhya, S; Chang, CM; Chuang, YC; Cooper, A; Dartois, N; Jouve, S; Nagari, B; Pai, V, 2011)	0.37
" The secondary outcome included clinical and microbiological failure, superinfections and adverse events (AEs)."	( Efficacy and safety of tigecycline: a systematic review and meta-analysis. Lador, A; Leibovici, L; Paul, M; Yahav, D, 2011)	0.37
" Adverse events were more frequent in the tigecycline group than in the control groups (1·45, 1·11-1·88), with significantly more vomiting and nausea."	( Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Arvanitidou, M; Haidich, AB; Kokkali, S; Tasina, E, 2011)	0.37
"Minocycline and doxycycline are safe and moderately effective disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of early, DMARD-naïve rheumatoid arthritis (RA), although little is known about their use outside clinical trials."	( Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Michaud, K; Mikuls, TR; Sayles, H; Smith, CJ, 2011)	0.37
"The Cochrane Skin Group's Trials Search Co-ordinator undertook searches exploring minocycline's adverse effects in EMBASE and MEDLINE in February 2012."	( Minocycline for acne vulgaris: efficacy and safety. Bennett, C; Eady, A; Garner, SE; Newton, JN; Popescu, CM; Thomas, K, 2012)	0.38
" For adverse effects, we selected additional studies that reported the number of adverse effects and the number of participants treated."	( Minocycline for acne vulgaris: efficacy and safety. Bennett, C; Eady, A; Garner, SE; Newton, JN; Popescu, CM; Thomas, K, 2012)	0.38
"Outcome measures used in the trials included lesion counts, acne grades/severity scores, doctors' and participants' global assessments, adverse effects, and dropout rates."	( Minocycline for acne vulgaris: efficacy and safety. Bennett, C; Eady, A; Garner, SE; Newton, JN; Popescu, CM; Thomas, K, 2012)	0.38
"The adverse effects studies must be interpreted with caution."	( Minocycline for acne vulgaris: efficacy and safety. Bennett, C; Eady, A; Garner, SE; Newton, JN; Popescu, CM; Thomas, K, 2012)	0.38
" Adverse events were reported in 46 (41."	( A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Arbeit, RD; Draper, MP; Hait, H; Noel, GJ; Tanaka, SK, 2012)	0.38
"Spontaneous reports in the United States Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database generated between January 1997 and December 2010."	( Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. Brown, J; Engell, C; Okon, E; van Manen, R, 2013)	0.39
" Disproportionality analysis uses an adverse event relative reporting ratio (RRR) to compare the occurrence of a specific adverse event with an index drug of interest to the occurrence of the same adverse event with similar agents or with all other FDA-approved prescription drugs."	( Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. Brown, J; Engell, C; Okon, E; van Manen, R, 2013)	0.39
"Probiotics may be considered a therapeutic option or adjunct for acne vulgaris by providing a synergistic antiinflammatory effect with systemic antibiotics while also reducing potential adverse events secondary to chronic antibiotic use."	( Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. Guiha, I; Jung, GW; Rao, J; Tse, JE, )	0.13
" Hence, new alternative schemes and monitoring of adverse effects to avoid treatment abandonment are important considerations."	( Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil. Cunha, CS; Cunha, Mda G; Maia, MV, )	0.13
" The mean time for the development of adverse effects after beginning the therapy was 15."	( Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil. Cunha, CS; Cunha, Mda G; Maia, MV, )	0.13
"Data on adverse events (AEs) were available for 198 cSSTI and 590 cIAI patients in three studies."	( Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. Bassetti, M; Bodmann, KF; Capparella, MR; Dupont, H; Eckmann, C; Guirao, X; Heizmann, WR; Montravers, P; Sánchez García, M; Simoneau, D, 2013)	0.39
" The most common adverse events were nausea and vomiting."	( Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Gandhi, A; Korth-Bradley, J; Matschke, K; Yamashita, N, 2014)	0.4
" Main adverse effects were gastrointestinal."	( [Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections: systematic review of literature]. Márquez-Peláez, S; Molina Linde, JM; Motiva Sánchez, V; Moya Cordero, P; Ruiz-Aragón, J, 2013)	0.39
" This retrospective observation study evaluated two-colistin and tigecycline-antibiotics profiles like treatment success rate, negative conversion rate, the length of hospital stay, intensive care unit (ICU) stay and antibiotics use, mortality rate during hospital stay and adverse event rate, based on the medical record of XDR-AB positive patients who were treated at least 5 d with those intravenous antibiotics."	( Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Ahn, HL; Han, OY; Kwon, SH; La, HO, 2014)	0.4
"9%) patients receiving minocycline suffered 55 adverse events (22 of them gastrointestinal), while 28 (33."	( Safety and efficacy comparison of minocycline microgranules vs lymecycline in the treatment of mild to moderate acne: randomized, evaluator-blinded, parallel, and prospective clinical trial for 8 weeks. Berber, A; de la Fuente-Garcia, A; Ocampo-Candiani, J; Trevino-Gomezharper, C; Velazquez-Arenas, LL, 2014)	0.4
" Adverse events and all-cause mortality were more common in the tigecycline group."	( Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Deng, Y; Fang, M; Han, Q; Shen, F; Xie, D; Zeng, H, 2015)	0.42
"Tigecycline is not as effective as other antibiotics with relatively more frequency of adverse events and higher mortality rate."	( Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Deng, Y; Fang, M; Han, Q; Shen, F; Xie, D; Zeng, H, 2015)	0.42
"In our study, intravitreal minocycline was toxic to the retina in albino rabbits even at a concentration of 62."	( Determination of the toxicity of intravitreal minocycline in rabbit eyes. Aghdam, KA; Falavarjani, KG; Hosseini, SB; Khanamiri, HN; Modarres, M; Pazouki, A; Pourhabibi, A, 2016)	0.43
" The primary outcome was the rate of clinical cure, and the secondary outcomes were mortality and adverse events (AEs)."	( Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia. Chen, L; Du, S; Long, LH; Wang, YL; Wu, Y; Xu, L, 2016)	0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" The primary end-point was the occurrence of hydraulic resistance and secondary safety end-point was adverse drug reactions related to the lock solutions."	( The CLOCK trial, a double-blinded randomized controlled trial: Trisodium citrate 30% and minocycline 3 mg/mL plus EDTA 30 mg/mL are effective and safe for catheter patency maintenance among CKD 5D patients on hemodialysis. Luiz, MV; Scavone, C; Tzanno, C, 2017)	0.46
" No serious adverse reactions were reported."	( DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Nieuwenburg, SA; Spuls, PI; van der Linden, MMD; van Rappard, DC; van Ratingen, AR, 2017)	0.46
"Because patients with abdominal solid organ transplants (SOTs) are at increased risk of polymicrobial intraabdominal infections (IAIs) following transplantation, the objective of this study was to compare the effectiveness and adverse event profile of tigecycline with those of other broad-spectrum therapies for polymicrobial IAIs in this population."	( Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections. Bingen, E; Liebenstein, T; Musuuza, J; Rose, WE; Safdar, N; Schulz, LT; Viesselmann, C, 2017)	0.46
" Patients receiving tigecycline experienced a higher rate of adverse events than those receiving comparator antibiotics (29."	( Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections. Bingen, E; Liebenstein, T; Musuuza, J; Rose, WE; Safdar, N; Schulz, LT; Viesselmann, C, 2017)	0.46
"Patients receiving tigecycline were less likely to achieve optimal clinical outcomes and had more adverse events."	( Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections. Bingen, E; Liebenstein, T; Musuuza, J; Rose, WE; Safdar, N; Schulz, LT; Viesselmann, C, 2017)	0.46
" Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI 95%) were calculated."	( Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. Carvalho, AF; Correll, CU; Facchini, S; Fornaro, M; Solmi, M; Stubbs, B; Thapa, N; Veronese, N, 2017)	0.46
"Neurotoxicity is an adverse effect patients experience during colistin therapy."	( Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress. Cappai, R; Ciccotosto, GD; Dai, C; Tang, S; Velkov, T; Wang, Y; Xiao, X, 2017)	0.46
" However, MC at high (1mM) concentration aggravated the toxic effect of PQ; (iii) MC protected and rescued DAergic neurons against the PQ toxic effect according to tyrosine hydroxylase (TH)>green-fluorescent protein (GFP) reporter protein microscopy and anti-TH Western blotting analysis; (iv) MC protected DAergic neurons against PQ/iron toxicity; (v) MC significantly abridged lipid peroxidation (LPO) in the protection, rescue and prevention treatment in TH>parkin-RNAi/+ flies against PQ or iron alone or combined (PQ/iron)-induced neuronal oxidative stress (OS)."	( Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: Implications for autosomic recessive juvenile parkinsonism. Jimenez-Del-Rio, M; Ortega-Arellano, HF; Velez-Pardo, C, 2017)	0.46
" QA at the concentration below 1 mM had no apparent toxic effects on cultured primary neurons or BV-2 cells."	( Microglia activation contributes to quinolinic acid-induced neuronal excitotoxicity through TNF-α. Feng, W; Han, R; Liu, ZQ; Miao, YZ; Qin, ZH; Wang, Y; Zhang, X, 2017)	0.46
" Secondary outcomes were all-cause mortality and nephrotoxic and non-nephrotoxic adverse events."	( Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. Apisarnthanarak, A; Chaiyakunapruk, N; Kengkla, K; Kongpakwattana, K; Saokaew, S, 2018)	0.48
"The study was conducted to evaluate the effect of minocycline against pesticide rotenone induced adverse effects in different rat brain regions."	( Minocycline diminishes the rotenone induced neurotoxicity and glial activation via suppression of apoptosis, nitrite levels and oxidative stress. Biswas, J; Gupta, P; Gupta, S; Singh, A; Singh, DK; Singh, S; Verma, DK, 2018)	0.48
"" Both doses appeared generally safe and well tolerated."	( A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea. Eini, M; Kedem, TH; Keynan, R; Mrowietz, U; Rom, D; Shirvan, M; Tamarkin, D, 2018)	0.48
" The primary outcome was treatment mortality rate, while the secondary outcomes were adverse events."	( Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. Bai, XR; Jiang, DC; Liu, JM; Yan, SY, 2018)	0.48
" No serious adverse events occurred on minocycline."	( A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study). Avendaño-Solá, C; Cazorla-Calleja, R; González-Marques, J; Iglesias-Escalera, G; Lara-Herguedas, J; Leiva, Á; López-Pájaro, LF; Marín-Serrano, ME; Rincón-Ortega, M; Román-Riechmann, E; Rossignoli-Palomeque, T; Ruiz-Antoran, B; Sancho-López, A; Valiente-Rodríguez, S, 2018)	0.48
" Treatment with minocycline appears safe and well tolerated; even if it cannot be completely ruled out that longer trials might be required for a potential minocycline effect to be expressed, available results and lack of knowledge on the actual mechanism of action do not support this hypothesis."	( A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study). Avendaño-Solá, C; Cazorla-Calleja, R; González-Marques, J; Iglesias-Escalera, G; Lara-Herguedas, J; Leiva, Á; López-Pájaro, LF; Marín-Serrano, ME; Rincón-Ortega, M; Román-Riechmann, E; Rossignoli-Palomeque, T; Ruiz-Antoran, B; Sancho-López, A; Valiente-Rodríguez, S, 2018)	0.48
" However, the adverse events (AEs) remain controversial."	( Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Chen, Z; Shi, X, 2018)	0.48
"Minocycline was safe for moderate to severe TBI at a dose twice that as recommended for treatment of infection."	( Safety and feasibility of minocycline in treatment of acute traumatic brain injury. Fath, J; Freese, K; Fuerst, D; Martin, HB; Meythaler, J; Peduzzi-Nelson, J; Reineke, J; Roskos, PT; Zokary, H, 2019)	0.51
"FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV)."	( Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study. Hooper, D; Jankicevic, J; Kircik, L; Lain, E; Moore, A; Raoof, TJ; Stuart, I; Sullivan, T; Zaiac, M, 2020)	0.56
" FMX101 4% was generally safe and well tolerated."	( Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study. Hooper, D; Jankicevic, J; Kircik, L; Lain, E; Moore, A; Raoof, TJ; Stuart, I; Sullivan, T; Zaiac, M, 2020)	0.56
"FMX101 4% topical minocycline foam was effective and safe for the treatment of moderate to severe AV."	( Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study. Hooper, D; Jankicevic, J; Kircik, L; Lain, E; Moore, A; Raoof, TJ; Stuart, I; Sullivan, T; Zaiac, M, 2020)	0.56
" Few adverse events, mostly mild to moderate, were reported."	( Topical minocycline foam 4%: Results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation. Dosik, J; Ellman, H; Stuart, I, 2019)	0.51
"Minocycline topical gel appears to be safe and tolerable at concentrations of 1% and 3%, and both concentrations significantly decreased inflammatory lesion counts, with a significantly larger proportion of patients achieving IGA success at week 12 in the minocycline 3% arm."	( A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea. Dhawan, S; Draelos, ZD; Graber, E; Lee, MS; Magrath, GN; Salman, M; Webster, G, 2020)	0.56
" These results suggest that minocycline may induce genotoxic effects even at concentrations considered previously safe and should be used with caution in translational studies."	( Genotoxic effect of non-lethal concentrations of minocycline in human glial cell culture. Araújo, TMC; Bittencourt, LO; Ferreira, RO; Leal, WG; Lima, RR; Nogueira, ICDC; Nogueira, LS; Oliveira, EHC; Puty, B; Vasconcelos, CP, 2020)	0.56
" Doxycycline has been postulated as the potential ideal candidate for further therapeutic development as it has fewer adverse effects than minocycline."	( Minocycline, but not doxycycline attenuates NMDA-induced [Ca2+]i and excitotoxicity. Chen, W; Du, N; Du, Y; Gu, H; Liu, Q; Lu, Y; Yang, Y, 2021)	0.62
" The majority of these patients become steroid-dependent and suffer from the adverse effects of long-term corticosteroid use."	( Comparison of the efficacy and safety of minocycline and clofazimine in chronic and recurrent erythema nodosum leprosum-A randomized clinical trial. Dogra, S; Hanumanthu, V; Narang, T; Thakur, V, 2021)	0.62
" Method All DILI cases of tetracycline antibiotics as primary suspected drugs were extracted from the US Food and Drug Administration adverse event reporting system (FAERS)."	( A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. Jiang, A; Liu, Y; Wei, C; Wu, B, 2022)	0.72
"3 was used to compare the treatment efficacy, time for the cough to subside, defervescence time, hospitalisation time, adverse events and other indicators."	( The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a meta-analysis. Lin, HJ; Liu, C; Shen, HX; Wang, GY; Xu, LJ; Yan, MX, 2022)	0.72
" The use of minocycline did not lead to significant adverse events (OR = 0."	( The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a meta-analysis. Lin, HJ; Liu, C; Shen, HX; Wang, GY; Xu, LJ; Yan, MX, 2022)	0.72
" Supporting this hypothesis, our previous studies found that intrathecal and intravenous morphine increase the number of activated microglia and macrophages present at the spinal lesion site, and that the adverse effects of intrathecal morphine can be blocked with intrathecal minocycline."	( Intrathecal minocycline does not block the adverse effects of repeated, intravenous morphine administration on recovery of function after SCI. Brakel, K; Bryan, J; Cunningham, R; Hook, MA; Moore, R; Rau, J; Stefanov, A; Terminel, M; Weise, L, 2023)	0.91
"This study evaluated the safe dosage of minocycline hydrochloride (Mino) eye drops and investigated the potential for the prevention or reduction of retinal damage in a diabetic rat model."	( Safety evaluation and pharmacodynamics of minocycline hydrochloride eye drops. Li, X; Pei, S; Ye, Z; Zhang, W; Zheng, D; Zhu, L, 2022)	0.72
"Mino eye drops at 1 mg/ml were safe when used in SD rats."	( Safety evaluation and pharmacodynamics of minocycline hydrochloride eye drops. Li, X; Pei, S; Ye, Z; Zhang, W; Zheng, D; Zhu, L, 2022)	0.72
" Cell culture studies have shown quinolones to be highly toxic to TM fibroblasts."	( Cytotoxicity of Tetracyclines in Human Tympanic Membrane Fibroblasts. Antonelli, PJ; Dirain, CO, 2023)	0.91
"Tetracyclines are less toxic to cultured TM fibroblasts than ciprofloxacin."	( Cytotoxicity of Tetracyclines in Human Tympanic Membrane Fibroblasts. Antonelli, PJ; Dirain, CO, 2023)	0.91
" pylori eradication and adverse events (AEs)."	( Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs. Gao, W; Wang, L; Yin, Y; Zhang, X; Zhu, M, 2023)	0.91
" However, the plasma concentration of tigecycline is not correlated with clinical efficacy and adverse reactions."	( Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units. Bai, XR; Fan, L; Li, WC; Lou, R; Qu, X; Wang, YG; Wang, ZZ; Wu, YC; Yan, SY; Zhang, L; Zhang, W, 2023)	0.91

Excerpt	Reference	Relevance
" Half-life was calculated as 15."	( [Activity in vitro and pharmacokinetics of minocycline (author's transl)]. Grahmann, H; Malerczyk, V; Preuss, I; Schmidt, K; Simon, C, 1976)	0.26
" Pharmacokinetic studies showed that the Cmax and 0-11 h AUC values in blood were higher for doxycycline, whereas the sputum Cmax was, on average, higher for minocycline because of the greater penetration of the latter."	( Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. Davies, BI; Maesen, FP; van den Bergh, JJ, 1989)	0.28
" The influence of age, renal disease, malnutrition and hyperlipidaemia is reviewed, together with the main pharmacokinetic interactions."	( Clinical pharmacokinetics of doxycycline and minocycline. Houin, G; Saivin, S, 1988)	0.27
" Pharmacokinetic evaluation of the serum drug concentration vs time data was performed, using a noncompartmental model based on statistical moment theory."	( Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. Green, NK; Wilson, RC, 1986)	0.27
" Pharmacokinetic evaluation of the serum drug concentration versus time data was performed, using the 2-compartment open model, the 3-compartment open model, and a noncompartmental model involving use of the statistical moment theory."	( Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. Goetsch, DD; Kemp, DT; Kitzman, JV; Wilson, RC, 1985)	0.27
"The pharmacokinetic disposition of minocycline and vancomycin was studied in New Zealand White rabbits before initiating an experimental staphylococcal endocarditis protocol."	( Pharmacokinetics of minocycline and vancomycin in rabbits. Freeman, CD; Nicolau, DP; Nightingale, CH; Quintiliani, R, 1993)	0.29
"A pharmacokinetic study of minocycline was performed in 12 debilitated elderly patients who had suffered from acute bacterial respiratory infections."	( Pharmacokinetic characteristics of minocycline in debilitated elderly patients. Koike, Y; Kuyama, Y; Matsuyama, N; Minshita, S; Sanaka, M; Takano, K; Yamakana, M; Yamamoto, T, 1999)	0.3
"The in vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) were assessed in an experimental murine thigh infection model in neutropenic mice."	( In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Andes, D; Conklin, B; Craig, WA; Stamstad, TJ; van Ogtrop, ML; Vesga, O; Weiss, WJ, 2000)	0.31
" Full pharmacokinetic profiles of tigecycline were determined in two of these studies."	( Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Micalizzi, M; Muralidharan, G; Raible, D; Speth, J; Troy, S, 2005)	0.33
" The peak tigecycline concentration and half-life in serum were greater than those in blister fluid."	( Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Harper, D; Nicolau, DP; Nightingale, CH; Ong, CT; Sun, HK; Troy, S; Umer, A, 2005)	0.33
" Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters."	( Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Fruncillo, RJ; Micalizzi, M; Muralidharan, G; Raible, DG; Troy, SM, 2005)	0.33
"The steady-state serum and intrapulmonary pharmacokinetic and pharmacodynamic parameters of tigecycline were determined after intravenous administration in 30 subjects."	( Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Conte, JE; Golden, JA; Kelly, MG; Zurlinden, E, 2005)	0.33
" Pharmacokinetic analysis of data from phase 1 trials of healthy subjects indicate that tigecycline has a large volume of distribution, signifying extensive tissue penetration, and a long terminal elimination half-life (approximately 40 h), easily allowing for twice-daily dose administration."	( Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Ambrose, PG; Ellis-Grosse, EJ; Grasela, TH; Meagher, AK, 2005)	0.33
"We inoculated an in vitro pharmacodynamic model simultaneously with clinical isolates of methicillin-resistant Staphylococcus aureus and an enterocin-producing enterococcus (vancomycin-resistant Enterococcus faecalis, ampicillin susceptible) at 7 log10 CFU/ml to examine enterocin effects and antimicrobial activity on staphylococci."	( Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Chin, JN; LaPlante, KL; Leuthner, KD; Rybak, MJ, 2006)	0.33
" A population pharmacokinetic (PK) model for tigecycline was developed for patients with cSSSI or cIAI enrolled in two phase 2 clinical trials, and the influence of selected demographic factors and clinical laboratory measures was investigated."	( Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Cirincione, BB; Korth-Bradley, JM; Ludwig, EA; Meagher, AK; Owen, JS; Van Wart, SA, 2006)	0.33
" A structural population pharmacokinetic model for tigecycline was developed based on data pooled from 5 phase I studies."	( Population pharmacokinetics of tigecycline in healthy volunteers. Cirincione, BB; Korth-Bradley, JM; Ludwig, EA; Meagher, AK; Owen, JS; Van Wart, SA, 2007)	0.34
" After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55."	( Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. DeMaio, W; Harper, D; Hoffmann, M; Jordan, RA; Scatina, J; Speth, J; Talaat, R, 2007)	0.34
"Tigecycline and ciprofloxacin were employed as the model compounds to study the effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA), which is used during plasma sample preparations, on the determination of pharmacokinetic parameters."	( Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin. Chen, Q; Ciccotto, SL; Ortiga, R; Ramsay, KA; Strauss, JR; Tang, W; Tung, EC, 2008)	0.35
"A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)."	( A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
" We predicted the pharmacodynamic cumulative fraction of response (CFR) of tigecycline against bacteria implicated in complicated skin and skin structure infections and compared it with the CFRs for piperacillin/tazobactam, ceftriaxone, levofloxacin, and imipenem/cilastatin."	( Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
"Tigecycline monotherapy had a likelihood of achieving its requisite pharmacodynamic exposure similar to that of combinations of piperacillin/tazobactam or imipenem/cilastatin plus vancomycin for the empiric treatment of complicated skin and skin structure infections."	( Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"Free drug serum concentrations of minocycline associated with the doses given to humans (100 mg every 12 hours for 24 hours) were simulated in an in vitro hollow-fiber pharmacokinetic model."	( Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Bowker, KE; Macgowan, AP; Noel, AR, 2008)	0.35
" Significant pharmacokinetic data are now available from the studies of infected patients, as is information on tissue distribution."	( Tigecycline pharmacokinetic/pharmacodynamic update. MacGowan, AP, 2008)	0.35
" The consideration of the pharmacokinetic and pharmacodynamic properties of tigecycline may aid in further understanding the therapeutic role of this agent."	( Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Dimopoulos, G; Falagas, ME; Karageorgopoulos, DE, 2009)	0.35
" A previously derived patient population pharmacokinetic model and Monte Carlo simulation (9999 patients) were used to create a likelihood distribution of tigecycline exposure, as measured by the area under the concentration-time curve at 24 h (AUC(24))."	( Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Ambrose, PG; Bhavnani, SM; Cirincione, BB; Ellis-Grosse, E; Meagher, AK; Passarell, JA; Van Wart, SA, 2009)	0.35
" Although this compound is under investigation for this indication, supportive pharmacodynamic data are not yet available at this infection site."	( Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Kim, A; Koomanachai, P; Nicolau, DP, 2009)	0.35
"The pharmacokinetic profile of tigecycline was evaluated in infected neutropenic mice."	( Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Kim, A; Koomanachai, P; Nicolau, DP, 2009)	0.35
"Tigecycline displayed linear pharmacokinetics with a mean half-life of 11."	( Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. Kim, A; Koomanachai, P; Nicolau, DP, 2009)	0.35
" TGC displayed linear PK and had a mean half-life of 10."	( Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Banevicius, MA; Crandon, JL; Koomanachai, P; Nicolau, DP; Peng, L, 2009)	0.35
" Pharmacokinetic data were derived using noncompartmental methods."	( Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. Baird-Bellaire, SJ; Böhmer, GM; Buecheler, R; Gleiter, CH; Korth-Bradley, JM; Morgan, MY; Patat, AA; Troy, SM, 2011)	0.37
"This study explored tigecycline exposure-bacterial responses in pharmacodynamic simulations (in vitro kinetic model) using different inocula."	( Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Aguilar, L; Alou, L; Cafini, F; Garcia-Escribano, N; Garcia-Rey, C; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2010)	0.36
" Lastly, we explain the combination of these three antibiotics administered to increase microbiologic and pharmacodynamic yield."	( A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Barrientos, A; Calvo, N; Candel, FJ; Culebras, E; Head, J; Matesanz, M; Picazo, J; Sánchez, A, 2010)	0.36
"5 healthy Thoroughbred mares for the pharmacokinetic experiment and 6 healthy Thoroughbred mares for the tissue distribution experiment."	( Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. Anzai, T; Hobo, S; Katayama, Y; Kurosawa, M; Kuwajima, M; Nagata, S; Yamashita, S, 2010)	0.36
" The pharmacokinetic and tissue distribution data should aid in the appropriate use of minocycline in horses."	( Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. Anzai, T; Hobo, S; Katayama, Y; Kurosawa, M; Kuwajima, M; Nagata, S; Yamashita, S, 2010)	0.36
" Herein, tigecycline disposition in patients with community- or hospital-acquired pneumonia was described using a population pharmacokinetic model."	( Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Ambrose, PG; Bhavnani, SM; Cooper, A; Dukart, G; Forrest, A; Korth-Bradley, J; Rubino, CM, 2010)	0.36
" The present article reviews the pharmacokinetic properties of vancomycin, linezolid, tigecycline and daptomycin."	( Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Derendorf, H; Estes, KS, 2010)	0.36
" An in vitro pharmacodynamic model was used to simulate adult steady-state epithelial lining fluid concentrations of tigecycline (50 mg every 12 h) given alone and in combination with either meropenem (2 g by 3-hour infusion every 8 h) or rifampin (600 mg every 12 h)."	( In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Koomanachai, P; Kuti, JL; Nicasio, AM; Nicolau, DP; Wiskirchen, DE, 2011)	0.37
" However, there are no pharmacokinetic or safety data available regarding the use of oral minocycline in horses."	( Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. Altier, C; Aprea, MS; Divers, TJ; Fortier, LA; McCarrel, TM; Papich, MG; Schnabel, LV, 2012)	0.38
"The pharmacokinetic parameters of tigecycline were assessed in subjects with severe renal impairment (creatinine clearance <30 mL/min, n = 6), subjects receiving hemodialysis (4 received tigecycline before and 4 received tigecycline after hemodialysis), and subjects with age-adjusted, normal renal function (n = 6) after administration of single 100-mg doses."	( Tigecycline pharmacokinetics in subjects with various degrees of renal function. Fruncillo, RJ; Korth-Bradley, JM; Matschke, K; Muralidharan, G; Raible, DG; Speth, JL; Troy, SM, 2012)	0.38
"The aim of this study was to assess the pharmacokinetic (PK) properties, safety profile, and descriptive efficacy of tigecycline."	( Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Balter, I; Cooper, CA; Dartois, N; Jouve, S; Korth-Bradley, J; Purdy, J; Yan, JL, 2012)	0.38
"The methodology included the following steps: acquisition of microbiological and pharmacokinetic data, Monte Carlo simulation, estimation of the probability of target attainment (PTA), and calculation of the cumulative fraction of response (CFR)."	( Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Betriu, C; Canut, A; Gascón, AR; Isla, A, 2012)	0.38
" The pharmacodynamic study was carried out using elevated plus maze (EPM) and Morris water maze (MWM) behavioral models for nootropic activity in swiss albino mice; and biochemical estimations (acetylcholine esterase, reduced glutathione, malondialdehyde and brain nitrite level)."	( Formulation, optimization, in vivo pharmacokinetic, behavioral and biochemical estimations of minocycline loaded chitosan nanoparticles for enhanced brain uptake. Mishra, DN; Nagpal, K; Singh, SK, 2013)	0.39
" baumannii using an in vitro pharmacodynamic model."	( In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. Hagihara, M; Housman, ST; Kuti, JL; Nicolau, DP, 2013)	0.39
" Serial blood samples and urine were collected, drug concentrations determined, and pharmacokinetic parameters calculated."	( Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Gandhi, A; Korth-Bradley, J; Matschke, K; Yamashita, N, 2014)	0.4
" baumannii isolates were evaluated using an in vitro pharmacodynamic model."	( In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Hagihara, M; Housman, ST; Kuti, JL; Nicolau, DP, 2014)	0.4
" This validated method was successfully applied to a pharmacokinetic study in critically ill patients."	( Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. Cheng, X; Dong, H; Dong, Y; Wang, T; Wang, X; Wang, Y; Xie, J; Xing, J; Zheng, X; Zhou, L, 2014)	0.4
" The goal of our research was to assess the clinical efficacy of tigecycline at different doses by using a pharmacokinetic/pharmacodynamic (PK/PD) model which can incorporate pharmacokinetic data of tigecycline from patients with pneumonia and MICs of MDR-Ab from a tertiary hospital."	( A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Bai, N; Cai, Y; Cui, JC; Liang, BB; Liu, YP; Ni, WT; Wang, R, 2014)	0.4
" Pharmacokinetic analysis was performed on plasma and ISF concentrations."	( Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. Guardabassi, L; Maaland, MG; Papich, MG, 2014)	0.4
" A one-compartment pharmacokinetic model was fit to the oral data and a two-compartment model to the IV data via a computer program."	( Pharmacokinetics of minocycline in domestic cats. Cohn, LA; Kerl, ME; Papich, MG; Tynan, BE, 2016)	0.43
" Based on the MICs and the population pharmacokinetic parameters of the investigated antimicrobials, a Monte Carlo simulation was performed to simulate the pharmacokinetic/pharmacodynamic (PK/PD) indices of different regimens."	( A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Cai, X; Cui, J; Ni, W; Wei, C, 2015)	0.42
" Minocycline plasma drug concentrations were measured using high-performance liquid chromatography using ultraviolet detection and were analysed with compartmental modelling to determine primary pharmacokinetic parameters."	( Effect of feeding on the pharmacokinetics of oral minocycline in healthy research dogs. Cole, LK; Hnot, ML; Lorch, G; Papich, MG; Rajala-Schultz, PJ, 2015)	0.42
"Because feeding was a significant source of variation for the population's primary pharmacokinetic parameters and fasted dogs had higher minocycline concentrations, we recommend administering minocycline without food."	( Effect of feeding on the pharmacokinetics of oral minocycline in healthy research dogs. Cole, LK; Hnot, ML; Lorch, G; Papich, MG; Rajala-Schultz, PJ, 2015)	0.42
" Here, the pharmacodynamic activities of polymyxin B (PMB) (2-20 mg/L) and tigecycline (0."	( Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Bulitta, JB; Diep, J; Forrest, A; Holden, PN; Li, J; Ly, NS; Nation, RL; Rao, GG; Tsuji, BT, 2016)	0.43
" In this study, a single-compartment dilutional pharmacokinetic model was used to determine the relationship between MNO exposure and antibacterial effect, including the risk of resistance emergence, against strains of Acinetobacter baumannii."	( Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. Alfouzan, WA; Attwood, MLG; Bowker, KE; MacGowan, AP; Noel, AR; Tomaselli, SG, 2017)	0.46
" Values of half-life in the elimination phase were 23."	( Pharmacokinetics of tigecycline in turkeys following different routes of administration. Jaroszewski, JJ; Jasiecka-Mikołajczyk, A; Ziółkowski, H, 2018)	0.48
" This validated method was successfully applied to a TIG pharmacokinetic study in turkey after intravenous and oral administration at a dose of 10 mg/kg at various time-points."	( Determination of tigecycline in turkey plasma by LC-MS/MS: validation and application in a pharmacokinetic study. Jaroszewski, JJ; Jasiecka-Mikołajczyk, A, 2017)	0.46
"3 μg/mL, and terminal half-life was 11."	( Pulmonary disposition and pharmacokinetics of minocycline in adult horses. Austin, SA; Echeverria, KO; Foreman, JH; Giguère, S; Lascola, KM, 2017)	0.46
"Tetracyclines are widely used as oral therapy of MRSA infection, however, the pharmacodynamic underpinning is absent."	( The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)	0.62
"We employed an in vitro pharmacokinetic model to study the pharmacodynamics of minocycline alone and in combination with rifampicin."	( The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)	0.62
" However, no pharmacodynamic data are available to guide dosing or justify this breakpoint."	( Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. Fratoni, AJ; Kuti, JL; Nicolau, DP, 2022)	0.72
" Monte Carlo simulation was employed to assess the PTA for achieving defined pharmacodynamic thresholds in critically ill patients."	( Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. Fratoni, AJ; Kuti, JL; Nicolau, DP, 2022)	0.72

Excerpt	Reference	Relevance
" The Lewis lung carcinoma was used to assess the response of both the primary tumor and metastatic lung disease to treatment with minocycline (14 x 5 mg/kg) given alone or in combination with several cytotoxic anticancer drugs or with radiation delivered locally to the primary tumor."	( Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Frei, E; Herman, TS; Holden, SA; Menon, K; Schwartz, GN; Sotomayor, EA; Teicher, BA, 1992)	0.28
" We suggest a periodic ophthalmologic examination during systemic therapy with vitamin A combined with minocycline to detect the early occurrence of pseudotumor cerebri."	( Pseudotumor cerebri induced by vitamin A combined with minocycline. Aviel, E; Leibowitz, E; Moskowitz, Y; Ronen, M, 1993)	0.29
"The efficacy of atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, and minocycline was examined in vitro and in a murine model of acute toxoplasmosis."	( In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Derouin, F; Pudney, M; Romand, S, 1993)	0.29
"Glycoside antibiotics including the macrolide antibiotics azithromycin, clarithromycin, and erythromycin and the aminoglycoside paromomycin were administered alone or combined with doxycycline, minocycline, or tetracycline to neonatal BALB/c mice experimentally infected with Cryptosporidium parvum."	( Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice. Ellis, W; Fayer, R, 1993)	0.29
"The in vivo synergistic effect of cefodizime (CDZM) in combination with minocycline (MINO) against methicillin-resistant Staphylococcus aureus (MRSA) was investigated."	( [Therapeutic efficacy of cefodizime in combination with minocycline against systemic infection caused by methicillin-resistant Staphylococcus aureus in immunocompromised tumour bearing mice]. Deguchi, K; Furukawa, T; Hyodo, A; Miyake, Y; Shimizu, C; Uji, T, 1993)	0.29
"The anticryptosporidial activity of four macrolides alone and in combination with other antimicrobial agents was investigated against ten clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients."	( In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. Cirioni, O; Giacometti, A; Scalise, G, 1996)	0.29
" In vitro studies with isolated monkey liver microsomes confirmed these drug-drug metabolic interactions detected at the cellular level."	( Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes. Bynon, S; Eckoff, D; Placidi, L; Scott, EC; Sommadossi, JP, 1999)	0.3
"The in-vitro activity of rifabutin and albendazole alone and in combination with clarithromycin, etoposide, minocycline and pyrimethamine was investigated against four clinical isolates of Pneumocystis carinii."	( In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. Barchiesi, F; Cirioni, O; Fortuna, M; Giacometti, A; Scalise, G, 1999)	0.3
"The in vitro activity of lactoferrins alone and in combination with clarithromycin, minocycline and pyrimethamine was investigated against three clinical isolates of Pneumocystis carinii."	( Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. Barchiesi, F; Cirioni, O; Giacometti, A; Scalise, G, 2000)	0.31
"The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated."	( Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. Barchiesi, F; Cirioni, O; Fineo, A; Giacometti, A; Scalise, G, 2001)	0.31
" In the present study effects of minocycline, an anti-inflammatory agent, alone or in combination with mild hypothermia, on focal embolic brain ischemia have been examined."	( Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Shuaib, A; Wang, CX; Yang, T, 2003)	0.32
" We also evaluated the inhibitory activity of cefazolin or cefotaxime combined with minocycline."	( In vitro antimicrobial effect of cefazolin and cefotaxime combined with minocycline against Vibrio cholerae non-O1 non-O139. Chuang, YC; Ko, WC; Liu, CY; Liu, YC; Su, BA; Tang, HJ; Wang, YY, 2005)	0.33
"Microdilution chequerboard analysis of tigecycline in combination with amikacin, ampicillin/sulbactam, azithromycin, ciprofloxacin, colistin, imipenem, levofloxacin, piperacillin, piperacillin/tazobactam, polymyxin B, rifampicin, minocycline and vancomycin resulted in an interpretation of either no interaction or synergy."	( In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. Bradford, PA; Jones, CH; Labthavikul, P; Petersen, PJ, 2006)	0.33
"2 was combined with clarithromycin and minocycline."	( In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. Cirioni, O; Della Vittoria, A; Giacometti, A; Kamysz, W; Nadolski, P; Riva, A; Scalise, G; Silvestri, C; Łukasiak, J, 2007)	0.34
"The activities of tigecycline alone and in combination with other antimicrobials are not well defined for carbapenem-intermediate or -resistant Acinetobacter baumannii (CIRA)."	( In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Noskin, GA; Obias, A; Postelnick, MJ; Qi, C; Scheetz, MH; Warren, JR; Zembower, T, 2007)	0.34
"To observe the clinical efficacy of Chibixiao Recipe (CBX) in combination with minocycline and spironolactone in treating rosacea in females."	( Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. Guo, W; Yu, TG; Zheng, YZ; Zhu, JT, 2006)	0.33
"CBX in combination with Western medicine has effect in treating rosacea superior to that of Western medicine alone, and could effectively reduce recurrent rate and the serum level of testosterone."	( Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. Guo, W; Yu, TG; Zheng, YZ; Zhu, JT, 2006)	0.33
"This study tested the potential antidepressant activity of minocycline alone or combined with two traditional antidepressant drugs or several glutamate receptor antagonists, using the time sampling method in the forced swimming test."	( Antidepressant-like actions of minocycline combined with several glutamate antagonists. Jaramillo-Jaimes, MT; Molina-Hernández, M; Olivera-Lopez, JI; Pérez-García, J; Tellez-Alcántara, NP, 2008)	0.35
"To test the activity of tigecycline combined with 16 antimicrobials in vitro against 22 gram-positive and 55 gram-negative clinical isolates."	( In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. Entenza, JM; Giddey, M; Moreillon, P; Vouillamoz, J, 2008)	0.35
"This study evaluated vancomycin susceptibility and activity alone and in combination with rifampicin and tigecycline against low-biofilm- and high-biofilm-producing methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates."	( Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. Poppens, PT; Rose, WE, 2009)	0.35
" Time-kill analysis was performed on six low- and six high-biofilm-producing isolates with 15 mg/L vancomycin alone and in combination with rifampicin or tigecycline at 4x MIC."	( Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. Poppens, PT; Rose, WE, 2009)	0.35
"Tigecycline has been investigated in combination with other antibacterials against a wide range of susceptible and multiresistant Gram-positive and Gram-negative bacteria."	( Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Entenza, JM; Moreillon, P, 2009)	0.35
" We investigated the effects of vancomycin (VAN), daptomycin (DAP), fosfomycin (FOS), tigecycline (TGC), and ceftriaxone (CRX), alone and in combination with azithromycin (AZI), on established biofilms of Staphylococcus epidermidis."	( Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Graninger, W; Hajdu, S; Hirschl, AM; Holinka, J; Lassnigg, AM; Presterl, E, 2009)	0.35
"We investigated the activity of tigecycline in combination with gentamicin for the treatment of biofilm-forming methicillin-resistant and sensitive Staphylococcus aureus in an in vitro pharmacodynamic model."	( In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. LaPlante, KL; McConeghy, KW, 2010)	0.36
"This study evaluated the activity of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli co-producing extended-spectrum β-lactamases and acquired AmpC β-lactamases."	( Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Hur, J; Kim, HS; Lee, KM; Park, MJ; Park, MS; Song, W; Woo, H; Yim, H, 2011)	0.37
"This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA)."	( In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus. Cai, Y; Falagas, ME; Karageorgopoulos, DE; Liang, B; Liu, Y; Liu, Z; Song, X; Sun, C; Wang, R; Yu, X, 2011)	0.37
" In conclusion, our results suggested a strong activity of tigecycline alone and in combination with other antimicrobial agents against multi-resistant Gram-positive organisms isolated from wound infections."	( In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Arzeni, D; Brescini, L; Cirioni, O; Ganzetti, G; Ghiselli, R; Giacometti, A; Guerrieri, M; Offidani, A; Orlando, F; Provinciali, M; Silvestri, C; Simonetti, O; Staffolani, S, 2012)	0.38
"The aim of this study was to investigate the in vitro activity of minocycline combined with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii (CRAB)."	( In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii. Mao, Y; Pei, G; Sun, Y, 2012)	0.38
"The purpose of this study is to evaluate and compare the clinical and radiographic effectiveness of Ciprofloxacin, Minocycline, Metronidazole combination with Ciprofloxacin, Minocycline and Tinidazole combination when used for Lesion Sterilization and Tissue Repair in primary teeth."	( In vivo evaluation of lesion sterilization and tissue repair in primary teeth pulp therapy using two antibiotic drug combinations. Anantharaj, A; Jaya, AR; Praveen, P; Rani, PS; Venkataraghavan, K, 2012)	0.38
" The purpose of this study was to investigate the clinical outcomes of patients with healthcare-associated infections (HAIs) caused by MDRAB who were treated with imipenem/cilastatin and sulbactam, and TG alone or in combination with other antibiotics."	( Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Hsueh, PR; Lee, YT; Tsao, SM, 2013)	0.39
"The aim of this study was to evaluate the in vitro activity of doripenem (DOR) alone and in combination with a variety of commonly used anti-Acinetobacter chemotherapeutic agents against 22 primary multidrug-resistant (MDR) Acinetobacter baumannii isolates (including 17 isolates that were resistant to DOR) from Intensive Care Unit patients."	( In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L, 2013)	0.39
" We carried out this study to determine the mutant prevention concentration (MPC) of linezolid when combined with minocycline against VRE strains, to determine the mechanism of drug resistance in vitro, and to provide a theoretical basis for the rational use of drugs against VRE."	( Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci. Jiang, TT; Li, L; Su, JR; Wu, J, 2013)	0.39
" decreased dramatically when combined with minocycline, and vice versa."	( Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci. Jiang, TT; Li, L; Su, JR; Wu, J, 2013)	0.39
"5% of the strains for meropenem combination with tigecycline."	( Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Labrou, M; Manousaka, S; Michail, G; Pitiriga, V; Pournaras, S; Sakellaridis, N; Tsakris, A, 2013)	0.39
" More generally, these results suggest that traditional therapy in combination with local, as opposed to systemic, delivery of angiogenesis inhibitors may be able to increase median survival for patients with glioblastoma."	( Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. Bow, H; Brem, H; Hwang, LS; Murray, L; Salditch, Q; Schildhaus, N; Tyler, B; Weingart, J; Xing, J; Ye, X; Zhang, Y, 2014)	0.4
" Tigecycline in combination with rifampin demonstrated higher activity against bacteria embedded in biofilms than tigecycline alone."	( Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm. Kaznowski, A; Szczuka, E, 2014)	0.4
" We compared the synergistic activity and post-antibiotic effect (PAE) of colistin in combination with other antimicrobials against colistin-susceptible and -resistant KPC-Kp bloodstream isolates."	( In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. Ambretti, S; Bonora, S; Gaibani, P; Landini, MP; Lewis, RE; Lombardo, D; Mercuri, M, 2014)	0.4
" In time-kill assays, COL combined with either RIF or TGC was superior to single agents, but only the COL/RIF regimen was reliably bactericidal."	( Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Betts, JW; Phee, LM; Wareham, DW; Woodford, N, 2014)	0.4
" Moreover, tigecycline in combination with cefoperazone-sulbactam appeared to be more effective than tigecycline in combination with sulbactam against XDRAB."	( In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Bai, Y; Di, X; Liu, B; Liu, Y; Wang, J; Wang, R; Zhang, X, 2015)	0.42
"Several antibiotics have shown promising anti-malarial effects and have been useful for malarial chemotherapy, particularly in combination with standard anti-malarial drugs."	( In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. Sahu, R; Tekwani, BL; Walker, LA, 2014)	0.4
"Tigecycline was tested in vitro against chloroquine (CQ)-sensitive (D6) and resistant strains (W2) of Plasmodium falciparum alone and in combination with CQ."	( In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. Sahu, R; Tekwani, BL; Walker, LA, 2014)	0.4
"Results indicate prominent anti-malarial action of tigecycline in vitro and in vivo in combination with CQ and support further evaluation of tigecycline as a potential combination candidate for treatment of drug-resistant cases of malaria."	( In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. Sahu, R; Tekwani, BL; Walker, LA, 2014)	0.4
"Colistin, tigecycline, levofloxacin, tobramycin, and rifampin alone and in combination with doripenem were investigated for their in vitro activities and postantibiotic effects (PAEs) on Klebsiella pneumoniae."	( Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit. Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M, 2014)	0.4
" haemolyticus strains isolated from bloodstream infections and assess in vitro the activity of rifampicin combined with daptomycin or tigecycline against bacteria growing in a biofilm."	( In Vitro Activity of Rifampicin Combined with Daptomycin or Tigecycline on Staphylococcus haemolyticus Biofilms. Grabska, K; Kaznowski, A; Szczuka, E, 2015)	0.42
" Synergy was observed when plazomicin was combined with meropenem, colistin or fosfomycin against both isolates, whilst the combination with tigecycline resulted in indifference."	( In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Culebras, E; Pena, I; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I, 2015)	0.42
"This study investigated the minimum inhibitory concentration (MIC) values and in vitro activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia (VAP) using the E-test method."	( In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia. Aydin, M; Ceylan, MR; Cikman, A; Gulhan, B; Karagoz, A; Karakecili, F; Parlak, M, 2015)	0.42
" The in vitro activity of colistin in combination with tigecycline was evaluated using the fractional inhibitor concentration (FIC) index."	( In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia. Aydin, M; Ceylan, MR; Cikman, A; Gulhan, B; Karagoz, A; Karakecili, F; Parlak, M, 2015)	0.42
" The in vivo studies showed that azithromycin (20 mg/kg/day twice daily) alone or in combination with minocycline (10 mg/kg/day twice daily) significantly decreased the fungal burden."	( In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. Alves, SH; Azevedo, MI; Driemeier, D; Ferreiro, L; França, RT; Jesus, FP; Lopes, ST; Loreto, ÉS; Ludwig, A; Pilotto, MB; Ribeiro, TC; Santurio, JM; Souza, SO; Tondolo, JS, 2016)	0.43
" Herein, we investigated by a retrospective chart review the effect of prophylactic oral minocycline in combination with skin treatment using moisturizer on the incidence of skin disorders and tumor response in metastatic colorectal cancer patients who received panitumumab."	( Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. Fujii, H; Iihara, H; Ishihara, M; Itoh, Y; Matsuhashi, N; Takahashi, T; Yamada, M; Yoshida, K, 2015)	0.42
"Prophylactic oral minocycline combined with skin care reduced panitumumab-induced acneiform rash without a significant influence on tumor response."	( Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. Fujii, H; Iihara, H; Ishihara, M; Itoh, Y; Matsuhashi, N; Takahashi, T; Yamada, M; Yoshida, K, 2015)	0.42
" The purpose of this intervention was to evaluate the efficacy of non-ablative fractional photothermolysis in combination with the Q-switched alexandrite laser for the treatment of type I minocycline pigmentation on the face."	( Complete resolution of minocycline pigmentation following a single treatment with non-ablative 1550-nm fractional resurfacing in combination with the 755-nm Q-switched alexandrite laser. DeLozier, WL; Friedman, PM; Geddes, E; Vangipuram, RK, 2016)	0.43
"The aims of this study were to assess that the effects of bone marrow mesenchymal stem cells (BMSCs) combination with minocycline improve spinal cord injury (SCI) in rat model."	( Bone marrow mesenchymal stem cells combined with minocycline improve spinal cord injury in a rat model. Chen, D; Fu, Y; Gao, M; Lv, G; Zeng, W, 2015)	0.42
" In this study, we aimed to evaluate the efficacy of LPC in combination with colistin, tigecycline, or imipenem in experimental murine models of peritoneal sepsis and pneumonia."	( Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models. Ayerbe Algaba, R; Díaz, C; Gutiérrez Valencia, A; Jiménez Mejías, ME; López Cortés, LF; Pachón Ibáñez, ME; Pachón, J; Parra Millán, R; Pérez Del Palacio, J; Sánchez Encinales, V; Smani, Y, 2016)	0.43
" Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains."	( Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model. Cong, Y; Fan, B; Guan, J; Wang, X, 2016)	0.43
" We investigated the activity of various antibiotics in combination with polymyxin B using time-kill studies (TKS)."	( In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B. Cai, Y; Chan, EC; Hong, Y; Hsu, LY; Koh, TH; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Tan, TT; Tan, TY; Teo, J, 2016)	0.43
" Data from these in vitro and in vivo studies demonstrate that minocycline does not diminish the cytotoxic and tumor-suppressive effects of this chemotherapeutic drug combination in TNBC cells."	( Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Chen, CS; DeVries, AC; Himmel, LE; Kulp, SK; Lustberg, MB; Poi, M, 2016)	0.43
"To investigate the effect of minocycline hydrochloride combined with Vitapex in treating senile chronic periodontal-endodontic combined lesions."	( [Analysis of minocycline hydrochloride combined with Vitapex in treating senile chronic periodontal-endodontic combined lesions]. Liu, XH; Liu, ZY; Yang, J; Zhang, JD; Zhang, L, 2016)	0.43
"For chronic periodontitis and endodontic lesions, besides conventional root canal therapy, Vitapex combined with minocycline hydrochloride can significantly improve the clinical effect."	( [Analysis of minocycline hydrochloride combined with Vitapex in treating senile chronic periodontal-endodontic combined lesions]. Liu, XH; Liu, ZY; Yang, J; Zhang, JD; Zhang, L, 2016)	0.43
" The SBPI analysis showed that CAZ-AVI in combination with imipenem achieved higher SBPI values than other CAZ-AVI-based combinations."	( In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL, 2017)	0.46
" The lead candidate was then tested against a panel of clinical CREs, a bactericidal/static determination assay, a time-kill assay and a checkerboard assay to evaluate its suitability for use in combination with Tigecycline against CRE infections."	( Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections. Chia, CSB; Ching, HSV; Hill, J; Jureen, R; Ng, FM; Ng, SMS; Sioson, JSP; Teo, JWP; Yap, JM, 2018)	0.48
" This study was designed to investigate the effectiveness of photodynamic therapy (PDT) combined with minocycline in moderate to severe facial acne and influence on quality of life (QOL)."	( Efficacy of photodynamic therapy combined with minocycline for treatment of moderate to severe facial acne vulgaris and influence on quality of life. Li, C; Liu, P; Xu, X; Zhang, X; Zhao, Z; Zheng, Y, 2017)	0.46
"This study aimed to evaluate the efficacy of 2% minocycline hydrochloride combined with flap surgery in the treatment of chronic periodontitis."	( [Efficacy of minocycline hydrochloride combined with flap surgery for chronic periodontitis: a Meta-analysis]. Bai, YL; Gan, Y; Huang, J; Zhang, ZW; Zheng, TJ, 2018)	0.48
"05), but the improvement in CAL was significantly improved by minocycline hydrochloride combined with flap therapy."	( [Efficacy of minocycline hydrochloride combined with flap surgery for chronic periodontitis: a Meta-analysis]. Bai, YL; Gan, Y; Huang, J; Zhang, ZW; Zheng, TJ, 2018)	0.48
"Periodontal flap combined with minocycline adjuvant therapy for chronic periodontitis is effective in short-term observations."	( [Efficacy of minocycline hydrochloride combined with flap surgery for chronic periodontitis: a Meta-analysis]. Bai, YL; Gan, Y; Huang, J; Zhang, ZW; Zheng, TJ, 2018)	0.48
"This study examined the effect of minocycline alone and in combination with immunotherapy against pythiosis."	( In vivo effect of minocycline alone and in combination with immunotherapy against pythium insidiosum. Alves, SH; Driemeier, D; Ferreiro, L; Jesus, FPK; Loreto, ÉS; Santurio, JM; Schlemmer, KB; Tondolo, JSM; Zimmermann, CEP, 2020)	0.56
" However, few reports focused on the effect of xipayi mouth rinse combined with minocycline on periodontal pathogens."	( Effects of xipayi mouth rinse combined with minocycline on localized aggressive periodontitis' therapeutic effect and the levels of CRP, TNF-α, IL-6 in serum. Cai, Y; Chen, X; He, Z; Song, S; Wang, L; Yu, Q; Zhao, H, 2020)	0.56
" Then, 48 patients in the experimental group were treated with xipayi mouth rinse combined with minocycline after primary periodontal treatment."	( Effects of xipayi mouth rinse combined with minocycline on localized aggressive periodontitis' therapeutic effect and the levels of CRP, TNF-α, IL-6 in serum. Cai, Y; Chen, X; He, Z; Song, S; Wang, L; Yu, Q; Zhao, H, 2020)	0.56
"Xipayi mouth rinse, combined with minocycline in the treatment of localized aggressive periodontitis, can significantly improve the periodontal gingival condition and reduce the level of inflammatory factors."	( Effects of xipayi mouth rinse combined with minocycline on localized aggressive periodontitis' therapeutic effect and the levels of CRP, TNF-α, IL-6 in serum. Cai, Y; Chen, X; He, Z; Song, S; Wang, L; Yu, Q; Zhao, H, 2020)	0.56
"We employed an in vitro pharmacokinetic model to study the pharmacodynamics of minocycline alone and in combination with rifampicin."	( The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)	0.62
"An exposure-ranging design was used to establish fAUC/MIC targets for static, -1 log drop and -2 log drop effects against Staphylococcus aureus for minocycline and in combination with rifampicin."	( The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)	0.62
" Since activated microglia, impaired serotonergic and noradrenergic neurotransmission and overexpressed sodium channels are implicated in oxaliplatin-induced pain, this in vivo study assessed the effect of minocycline, a microglial activation inhibitor used alone or in combination with ambroxol, a sodium channel blocker, or duloxetine, a serotonin and noradrenaline reuptake inhibitor, on oxaliplatin-induced tactile allodynia and cold hyperalgesia."	( The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice. Furgała-Wojas, A; Sałat, K; Sałat, R, 2021)	0.62
"Purpose: To investigate the therapeutic effects of minocycline combined with tinidazole in the treatment of chronic periodontitis (CP)."	( Effects Of Minocycline Combined With Tinidazole For Treatment Of Chronic Periodontitis. Gu, J; Huang, J; Xue, J, 2021)	0.62
"This study aimed to assess the effect of diode laser combined with minocycline hydrochloride in conventional nonsurgical periodontal therapy."	( Effect of diode laser combined with minocycline hydrochloride in nonsurgical periodontal therapy: a randomized clinical trial. Wang, X; Wang, Y; Yang, C, 2022)	0.72
"The synergistic effect of SRP and 809 nm diode laser combined with minocycline hydrochloride could play an efficient and reliable effect in the nonsurgical periodontal treatment approach."	( Effect of diode laser combined with minocycline hydrochloride in nonsurgical periodontal therapy: a randomized clinical trial. Wang, X; Wang, Y; Yang, C, 2022)	0.72
"We aimed to evaluate the safety and efficiency of IPL combined with minocycline in treating acne vulgaris in a randomized trial."	( A randomized, controlled trial of intense pulsed light in combination with minocycline hydrochloride for the treatment of inflammatory acne vulgaris. Gao, L; Li, K; Qu, H; Wang, G; Wang, Y; Yang, F, 2022)	0.72
"IPL in combination with minocycline shows a better clinical efficacy for the treatment of inflammatory acne vulgaris than minocycline alone, and it is safe."	( A randomized, controlled trial of intense pulsed light in combination with minocycline hydrochloride for the treatment of inflammatory acne vulgaris. Gao, L; Li, K; Qu, H; Wang, G; Wang, Y; Yang, F, 2022)	0.72
" Following the intraperitoneal (IP) administration of AFB1 at dose of 2 mg/kg, minocycline (45 and 90 mg/kg, IP) and dexamethasone (5 and 20 mg/kg, IP) were administered alone and combined with NAC (200 mg/kg, IP) and vitamin E (600 mg/kg, IP)."	( The effects of dexamethasone and minocycline alone and combined with N-acetylcysteine and vitamin E on serum matrix metalloproteinase-9 and coenzyme Q10 levels in aflatoxin B1 administered rats. Bahcivan, E; Dik, B; Eser Faki, H; Ozdemir Kutahya, Z; Tras, B; Uney, K, 2022)	0.72

Excerpt	Reference	Relevance
"Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration."	( Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Avery, GS; Brogden, RN; Speight, TM, 1975)	0.25
"The authors studied the bioavailability of minocycline in sebum and serum."	( Absence of minocycline in sebum? Agache, P; Aubin, F; Blanc, D; Guinchard, C, 1989)	0.28
" Computer simulations run on this occasion showed that the stoichiometry of these species do actually condition the bioavailability of the antibiotics in blood plasma during treatment, the fraction of free base being quite negligible with regard to the metal-bound one."	( Metal ion-tetracycline interactions in biological fluids. Part 3. Formation of mixed-metal ternary complexes of tetracycline, oxytetracycline, doxycycline and minocycline with calcium and magnesium, and their involvement in the bioavailability of these an Berthon, G; Brion, M; Lambs, L, 1984)	0.27
" The results were used, together with those previously obtained on the complexation of these tetracyclines with proton and calcium, to assess the influence of the two alkali earth metal ions on the bioavailability of these drugs in blood plasma."	( Metal ion-tetracycline interactions in biological fluids. 2. Potentiometric study of magnesium complexes with tetracycline, oxytetracycline, doxycycline, and minocycline, and discussion of their possible influence on the bioavailability of these antibioti Berthon, G; Brion, M; Lambs, L, 1983)	0.27
"The dissimilar bioavailability and antimicrobial efficacy between the two bacteriostatic agents may impart different clinical efficacy."	( A pilot study on bacterial viability in acne. Assessment using dual flow cytometry on microbials present in follicular casts and comedones. Arrese, JE; Avila-Camacho, M; Goffin, V; Greimers, R; Piérard, GE, 1998)	0.3
" All of these older drugs are well absorbed by the oral route, attaining serum levels equivalent to those achieved by parenteral administration."	( New uses of older antibiotics. Cunha, BA; Klein, NC, 2001)	0.31
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"Minocycline is an oral tetracycline derivative with good bioavailability in the central nervous system (CNS)."	( PEG minocycline-liposomes ameliorate CNS autoimmune disease. Ben, LH; Cravens, PD; Eagar, TN; Frohman, EM; Hu, W; Kieseier, BC; Metselaar, J; Racke, MK; Singh, MP; Stüve, O, 2009)	0.35
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."	( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010)	0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Several analogs have also shown promising oral bioavailability in rats and cynomolgus monkey."	( Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs. Clark, RB; Hunt, DK; Lofland, D; O'Brien, WJ; Plamondon, L; Sun, C; Xiao, XY, 2011)	0.37
" The relative bioavailability of tetracyclines may be reduced if administered with sucralfate, but studies confirming these interactions in dogs are not available."	( Effect of sucralfate on oral minocycline absorption in healthy dogs. Harris, A; Heinrich, E; KuKanich, B; KuKanich, K, 2014)	0.4
" Oral bioavailability was approximately 62%."	( Pharmacokinetics of minocycline in domestic cats. Cohn, LA; Kerl, ME; Papich, MG; Tynan, BE, 2016)	0.43
" Bioavailability was significantly higher in foals (57."	( Comparative pharmacokinetics of minocycline in foals and adult horses. Berghaus, LJ; Burton, AJ; Giguère, S; Haspel, AD, 2017)	0.46
"To characterize minocycline pharmacokinetics and relative bioavailability following multiple-dose topical administration of minocycline hydrochloride (HCl) foam 4% (FMX101 4%) as compared with single-dose oral administration of minocycline HCl extended-release tablets (Solodyn®) in subjects with moderate-to-severe acne."	( Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. deVries, T; Ellman, H; Jones, TM, 2017)	0.46
" RESULTS Mean bioavailability of minocycline was 48% (range, 35% to 75%)."	( Pulmonary disposition and pharmacokinetics of minocycline in adult horses. Austin, SA; Echeverria, KO; Foreman, JH; Giguère, S; Lascola, KM, 2017)	0.46
" It is well absorbed from oral administration, it has less protein binding than doxycycline (65% vs 92%) allowing for better distribution into tissue, and it is approximately two times more lipophilic than doxycycline, which may result in better intracellular penetration."	( Considerations for using minocycline vs doxycycline for treatment of canine heartworm disease. Papich, MG, 2017)	0.46
"Variable absorption rate is one of the biggest problems of fat grafting and one of the most important causes of fat graft volume loss is apoptosis."	( The Effect of Minocycline on Fat Graft Survival and Apoptotic Pathway. Çenetoğlu, S; Elmas, Ç; Güney, K; Özel, B; Seymen, C; Tatar, S; Tuncer, S, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The authors further explore biomaterials that have been utilized to increase the bioavailability and bioactivity of antiangiogenic factors for better antitumor responses in GBM."	( Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. Chew, SA; Ding, MH; Hasbum, A; Jr, JAA; Levy, A; Quintanilla, J, 2021)	0.62
"To investigate how cyclosporine A, a nonspecific efflux-pump blocker, affects the plasma concentrations and oral bioavailability of tigecycline, oxytetracycline, chlortetracycline, doxycycline, minocycline, and tetracycline."	( Bioavailability of tetracyclines is substantially increased by administration of cyclosporine A, a non-specific efflux-pump blocker. Ziółkowski, H, 2023)	0.91
" Interestingly, the bioavailability of the tetracyclines was around two times higher after orally administering cyclosporine A than after intravenously administering it (P < 0."	( Bioavailability of tetracyclines is substantially increased by administration of cyclosporine A, a non-specific efflux-pump blocker. Ziółkowski, H, 2023)	0.91

Excerpt	Relevance	Reference
" It is concluded that minocycline in a dosage of 50 mg twice daily is a safe and effective antibiotic for those patients with tetracycline-recalcitrant acne vulgaris."	( Low-dose minocycline therapy in tetracycline-recalcitrant acne vulgaris. Cullen, SI, 1978)	0.26
" calcoaceticus in mice, minocycline was, in general, more active than gentamicin or polymyxin on a dosage basis and significantly more active on a blood-level basis."	( In vitro and in vivo activities of minocycline and other antibiotics against Acinetobacter (Herellea-Mima). Kuck, NA, 1976)	0.26
"The incidence of side effects due to two dosage regimens of minocycline was examined over a 5-day period."	( Side effects of minocycline: different dosage regimens. Ashikaga, T; Fink, TJ; Gump, DW; Radin, AM, 1977)	0.26
"For antibacterial prophylaxis in intraocular surgery minocycline was administered in oral dosage in 22 cataract-patients."	( [Concentration of minocycline in human aqueous humor after oral administration (author's transl)]. Hartwig, H; Krasemann, C; Mester, U, 1978)	0.26
" Minocycline dosage was 100 mg every 12 h for 5 days, and placebo was administered in an identical manner."	( Side effects of minocycline: a double-blind study. Fanning, WL; Gump, DW; Sofferman, RA, 1977)	0.26
" It is suggested that the usual dosage regimen should be used in patients with renal disease."	( One-dose and multiple-dose kinetics of minocycline in patients with renal disease. Dettli, L; Sklenar, I; Spring, P, 1977)	0.26
" At repeated administrations daily dosage of 100 mg was too low of 200 mg sufficient to obtain the same serum levels as after the initial dose of 200 mg."	( [Activity in vitro and pharmacokinetics of minocycline (author's transl)]. Grahmann, H; Malerczyk, V; Preuss, I; Schmidt, K; Simon, C, 1976)	0.26
" Three groups of contacts received different lots of minocycline and different dosage regimens."	( Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients. Altman, R; Black, K; Drew, TM; Goldfield, M, 1976)	0.26
" For patients with moderate Ccr 30 approximately 60 ml/min, as entered into the present study, the usual dosage of minocycline intravenous instillation for less than 7 days would not cause adverse reaction on renal functions."	( [Clinical studies with minocycline intravenous instillation. Chemotherapy in patients with renal impairment (author's transl)]. Nakamura, H; Nakano, H; Nanba, K; Sekine, O; Usuda, Y, 1977)	0.26
" It has the following advantages: (1) it is administered orally on a twice-daily dosage schedule, which facilitates patient compliance; (2) its toxicity is well defined and is not troublesome during short-term therapy; and (3) it penetrates tissues in therapeutic amounts and yields serum levels that are well above the minimum inhibitory concentrations of most staphylococci."	( Minocycline in staphylococcal soft-tissue infections. Barnwell, PA; Raff, MJ; Rogers, J; Waterman, N, 1975)	0.25
" In January 1975, a questionnaire on adverse reactions was completed by all 29 staff members of a North Georgia hospital who had taken minocycline at the recommended dosage after exposure to a suspected meningococcal meningitis case and by 25 age-, sex-, and occupation-matched non-treated controls."	( Vestibular reactions associated with minocycline. Daniel, B; Jacobson, JA, 1975)	0.25
" Laboratory and clinical data are presented to question the validity of selected advertisements which (1) encourage the use of Keflex for severe respiratory infections in children, (2) recommend the use of Keflex for the treatment of bacterial bronchitis, (3) suggest that high tissue penetration is a unique property of Vibramycin, (4) present pooled susceptability data which do not reflect microbial resistance patterns in the patient's hospital, (5) recommend twice-daily administration of Ancef for urinary tract infections but do not clearly state the potential danger of this regimen for other infections, (6) suggest that gentamicin should be given to adults in only two dosage sizes for the treatment of serious Gram-negative infections, and (7) lead the reader to assume that only women need to be treated for Trichomonas infections."	( Need for "counter-detailing" antibiotics. Hendeles, L, 1976)	0.26
" In the comparative study of chronic prostatitis, minocycline and doxycycline were given on the same dosage schedule, milligram for milligram: a loading dose of 200 mg."	( Treatment of chronic prostatitis. Comparison of Minocycline and Doxycycline. Brannan, W, 1975)	0.25
" In the dosage used it was also successful against gonorrhoea in seven patients treated."	( Minocycline in the treatment of non-gonococcal urethritis. Fazluddin, CM; Sparrow, RW; Willcox, RR, 1975)	0.25
" It appears, therefore, that a faily high proportion fo tetracycline-resistant strains isolated at the present time are resistant of concentrations of minocycline unattainbale in vivo with the recommended dosage forthis antibiotic (Fishk & Tunevall, 1969)."	( The genetics of tetracycline resistance in Staphylococcus aureus. Asheshov, EH, 1975)	0.25
" After identical multiple oral dosage regimens serum levels of antibiotic were comparable in normal and mildly uremic subjects."	( Pharmacokinetics of minocycline in renal failure. Craig, WA; Shaw, WR; Tse, FL; Uman, SJ; Welling, PG, 1975)	0.25
" twice a day starting eight to twelve hours before biopsy and continuing at this dosage for five days after biopsy."	( Prevention of infection during transrectal biopsy of prostate through double-glove technique. Buedingen, RP, 1976)	0.26
" At a dosage of 25 mg/kg, minocycline was more active than clarithromycin at a dosage of 50 mg/kg."	( Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Grosset, JH; Ji, B; Perani, EG, 1991)	0.28
"The authors evaluated the activity of Minocycline in 30 male patients with urinary tract infection caused by Chlamydia trachomatis (Ct) and alterations of the seminal parameters using three different dosage schedules (100 mg/day for 10 days, 200 mg/day for 10 days and 200 mg/day for 20 days)."	( [Male genito-urinary tract infection caused by Chlamydia trachomatis and seminal characteristics: use of minocycline]. Alfano, P; Anticoli-Borza, L; Basile, A; Fabbri, G; Gandini, L; Lenzi, A; Lombardo, F, 1990)	0.28
" Drug dosage was one 100 mg capsule twice daily for seven days."	( Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. Davies, BI; Maesen, FP; van den Bergh, JJ, 1989)	0.28
" The twice-daily dosage and ease of absorption from the gastrointestinal tract offer significant advantages over other tetracyclines."	( Therapeutic focus. Minocycline in the treatment of acne. Freeman, K, 1989)	0.28
" These guidelines are based on data on antibiotic concentrations attainable in serum following various dosage regimens."	( Antibiotic susceptibility of anaerobic bacteria from the human oral cavity. Baker, PJ; Evans, RT; Genco, RJ; Slots, J, 1985)	0.27
" The negative gene dosage effect resulted from decreased expression of two mechanisms (1 and 2) consequent on enhanced expression of the third mechanism."	( Reduced expression of Tn 10-mediated tetracycline resistance in Escherichia coli containing more than one copy of the transposon. Chopra, I; Shales, SW; Wallace, LJ; Ward, JM, 1981)	0.26
" The higher daily dosage did not improve outcome."	( Therapy for nongonococcal urethritis: double-blind randomized comparison of two doses and two durations of minocycline. Alexander, ER; Bowie, WR; Floyd, JF; Holmes, KK; Stimson, JB, 1981)	0.26
" The effects of minocycline on viability by mouse foot pad inoculation and palmitic acid oxidation assays were noted beginning at 10 to 14 days of daily dosing and becoming more definite after 30 days of treatment."	( Minocycline in lepromatous leprosy. Abalos, RM; dela Cruz, EC; Fajardo, TT; Franzblau, SG; Villahermosa, LG; Walsh, GP, 1995)	0.29
" Mice were dosed orally, commencing at 7 days after infection, with minocycline, doxycycline, or amoxicillin-clavulanate."	( Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin. Beale, AS; Upshon, PA, 1994)	0.29
" Taking into account the effectiveness of the drugs and the comparative pharmacokinetic data, we propose that the optimal dosage in human trials is CLARI 1000 mg per month or MINO 200 mg per month."	( Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Grosset, JH; Ji, B; Perani, EG; Pétinon, C; Xiong, JH, 1994)	0.29
" The in vivo efficacies of the glycylcyclines against acute lethal infections in mice when dosed intravenously were reflective of their in vitro activities."	( In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Jacobus, NV; Lee, VJ; Petersen, PJ; Sum, PE; Tally, FP; Testa, RT, 1993)	0.29
" No statistically significant differences were noted in the volume of distribution or the half-life of the individual dosing regimens for either agent."	( Pharmacokinetics of minocycline and vancomycin in rabbits. Freeman, CD; Nicolau, DP; Nightingale, CH; Quintiliani, R, 1993)	0.29
"Following percutaneous insertion of a pericardial drain, minocycline was administered at a dosage of 10 mg/kg every 48 h until fluid drainage stopped or until further therapy was deemed necessary."	( Intrapericardial minocycline sclerosis for malignant pericardial effusion. Ben Yosef, R; Lashevsky, I; Markiewicz, W; Reisner, S; Rinkevich, D, 1996)	0.29
" However, gastrointestinal adverse events were quite frequent among patients treated with CLARI-MINO, with or without OFLO, and may be attributed to the higher dosage of CLARI or MINO or to the combination of CLARI-MINO plus OFLO."	( Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Grosset, JH; Jamet, P; Ji, B; Lienhardt, C; Perani, EG; Petinon, C; Sow, S, 1996)	0.29
" Dose-response studies show that doxycycline is the most potent-analogue in abolishing tTA activity."	( Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues. A-Mohammadi, S; Alvarez-Vallina, L; Ashworth, LJ; Hawkins, RE, 1997)	0.3
" In mouse experiments, the activity of a single dose of the combination OFLO-MINO was dosage related; the higher dosage of the combination displayed bactericidal activity which was significantly inferior to that of a single dose of RMP, whereas the lower dosage did not exhibit a bactericidal effect."	( Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Diderot, V; Grosset, J; Ji, B; Lienhardt, C; Perani, E; Sow, S, 1998)	0.3
" Tolerance to the drugs was generally good, apart from three cases of hepatic disturbances and three cases of ototoxicity, which required a decrease in clarithromycin dosage after a short interruption of treatment."	( Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Igual, J; Roussel, G, 1998)	0.3
" Alternate-day dosing was as effective as consecutive day administration."	( Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. Anderson, GL; Bond, SJ; Gupta, SC; Klein, SA; Yacoub, OA, 1999)	0.3
" He analyzes the assumed mechanism of action, dosage and the most frequently encountered undesirable effects of treatment."	( [Minocycline in the treatment of rheumatoid arthritis]. Alusík, S, 1998)	0.3
"06), suggesting that dosage should be adjusted by body weight when administered to debilitated elderly patients."	( Pharmacokinetic characteristics of minocycline in debilitated elderly patients. Koike, Y; Kuyama, Y; Matsuyama, N; Minshita, S; Sanaka, M; Takano, K; Yamakana, M; Yamamoto, T, 1999)	0.3
" Administered as single doses, MXFX in a dosage of 150 mg per kg was more active than OFLO in the same dosage, and displayed the same level of activity as RMP in a dosage of 10 mg per kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT in a dosage of 10 mg per kg was more bactericidal than RMP administered in the same dosage, and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99."	( Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Grosset, J; Ji, B, 2000)	0.31
" Proposed dosage is 100 mg per day in sexually transmissible disease with a reduction to 50 mg per day after 15 days in acne."	( [Minocycline]. Bernier, C; Dréno, B, 2001)	0.31
" The primary end points of the study were 1) the percentage of patients with an American College of Rheumatology (ACR) 50% improvement (ACR50) response at 2 years, and 2) the dosage of prednisone at 2 years."	( Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Blakely, KW; Eckhoff, PJ; Fernandez, AM; Haire, CE; Klassen, LW; Leff, RD; Mallek, JA; Moore, GF; O'Dell, JR; Palmer, WR; Paulsen, GA; Sems, KM; Wees, SJ, 2001)	0.31
"Even though minocycline and doxycycline did not substitute for PCP, pretreatment with 32 mg/kg of either drug produced leftward shifts in the PCP dose-response curve."	( Enhancement of the discriminative stimulus effects of phencyclidine by the tetracycline antibiotics doxycycline and minocycline in rats. Balster, RL; Li, H; Munzar, P; Nicholson, KL; Wiley, JL, 2002)	0.31
"5 CFU/g for four different dosing regimens."	( Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Edelstein, MA; Edelstein, PH; Weiss, WJ, 2003)	0.32
" We show that at therapeutic dosage (or at micromolar range), flavopiridol almost completely prevents colchicine-induced apoptosis in cerebellar granule neurones."	( Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Bravo, R; Bruna, A; Caelles, C; Camarasa, J; Camins, A; Canudas, AM; Escubedo, E; Jiménez, A; Jorda, EG; Pallàs, M; Pubill, D; Verdaguer, E, 2003)	0.32
" Tigecycline is only available in an injectable formulation for clinical use unlike currently marketed tetracyclines that are available in oral dosage forms."	( The glycylcyclines: a comparative review with the tetracyclines. Embil, J; Gin, A; Hoban, DJ; Homenuik, K; Karlowsky, JA; Nichol, K; Noreddin, A; Vercaigne, L; Zhanel, GG, 2004)	0.32
" This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies."	( Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Arora, A; Borlongan, CV; Edwards, DJ; Fagan, SC; Feuerstein, G; Hess, DC; Xu, L, 2004)	0.32
"The neuroprotective action of minocycline at clinically suitable dosing regimens and at a therapeutic time window of at least 4-5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of stroke."	( Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. Borlongan, CV; Edwards, D; Fagan, SC; Feuerstein, G; Hess, DC; Hill, WD; Waller, JL; Xu, L; Zheng, J, 2004)	0.32
" Relapses did not occur with the tapering of PSL dosage when the ELISA values decreased to 40% of initial values, although they were still not within the normal range."	( Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. Esaki, C; Ichiki, Y; Izumi, T; Kitajima, Y, 2004)	0.32
" Unlike existing tetracyclines, tigecycline is only available as an intravenous preparation, is administered twice daily although its long half life and post-antibiotic effect may make once daily dosing possible, appears to have good tissue penetration (e."	( Tigecycline: clinical evidence and formulary positioning. Nathwani, D, 2005)	0.33
" Based on pharmacokinetics, no dosage adjustment is warranted based on age or sex."	( Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Fruncillo, RJ; Micalizzi, M; Muralidharan, G; Raible, DG; Troy, SM, 2005)	0.33
" Tetracycline, oxytetracycline, chlortetracycline and minocycline all effectively induced the resulting Escherichia coli MC4100/pTGM biosensor and similar dose-response characteristics were recorded by flow cytometry for all four compounds."	( Construction of an extended range whole-cell tetracycline biosensor by use of the tet(M) resistance gene. Bahl, MI; Hansen, LH; Sørensen, SJ, 2005)	0.33
" Intravenously administered tigecycline (recommended dosage regimen 100 mg initially, followed by 50 mg every 12 hours for 5-14 days) has been approved by the US FDA for the treatment of cSSSIs and cIAIs."	( Tigecycline. Curran, MP; Frampton, JE, 2005)	0.33
" In the present study, we determined the dose-response effects of doxycycline and minocycline on cerebral MMP-9 using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain."	( Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. Guglielmo, BJ; Huang, Y; Lee, CZ; Lin, E; Liu, W; Yang, GY; Yao, JS; Young, WL; Zhai, W, 2006)	0.33
" These dosage effects can be studied by conditionally expressing such proteins at different levels."	( A gene regulation system with four distinct expression levels. Berens, C; Danke, C; Gmeiner, P; Hillen, W; Jäck, HM; Krueger, C; Lochner, S; Pfleiderer, K; Schuh, W, 2006)	0.33
"This system shows that a promoter can be adjusted to different activities and provides an excellent strategy to investigate protein dosage effects."	( A gene regulation system with four distinct expression levels. Berens, C; Danke, C; Gmeiner, P; Hillen, W; Jäck, HM; Krueger, C; Lochner, S; Pfleiderer, K; Schuh, W, 2006)	0.33
"The pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy, adverse events, dosage and administration, drug interactions, and place in therapy of tigecycline are reviewed."	( Tigecycline: a new glycylcycline antimicrobial agent. Kasbekar, N, 2006)	0.33
" Hepatic dosage adjustment is necessary for severe disease; however, no dosage adjustments are necessary for patients with renal impairment."	( Tigecycline: a new glycylcycline antimicrobial agent. Kasbekar, N, 2006)	0.33
" The recommended dosage of tigecycline is 100 mg IV given as a loading dose, followed by 50 mg IV g12h for 5 to 14 days."	( Tigecycline: a glycylcycline antimicrobial agent. Doan, TL; Fung, HB; Mehta, D; Riska, PF, 2006)	0.33
" Tigecycline was aggressively administered at twice the recommended dosage for overt liver failure in light of the severity of this patient's condition."	( Peritoneal fluid penetration of tigecycline. Nicolau, DP; Noskin, GA; Postelnick, MJ; Reddy, P; Scheetz, MH; Stosor, V; Zembower, TR, 2006)	0.33
" We conclude that the neuroprotective mechanism of minocycline is likely not related to direct inhibition of mPT and propose that the mitochondrial effects of minocycline may contribute to toxicity rather than tissue protection at high dosing in animals and humans."	( Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Ekdahl, CT; Elmér, E; Hansson, MJ; Månsson, R; Morota, S; Uchino, H, 2007)	0.34
" Area under the concentration time curve to minimum inhibitory concentration (AUC/MIC) values for tigecycline ranged from 79 to 158 microg h/mL and tigecycline concentrations remained above the MIC (T>MIC) throughout the simulated dosing interval."	( In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Garrison, MW; Nuemiller, JJ, 2007)	0.34
" Acute vestibular adverse events (AVAEs) appeared to be dose proportional, with the incidence being similar in the lowest (1 mg/kg) dosing group (24%) and in the placebo group (26%)."	( Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Plott, RT; Stewart, DM; Torok, HM; Weiss, JS, 2006)	0.33
" A dose-response study with adenoviral vector-mediated vascular endothelial growth factor and a time course study at both 24 and 48 hours postinjection were performed."	( Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Lee, CZ; Xue, Z; Yang, GY; Young, WL; Zhu, Y, 2007)	0.34
" Minocycline at a dosage of 200 mg was administered orally for 5 days."	( Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Anca-Hershkowitz, M; Boaz, M; Dabby, R; Gilad, R; Lampl, Y; Lorberboym, M; Rapoport, A; Sadeh, M, 2007)	0.34
" Finally, minocycline, a drug widely reported to reduce damage in several models of brain injury, was used to test the hypothesis that it can reduce up-regulation of inflammation-related genes when administered using a clinically relevant dosing regime: intraperitoneal injection beginning 6 h after ICH."	( Evolution of the inflammatory response in the brain following intracerebral hemorrhage and effects of delayed minocycline treatment. Schlichter, LC; Wasserman, JK; Zhu, X, 2007)	0.34
" It has rapid bactericidal activity against growing and stationary-phase bacteria, once-daily dosing regimen, and has a low potential for the development of resistance."	( Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Ziglam, H, 2007)	0.34
" Also, an extended-release (ER) tablet formulation of minocycline was approved by the FDA for the treatment of inflammatory lesions of moderate to severe acne vulgaris in patients 12 years and older based on large-scale phase 3 clinical trials that evaluated efficacy and safety, dose-response analysis, and long-term data."	( Recently approved systemic therapies for acne vulgaris and rosacea. Del Rosso, JQ, 2007)	0.34
" Therefore, a correct dosing regimen for the time-dependent molecules (i."	( [Pharmacological rationale for choice of antibiotics for intraabdominal infections]. Mazzei, T; Novelli, A, 2008)	0.35
" Two dosage regimens of minocycline were administered for one week; a high dose of 45 mg/kg 2h after hypoxia-ischemia then 22."	( Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Buller, KM; Carty, ML; Colditz, PB; Wixey, JA, 2008)	0.35
" In contrast, fractionation of the dose at a free AUC associated with a static effect indicated that once daily dosing was superior."	( Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Bowker, KE; Macgowan, AP; Noel, AR, 2008)	0.35
" This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of tigecycline."	( Tigecycline: a new antibiotic. Hylands, J, 2008)	0.35
" The subjects had 11 plasma samples drawn over a dosing interval on days 1, 15, and 30."	( Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Cruttenden, K; DiCenzo, R; Gelbard, H; Hochreiter, J; Mariuz, P; Peterson, DR; Rezk, NL; Schifitto, G, 2008)	0.35
"These results suggest that a dosage adjustment of either drug is not necessary during coadministration of tigecycline and warfarin."	( Evaluation of a potential tigecycline-warfarin drug interaction. Harper, DM; Matschke, K; Raible, DG; Speth, JL; Zimmerman, JJ, 2008)	0.35
" The most frequently suggested causes for explaining these continuous failures are unawareness of the correct dosage to be used, the ideal duration of the clinical trial in phase III, sample size, the search for a primary outcome for measurement other than survival, the need for biomarkers giving information on the progression of the disease and whether this is modified by the introduction of the drug for study."	( [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine]. Gámez, J, 2008)	0.35
" As new pharmacokinetic data emerge, clarification of the pharmacokinetic/pharmacodynamic (PK/PD) profile of colistin as well as appropriate dosing seems urgent, while development of resistance must be carefully monitored."	( Multidrug-resistant Gram-negative infections: what are the treatment options? Giamarellou, H; Poulakou, G, 2009)	0.35
"56 log(10) cfu/mL at 12 h (time of one dosing interval), with a bacteriostatic profile when considering 24 h colony counts (similar counts at 0 and 24 h)."	( In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline. Aguilar, L; Alou, L; Cafini, F; García-Escribano, N; García-Rey, C; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2009)	0.35
" Reduced CSF concentrations urge caution in the treatment of cerebritis with standard dosing of tigecycline."	( Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Levasseur, K; Nicolau, DP; Ray, L; Scheetz, MH, 2010)	0.36
" No adjustment of tigecycline maintenance dosage is warranted in patients with compensated or moderately decompensated cirrhosis; doses should be reduced by 50%, to 25 mg, every 12 hours in patients with severely decompensated disease."	( Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. Baird-Bellaire, SJ; Böhmer, GM; Buecheler, R; Gleiter, CH; Korth-Bradley, JM; Morgan, MY; Patat, AA; Troy, SM, 2011)	0.37
" A computerised pharmacodynamic bicompartmental model simulated three tigecycline twice-daily dosing regimens over 48h: 50mg (100mg loading dose); 100mg; and 150 mg."	( Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Aguilar, L; Alou, L; Cafini, F; Garcia-Escribano, N; Garcia-Rey, C; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2010)	0.36
" Nearly 70% of the respondent hospitals reported having a vancomycinspecific dosing or monitoring guideline in place."	( Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Hennenfent, J; Lambert, BL; McBride, MV; Rodvold, KA; Schiff, G; Schumock, GT; Trese, AM; Tverdek, F; Yang, Y, 2010)	0.36
"Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats."	( Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats. Abdel Baki, SG; Bergold, PJ; Fenton, AA; Haber, M; Schwab, B, 2010)	0.36
" This can prevent the development of intractable PHN and attenuate morphine antinociceptive tolerance and further improve the efficacy of morphine and therefore reducing its dosage and side effects."	( The combination of morphine and minocycline may be a good treatment for intractable post-herpetic neuralgia. Chen, S; Hui, H; Xue, Y; Zhang, D, 2010)	0.36
" These results suggest that neither drug has therapeutic efficacy, however dosing and/or administration issues may have played a role."	( Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury. Kelso, ML; Pauly, JR; Scheff, NN; Scheff, SW, 2011)	0.37
" Use of tetracycline for acne has yielded to second-generation molecules doxycycline and minocycline, which are associated with numerous benefits over their predecessor, especially less frequent dosing and improved safety."	( Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. Kircik, LH, 2010)	0.36
" the absence of a control group, their retrospective nature, variable dosing and duration of therapy, simultaneous administration of other antibiotics in >70% and a lack of resistance development monitoring."	( Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Giamarellou, H, 2010)	0.36
" For a successful therapy it is of vital importance that these compounds are used judiciously and dosed appropriately."	( Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Derendorf, H; Estes, KS, 2010)	0.36
"In conclusion, the present results indicate that minocycline in the given dosage has little or no effect on the recovery of human olfactory function following postinfectious olfactory loss."	( Treatment of postinfectious olfactory disorders with minocycline: a double-blind, placebo-controlled study. Herting, B; Hummel, T; Kern, R; Lill, K; Reden, J, 2011)	0.37
" For this study, mechanical hyperalgesia and IENF density were measured in rats receiving oxaliplatin, given at a dosage of 2 mg/kg every other day for four injections."	( Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Boyette-Davis, J; Dougherty, PM, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Based on these pharmacokinetic data, tigecycline requires no dosage adjustment in patients with renal impairment."	( Tigecycline pharmacokinetics in subjects with various degrees of renal function. Fruncillo, RJ; Korth-Bradley, JM; Matschke, K; Muralidharan, G; Raible, DG; Speth, JL; Troy, SM, 2012)	0.38
" Repeated oral dosing (days 14-20) with nimesulide attenuated pain behaviour and the activation of microglia in the ipsilateral spinal cord at day 21."	( The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain. Bennett, AJ; Burston, JJ; Chapman, V; Hathway, GJ; Kendall, DA; Pearson, RG; Sagar, DR; Scammell, BE; Woodhams, SG, 2011)	0.37
"Tigecycline, a broad-spectrum antibiotic used for treating serious bacterial infections in adults, may be suitable for pediatric use once an appropriate dosage is determined."	( Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Balter, I; Cooper, CA; Dartois, N; Jouve, S; Korth-Bradley, J; Purdy, J; Yan, JL, 2012)	0.38
"A tigecycline dosage of ∼1."	( Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Balter, I; Cooper, CA; Dartois, N; Jouve, S; Korth-Bradley, J; Purdy, J; Yan, JL, 2012)	0.38
" In this mouse model of surgical implant MSSA or MRSA infection, daptomycin and tigecycline prophylaxis were effective over a broader dosage range than vancomycin."	( Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Billi, F; Francis, KP; Miller, LS; Niska, JA; Pribaz, JR; Ramos, RI; Shahbazian, JH, 2012)	0.38
" Post-mortem brains were prepared either for immunohistology (n = 16) or for iron dosage (n = 8)."	( Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced MRI. Ballet, S; Berthezène, Y; Chauveau, F; Cho, TH; Dencausse, A; Durand, A; Marinescu, M; Nighoghossian, N; Riou, A; Wiart, M, 2013)	0.39
"At peak postnatal hyperbilirubinemia, j/j Gunn rat pups were dosed with sulfadimethoxine to induce bilirubin encephalopathy."	( Lipid peroxidation is not the primary mechanism of bilirubin-induced neurologic dysfunction in jaundiced Gunn rat pups. Daood, MJ; Hoyson, M; Watchko, JF, 2012)	0.38
" Minimal organ toxicity and lack of dosage adjustment in most patients are important considerations for tigecycline use."	( Tigecycline: an update. Babinchak, T; Stein, GE, 2013)	0.39
"6% for all patients who received the standard dosage (183/230), 86."	( Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. Bassetti, M; Bodmann, KF; Capparella, MR; Dupont, H; Eckmann, C; García, MS; Guirao, X; Heizmann, WR; Montravers, P; Simoneau, D, 2013)	0.39
" A lower CFR is predicted against certain Gram-negative pathogens with the current standard tigecycline dosing regimen, irrespective of TBW."	( Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. Pai, MP, 2014)	0.4
" The minocycline dosage ranged from 25-100 mg daily, based on weight."	( Electrocortical changes associated with minocycline treatment in fragile X syndrome. Adams, P; Chechi, T; Hagerman, R; Hessl, D; Leigh, MJ; Nanakul, R; Olichney, J; Schneider, A, 2013)	0.39
" However, when the MPCs of dual-drug therapy were in conjunction with clinical pharmacokinetic profiles, combinations may not strictly curb the occurrence of resistance at current dosage regimen."	( In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. Bai, N; Cai, X; Cai, Y; Cui, J; Liang, B; Ni, W; Wang, R, 2013)	0.39
" Adverse events were not correlated with dosing strategy."	( Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Christensen, DM; Griffin, AT; Harting, JA, 2013)	0.39
" Subjects in an ascending single-dose study (n = 40) received 25-150 mg intravenously, whereas subjects in two multiple-dose studies received every 12-hour (q12h) dosing with 25 mg (n = 10) or 25, 50, or 100 then 50 mg (n = 30)."	( Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Gandhi, A; Korth-Bradley, J; Matschke, K; Yamashita, N, 2014)	0.4
" The aim of this study was to evaluate the current standard tigecycline dosage regimen from a pharmacokinetic/pharmacodynamic (PK/PD) perspective."	( Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Cai, J; Chen, S; Dong, H; Dong, Y; Hu, S; Sun, J; Wang, T; Wang, X; Xie, J; Zhang, D; Zhang, W, 2014)	0.4
"Tigecycline exhibits excellent in vitro antimicrobial activity, however the standard tigecycline dosing regimen fails to achieve the best outcome in vivo for the common drug-resistant strains, including Acinetobacter baumannii, Enterobacter spp, and Klebsiella pneumoniae."	( Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Cai, J; Chen, S; Dong, H; Dong, Y; Hu, S; Sun, J; Wang, T; Wang, X; Xie, J; Zhang, D; Zhang, W, 2014)	0.4
"In the absence of new drugs on the horizon, rather than using a single fixed dosing regimen, tigecycline dosing needs to be optimized in order to achieve the desired successful clinical response and to prevent an escalation in drug resistance."	( Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Cai, J; Chen, S; Dong, H; Dong, Y; Hu, S; Sun, J; Wang, T; Wang, X; Xie, J; Zhang, D; Zhang, W, 2014)	0.4
" Under the diagnosis of cardiac tamponade, the patient was treated with pericardial drainage and local chemotherapy(intra-pericardial dosage of paclitaxel 45 mg and minocycline 100 mg)with the aim of preventing the accumulation of pericardial effusion."	( [A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillation of paclitaxel and minocycline]. Abe, S; Goto, H; Kamei, T; Nakajima, T; Taniwaka, K; Yoshioka, T, 2014)	0.4
" This study evaluated the pharmacokinetics of oral minocycline in dogs (M), determined the effects of concurrent administration of sucralfate and minocycline (MS) on minocycline pharmacokinetics, determined the effects of delaying sucralfate administration by 2 h (MS+2) on minocycline pharmacokinetics, and established dosing recommendations based on pharmacodynamic indices."	( Effect of sucralfate on oral minocycline absorption in healthy dogs. Harris, A; Heinrich, E; KuKanich, B; KuKanich, K, 2014)	0.4
"62% was predicted for tigecycline at current dosage (50 mg q12h)."	( A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Bai, N; Cai, Y; Cui, JC; Liang, BB; Liu, YP; Ni, WT; Wang, R, 2014)	0.4
"The aim of this study was to establish rational dosage recommendations for minocycline use in dogs."	( Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. Guardabassi, L; Maaland, MG; Papich, MG, 2014)	0.4
"Besides dosage recommendations for therapy of meticillin-resistant Staphylococcus pseudintermedius infections in dogs, the study also provides PK/PD data necessary to consider species-specific clinical breakpoints for minocycline susceptibility testing."	( Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. Guardabassi, L; Maaland, MG; Papich, MG, 2014)	0.4
" Tigecycline is relatively unstable after reconstitution, and this instability may limit the use of the drug in ambulatory infusions for the treatment of infection and may prevent the development of optimal dosing schedules for the treatment of AML."	( A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. Goard, CA; Gronda, M; Hurren, R; Jhas, B; Jitkova, Y; Schimmer, AD; Wang, X, 2014)	0.4
" The safety profile and efficacy of high dosing regimen use were investigated."	( High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Antonelli, M; Bello, G; Bernini, V; De Pascale, G; Maviglia, R; Montini, L; Pennisi, M; Spanu, T; Tumbarello, M, 2014)	0.4
" The objective of this in vitro study has been to determine what dosage of TG causes changes in the morphology and number of osteoblasts."	( In vitro evaluation of a multifunctional nano drug delivery system based on tigecycline-loaded calcium-phosphate/ poly-DL-lactide-co-glycolide. Ignjatović, NL; Lyngstadaas, SP; Ninkov, P; Sabetrasekh, R; Uskoković, DP, 2014)	0.4
" While the optimal dosage and the effects of long-term use still need to be determined, these findings suggest further investigation into the effect minocycline has on patients with Angelman syndrome is warranted."	( An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. Banko, JL; Ciarlone, SL; Gieron-Korthals, M; Grieco, JC; Heussler, HS; Philpot, RM; Schoenberg, MR; Smith, AG; Weeber, EJ, 2014)	0.4
" Dosage regimen of tigecycline: loading dose 100 mg, 50 mg every 12 hours as maintenance therapy for 2-4 weeks."	( [Efficacy of tigecycline in treating severe infections of patients with hematological diseases]. Fu, R; Gao, S; Guan, J; Hu, Z; Li, L; Liu, H; Qu, W; Shao, Q; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wang, Y; Wu, Y; Xing, L; Yu, H, 2014)	0.4
" The usual dosage of doxycycline or minocycline was 100mg intravenous or per os twice daily (usually with a 200mg loading dose for minocycline)."	( Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Falagas, ME; Kapaskelis, A; Roussos, NS; Triarides, NA; Vardakas, KZ, 2015)	0.42
" The purpose of this study was to determine the pharmacokinetics of minocycline in domestic cats in order to facilitate dosage decisions."	( Pharmacokinetics of minocycline in domestic cats. Cohn, LA; Kerl, ME; Papich, MG; Tynan, BE, 2016)	0.43
" Although some gastrointestinal upset may occur, one 50 mg capsule orally q24h would provide appropriate dosing for most cats."	( Pharmacokinetics of minocycline in domestic cats. Cohn, LA; Kerl, ME; Papich, MG; Tynan, BE, 2016)	0.43
" These studies show that aggressive polymyxin-based dosing in combination with clinically achievable tigecycline concentrations results in early synergistic activity that is not sustained beyond 8 h, whereas combinations with higher tigecycline concentrations result in sustained bactericidal activity against both isolates at both inocula."	( Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Bulitta, JB; Diep, J; Forrest, A; Holden, PN; Li, J; Ly, NS; Nation, RL; Rao, GG; Tsuji, BT, 2016)	0.43
" Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective."	( Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Steenbergen, J; Tanaka, SK; Villano, S, 2016)	0.43
" Oral minocycline dosed at 4 mg/kg every 12 h might be adequate for the treatment of susceptible bacterial infections in foals."	( Comparative pharmacokinetics of minocycline in foals and adult horses. Berghaus, LJ; Burton, AJ; Giguère, S; Haspel, AD, 2017)	0.46
"Tigecycline, one of the few therapeutic options against multidrug-resistant Acinetobacter baumannii, reaches subinhibitory serum concentrations only with cautious clinical dosing and pharmacokinetics."	( Biofilm Formation Restrained by Subinhibitory Concentrations of Tigecyclin in Acinetobacter baumannii Is Associated with Downregulation of Efflux Pumps. Cao, J; Chen, H; Liu, H; Zhang, X; Zhou, C; Zhou, T, 2017)	0.46
" In study 2, to test whether extended dosing of minocycline may be necessary to reduce the ongoing pathologic alterations, a separate group of animals received minocycline for 9days."	( Differential effects of minocycline on microglial activation and neurodegeneration following closed head injury in the neonate rat. Hanlon, LA; Huh, JW; Raghupathi, R, 2017)	0.46
" Designing rational dosage regimens for patients to maximize the antimicrobial activity and minimize the emergence and prevalence of resistance is recommended."	( Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update. Ardebili, A; Mardaneh, J; Razavi Nikoo, H, 2017)	0.46
" Although different dosing regimens have been studied, there is a lack of standardized comparator trials to determine optimal dosing and duration of each oral antibiotic used in acne."	( Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review. Bienenfeld, A; Nagler, AR; Orlow, SJ, 2017)	0.46
" Oral medications with effects on the ocular surface are of interest in patients where repeated topical dosing is limited."	( The presence of minocycline in the tear film of normal horses following oral administration and its anticollagenase activity. Gibson, DJ; Jeong, SY; Monk, CS; Plummer, CE, 2018)	0.48
"We present the case of a 72-year-old Greek woman with postoperative spondylodiscitis caused by a multidrug-resistant Acinetobacter baumannii strain that was successfully treated, after she declined surgical treatment, with prolonged and high dosage of tigecycline."	( Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report. Chrysanthidis, T; Georgiou, A; Loli, G; Metallidis, S; Morfesis, P; Nanoudis, S; Tsachouridou, O; Zebekakis, P, 2017)	0.46
" Minocycline is an attractive option because of the higher cost of doxycycline and new pharmacokinetic information for dogs that provides guidance for appropriate dosage regimens to achieve pharmacokinetic-pharmacodynamic (PK-PD) targets."	( Considerations for using minocycline vs doxycycline for treatment of canine heartworm disease. Papich, MG, 2017)	0.46
"A 47-year-old male patient with severe acute cholangitis who developed sepsis was treated with a high dosage (100 mg twice daily) of tigecycline."	( A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Dong, L; Wu, X; Zhang, X; Zhao, P, 2017)	0.46
"In this study, we tested our working hypothesis that inhibiting the activation of microglia by systemic minocycline treatments can decrease the dosage of local tramadol injection in inflammatory pain."	( Pain-Relieving Effectiveness of Co-Treatment with Local Tramadol and Systemic Minocycline in Carrageenan-Induced Inflammatory Pain Model. Mert, T; Sahin, E; Sahin, M; Yaman, S, 2018)	0.48
" Myelin content is restored by minocycline (MINO) plus n-acetylcysteine (NAC) or MINO alone when first dosed at 12 h after CHI."	( Minocycline plus N-acetylcysteine protect oligodendrocytes when first dosed 12 hours after closed head injury in mice. Bergold, PJ; Nikulina, E; Sangobowale, M, 2018)	0.48
" The risk of side effects was related to the TGC duration, although not increased as the dosage rose."	( Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Chen, Z; Shi, X, 2018)	0.48
" We recommend that veterinarians prescribe the recommended 10 mg/kg doxycycline for canine heartworm treatment and reduce the dosage to 5 mg/kg in cases of severe gastrointestinal side effects in order to improve owner compliance in administration of medications."	( Efficacy and side effects of doxycycline versus minocycline in the three-dose melarsomine canine adulticidal heartworm treatment protocol. Bradner, JL; Day, KM; Dzimianski, MT; Moorhead, AR; Savadelis, MD; Wolstenholme, AJ, 2018)	0.48
" Despite low toxicity, poor availability of silver cations mandates a high dosage to effectively eradicate infections."	( Minocycline and Silver Dual-Loaded Polyphosphoester-Based Nanoparticles for Treatment of Resistant Pseudomonas aeruginosa. Cannon, CL; Chen, Q; Li, R; Sacchettini, JC; Salazar, AJ; Shah, KN; Shah, PN; Wooley, KL; Zhang, F, 2019)	0.51
"We sought to assess whether CA use is associated with an increased risk of PTCS or papilledema and whether the risk depends upon dosage or duration of CA intake."	( Association between cycline antibiotic and development of pseudotumor cerebri syndrome. Blachley, TS; Eldweik, L; Lee, MS; McClelland, C; Stein, JD, 2019)	0.51
" Moreover, there was no dose-response effect whereby greater CA use was associated with a higher PTCS risk."	( Association between cycline antibiotic and development of pseudotumor cerebri syndrome. Blachley, TS; Eldweik, L; Lee, MS; McClelland, C; Stein, JD, 2019)	0.51
"Using patient-derived glioblastoma stem cell (GSC) cultures from 15 GBM patients, we described stem cell properties of individual cultures, determined the dose-response relationships of the drugs in the CUSP9, and assessed the efficacy the CUSP9 combination with TMZ in concentrations clinically achievable."	( The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019)	0.51
" Next, we performed a 28 day HFS-MAC model dose-response study in which we mimicked pulmonary concentration-time profiles achieved in patients."	( Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. Bendet, P; Deshpande, D; Gumbo, T; Hoefsloot, W; Koeken, VACM; Lee, PS; Magombedze, G; Pennings, L; Ruth, MM; Sangen, JJN; van Ingen, J; Wertheim, HFL; Zweijpfenning, S, 2019)	0.51
" Positron emission tomography (PET) imaging targeting the translocator protein (TSPO) was applied here to quantify effects of different dosing regimens of the anti-inflammatory drug minocycline during the latent phase in two rodent models of epileptogenesis."	( TSPO PET Identifies Different Anti-inflammatory Minocycline Treatment Response in Two Rodent Models of Epileptogenesis. Bankstahl, JP; Bankstahl, M; Bascuñana, P; Brackhan, M; Langer, BLN; Leiter, I; Ross, TL; Wolf, BJ, 2020)	0.56
" Patients received reirradiation with dosing based on radiation oncologist judgment, bevacizumab 10 mg/kg IV every two weeks, and oral minocycline twice a day."	( Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. Anker, CJ; Boucher, K; Burt, LM; Cohen, AL; Colman, H; Jensen, R; Johnson, B; Salzman, K; Shrieve, DC, 2020)	0.56
" Generally, a higher dosage of tigecycline for the treatment of serious infections has been recommended in previous reports."	( Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline. Leng, B; Shen, C; Wang, C; Wang, W; Yan, G; Zhang, W, 2021)	0.62
"The use of standard tigecycline dosing is predicted to have a good clinical outcome for patients suffering from complicated skin and skin structure infection (cSSSI) with MICs ≤ 0."	( Analysis based on Monte Carlo simulation: How effective is tigecycline in routine antimicrobial therapy? Bai, H; Fan, G; Jiang, K; Jin, L; Liu, X; Liu, Y; Ren, F; Sun, N; Wu, S, 2021)	0.62
" We then simulated 7-10 day human dosing of minocycline and the combination."	( The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)	0.62
" The addition of simulated free rifampicin associated with dosing 300 mg q12h reduced the 24 h minocycline fAUC/MICs."	( The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)	0.62
" These data show that in addition to the structural integrity of the dendritic arbor, spine and synapse density can be successfully targeted with drugs first dosed days after injury."	( Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury. Alexis, A; Bergold, PJ; Nikulina, E; Rahman, SN; Whitney, K, 2021)	0.62
" maltophilia isolates were examined, along with the pharmacokinetic profiles of 4 tetracycline derivatives, to predict achievable pharmacodynamic exposures with standard intravenous dosing regimens."	( An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Lasco, TM; Phe, K; Tam, VH; Zidaru, A, 2022)	0.72
"An integrated evaluation for antimicrobial formulary decision-making addressed local susceptibility data, pharmacokinetics, pharmacodynamics, dosing regimens, and drug acquisition costs."	( An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Lasco, TM; Phe, K; Tam, VH; Zidaru, A, 2022)	0.72
" The objective of this study is to investigate weight-based dosing protocols and the impact of food intake, including high-fat meals, on the absorption, and clinical efficacy of sarecycline, a novel oral narrow-spectrum third-generation tetracycline-class antibiotic approved by the Food and Drug Administration for acne vulgaris treatment."	( Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy. Baldwin, H; Bunick, CG; Carrothers, T; Damiani, G; Del Rosso, JQ; Graber, E; Grada, A; Hanze, E; McNamee, B; Moore, AY; Obagi, Z; Stein Gold, L, 2022)	0.72
" We first explored several different regimens of minocycline dosing with the initial dose 24 h after injury and 2 h prior to hypoxemia, utilizing short-term neuropathology to select the most promising candidate."	( Acute minocycline administration reduces brain injury and improves long-term functional outcomes after delayed hypoxemia following traumatic brain injury. Celorrio, M; Friess, SH; Payne, C; Shumilov, K; Vadivelu, S, 2022)	0.72
" However, no pharmacodynamic data are available to guide dosing or justify this breakpoint."	( Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. Fratoni, AJ; Kuti, JL; Nicolau, DP, 2022)	0.72
" Three periodontal drug products with different dosage forms were tested: Atridox, Arestin, and PerioChip."	( Modification of small dissolution chamber system for long-acting periodontal drug product evaluation. Li, SK; Murawsky, M; Wanasathop, A, 2022)	0.72
"A total of 40 patients were enrolled and randomly assigned into two groups which were either given minocycline (100 mg per day) for 8 weeks with IPL treatments three times at weeks 0, 4, and 8, or the same dosage of minocycline only."	( A randomized, controlled trial of intense pulsed light in combination with minocycline hydrochloride for the treatment of inflammatory acne vulgaris. Gao, L; Li, K; Qu, H; Wang, G; Wang, Y; Yang, F, 2022)	0.72
" Changes in rash grades were observed, as well as the dosage of minocycline."	( Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial. Cui, H; Li, J; Lu, X; Tan, K; Zhang, J; Zhang, X, )	0.13
"This study evaluated the safe dosage of minocycline hydrochloride (Mino) eye drops and investigated the potential for the prevention or reduction of retinal damage in a diabetic rat model."	( Safety evaluation and pharmacodynamics of minocycline hydrochloride eye drops. Li, X; Pei, S; Ye, Z; Zhang, W; Zheng, D; Zhu, L, 2022)	0.72
" Fewer studies with more delayed dosing have yielded similar results."	( Treating Traumatic Brain Injury with Minocycline. Bergold, PJ; Furhang, R; Lawless, S, 2023)	0.91

Pathway	Proteins	Compounds
Minocycline Action Pathway	1	4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLS protein	Homo sapiens (human)	Potency	15.8489	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	22.4255	0.0008	11.3822	44.6684	AID686978; AID686979
EWS/FLI fusion protein	Homo sapiens (human)	Potency	5.9947	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	26.8325	0.0002	29.3054	16,493.5996	AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Stromelysin-1	Homo sapiens (human)	IC50 (µMol)	290.0000	0.0000	1.1484	10.0000	AID1863876
Matrilysin	Homo sapiens (human)	IC50 (µMol)	125.0000	0.0014	2.0859	10.0000	AID1863877
Multidrug transporter MdfA	Escherichia coli K-12	IC50 (µMol)	2.6000	2.5000	2.5500	2.6000	AID71156
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0000	2.8005	10.0000	AID1210069
Matrix metalloproteinase-9	Homo sapiens (human)	IC50 (µMol)	180.0000	0.0000	0.7053	10.0000	AID1863879
Cytochrome P450 2J2	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0120	2.5312	9.4700	AID1210069
Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)	IC50 (µMol)	15.0000	2.4000	6.4097	9.0000	AID1734010
Protein-arginine deiminase type-4	Homo sapiens (human)	IC50 (µMol)	620.0000	2.5000	4.2000	5.9000	AID320706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Albumin	Homo sapiens (human)	Kd	12.0000	0.0893	3.3135	8.0000	AID557095
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
proteolysis	Stromelysin-1	Homo sapiens (human)
extracellular matrix disassembly	Stromelysin-1	Homo sapiens (human)
protein catabolic process	Stromelysin-1	Homo sapiens (human)
regulation of cell migration	Stromelysin-1	Homo sapiens (human)
collagen catabolic process	Stromelysin-1	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Stromelysin-1	Homo sapiens (human)
cellular response to reactive oxygen species	Stromelysin-1	Homo sapiens (human)
innate immune response	Stromelysin-1	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Stromelysin-1	Homo sapiens (human)
cellular response to lipopolysaccharide	Stromelysin-1	Homo sapiens (human)
cellular response to amino acid stimulus	Stromelysin-1	Homo sapiens (human)
cellular response to UV-A	Stromelysin-1	Homo sapiens (human)
cellular response to nitric oxide	Stromelysin-1	Homo sapiens (human)
regulation of neuroinflammatory response	Stromelysin-1	Homo sapiens (human)
response to amyloid-beta	Stromelysin-1	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Stromelysin-1	Homo sapiens (human)
extracellular matrix organization	Stromelysin-1	Homo sapiens (human)
membrane protein ectodomain proteolysis	Matrilysin	Homo sapiens (human)
membrane protein intracellular domain proteolysis	Matrilysin	Homo sapiens (human)
antibacterial peptide secretion	Matrilysin	Homo sapiens (human)
antibacterial peptide biosynthetic process	Matrilysin	Homo sapiens (human)
proteolysis	Matrilysin	Homo sapiens (human)
response to xenobiotic stimulus	Matrilysin	Homo sapiens (human)
extracellular matrix disassembly	Matrilysin	Homo sapiens (human)
positive regulation of cell migration	Matrilysin	Homo sapiens (human)
collagen catabolic process	Matrilysin	Homo sapiens (human)
regulation of cell population proliferation	Matrilysin	Homo sapiens (human)
defense response to Gram-negative bacterium	Matrilysin	Homo sapiens (human)
defense response to Gram-positive bacterium	Matrilysin	Homo sapiens (human)
extracellular matrix organization	Matrilysin	Homo sapiens (human)
regulation of cellular pH	Multidrug transporter MdfA	Escherichia coli K-12
sodium ion transmembrane transport	Multidrug transporter MdfA	Escherichia coli K-12
response to antibiotic	Multidrug transporter MdfA	Escherichia coli K-12
transmembrane transport	Multidrug transporter MdfA	Escherichia coli K-12
potassium ion transmembrane transport	Multidrug transporter MdfA	Escherichia coli K-12
proton transmembrane transport	Multidrug transporter MdfA	Escherichia coli K-12
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug transporter MdfA	Escherichia coli K-12
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
skeletal system development	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of protein phosphorylation	Matrix metalloproteinase-9	Homo sapiens (human)
proteolysis	Matrix metalloproteinase-9	Homo sapiens (human)
apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
embryo implantation	Matrix metalloproteinase-9	Homo sapiens (human)
cell migration	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular matrix disassembly	Matrix metalloproteinase-9	Homo sapiens (human)
macrophage differentiation	Matrix metalloproteinase-9	Homo sapiens (human)
collagen catabolic process	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to reactive oxygen species	Matrix metalloproteinase-9	Homo sapiens (human)
endodermal cell differentiation	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of DNA binding	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
ephrin receptor signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of keratinocyte migration	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to lipopolysaccharide	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to cadmium ion	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to UV-A	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Matrix metalloproteinase-9	Homo sapiens (human)
regulation of neuroinflammatory response	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of receptor binding	Matrix metalloproteinase-9	Homo sapiens (human)
response to amyloid-beta	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney development	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of cation channel activity	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular matrix organization	Matrix metalloproteinase-9	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
icosanoid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
regulation of heart contraction	Cytochrome P450 2J2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
protein poly-ADP-ribosylation	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
negative regulation of gene expression	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
chromatin organization	Protein-arginine deiminase type-4	Homo sapiens (human)
nucleosome assembly	Protein-arginine deiminase type-4	Homo sapiens (human)
chromatin remodeling	Protein-arginine deiminase type-4	Homo sapiens (human)
stem cell population maintenance	Protein-arginine deiminase type-4	Homo sapiens (human)
protein modification process	Protein-arginine deiminase type-4	Homo sapiens (human)
post-translational protein modification	Protein-arginine deiminase type-4	Homo sapiens (human)
innate immune response	Protein-arginine deiminase type-4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
endopeptidase activity	Stromelysin-1	Homo sapiens (human)
metalloendopeptidase activity	Stromelysin-1	Homo sapiens (human)
serine-type endopeptidase activity	Stromelysin-1	Homo sapiens (human)
protein binding	Stromelysin-1	Homo sapiens (human)
peptidase activity	Stromelysin-1	Homo sapiens (human)
metallopeptidase activity	Stromelysin-1	Homo sapiens (human)
zinc ion binding	Stromelysin-1	Homo sapiens (human)
endopeptidase activity	Matrilysin	Homo sapiens (human)
metalloendopeptidase activity	Matrilysin	Homo sapiens (human)
serine-type endopeptidase activity	Matrilysin	Homo sapiens (human)
protein binding	Matrilysin	Homo sapiens (human)
metallopeptidase activity	Matrilysin	Homo sapiens (human)
zinc ion binding	Matrilysin	Homo sapiens (human)
sodium:proton antiporter activity	Multidrug transporter MdfA	Escherichia coli K-12
potassium:proton antiporter activity	Multidrug transporter MdfA	Escherichia coli K-12
transmembrane transporter activity	Multidrug transporter MdfA	Escherichia coli K-12
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
endopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
metalloendopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
serine-type endopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
protein binding	Matrix metalloproteinase-9	Homo sapiens (human)
collagen binding	Matrix metalloproteinase-9	Homo sapiens (human)
peptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
metallopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
zinc ion binding	Matrix metalloproteinase-9	Homo sapiens (human)
identical protein binding	Matrix metalloproteinase-9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
iron ion binding	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
heme binding	Cytochrome P450 2J2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2J2	Homo sapiens (human)
transcription corepressor activity	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
protein binding	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
nucleotidyltransferase activity	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
NAD+ binding	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
protein-arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
calcium ion binding	Protein-arginine deiminase type-4	Homo sapiens (human)
protein binding	Protein-arginine deiminase type-4	Homo sapiens (human)
identical protein binding	Protein-arginine deiminase type-4	Homo sapiens (human)
histone arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R2 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R8 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R17 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R26 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
extracellular region	Stromelysin-1	Homo sapiens (human)
nucleus	Stromelysin-1	Homo sapiens (human)
mitochondrion	Stromelysin-1	Homo sapiens (human)
cytosol	Stromelysin-1	Homo sapiens (human)
extracellular matrix	Stromelysin-1	Homo sapiens (human)
extracellular space	Stromelysin-1	Homo sapiens (human)
extracellular region	Matrilysin	Homo sapiens (human)
extracellular matrix	Matrilysin	Homo sapiens (human)
extracellular exosome	Matrilysin	Homo sapiens (human)
extracellular space	Matrilysin	Homo sapiens (human)
plasma membrane	Multidrug transporter MdfA	Escherichia coli K-12
membrane	Multidrug transporter MdfA	Escherichia coli K-12
plasma membrane	Multidrug transporter MdfA	Escherichia coli K-12
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
extracellular region	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular space	Matrix metalloproteinase-9	Homo sapiens (human)
collagen-containing extracellular matrix	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular exosome	Matrix metalloproteinase-9	Homo sapiens (human)
tertiary granule lumen	Matrix metalloproteinase-9	Homo sapiens (human)
ficolin-1-rich granule lumen	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular space	Matrix metalloproteinase-9	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2J2	Homo sapiens (human)
extracellular exosome	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Cytochrome P450 2J2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2J2	Homo sapiens (human)
nucleus	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
cytoplasm	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
nucleus	Protein mono-ADP-ribosyltransferase PARP15	Homo sapiens (human)
nucleus	Protein-arginine deiminase type-4	Homo sapiens (human)
nucleoplasm	Protein-arginine deiminase type-4	Homo sapiens (human)
cytosol	Protein-arginine deiminase type-4	Homo sapiens (human)
protein-containing complex	Protein-arginine deiminase type-4	Homo sapiens (human)
nucleus	Protein-arginine deiminase type-4	Homo sapiens (human)
cytoplasm	Protein-arginine deiminase type-4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (822)

Assay ID	Title	Year	Journal	Article
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347081	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347084	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347158	ZIKV-mCherry secondary qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347087	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347088	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID544554	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID585734	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated metL gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID318654	Antibacterial activity against vancomycin-resistant Enterococcus faecium KU1778 clinical isolate by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID544954	Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID422942	Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
AID553506	Ratio of AUC to MIC in methicillin-resistant Staphylococcus aureus infected in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID557092	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1428626	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID373036	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ52 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID520958	Antimicrobial activity against Corynebacterium minutissimum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID70765	In vitro minimum inhibitory concentration against Escherichia coli UBMS 90-4 (tet M ribosomal protection).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID544956	Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID556348	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained from bronchial aspirations expressing 23S rRNA A2063G mutant gene and P1 RFLP type I gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
AID495517	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID278066	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID571765	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID571931	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-S623N mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID585739	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated nikD gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID565812	Antimicrobial activity against Neisseria meningitidis assessed as resistant isolate by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
AID396497	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(D), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID285162	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID278725	Antimicrobial activity against methicillin-resistant Staphylococcus aureus embedded in MRD biofilm model at 3 mg/ml after 15 mins in drug assessed as 24 hr regrowth	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID323256	Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID530583	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae isolate 2p with A2604G mutation by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID322986	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2063G mutant isolate 6	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID565309	Antibacterial activity against Mycoplasma genitalium by quantitative TaqMan PCR method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID601188	Antimicrobial activity against tetracycline-susceptible Klebsiella pneumoniae isolate 109 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID396268	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID544958	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID565315	Antibacterial activity against Mycoplasma genitalium TW48-5G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID555296	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID509849	Antibacterial activity against Escherichia coli DH10B expressing SK2 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID1781724	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID396272	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID67723	Minimum inhibition concentration against Enterococcus faecalis	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Synthesis and biological evaluation of 9-substituted tetracycline derivatives.
AID373040	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ58 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID429058	Antimicrobial activity against tetracycline-resistant Ureaplasma sp. isolate overexpressing tet(M) gene	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracyclines.
AID587830	Antibacterial activity against wild type Staphylococcus aureus Smith ATCC 13709 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID357125	Effect on IFN-gamma-induced STAT1 activation in Sprague-Dawley rat primary microglial cells at 100 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID1241221	Inhibition of pre-miR-372 (unknown origin) cleavage at U31, G32 and U33 at 1 to 100 uM after 15 mins by RNase footprinting assay in presence of RNase-S1	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID422943	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae harboring A2063G transition in domain V of 23S rRNA isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
AID553485	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMH 32024 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg administered every 12 hrs measured after 24 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID283217	Antimicrobial activity against Burkholderia cepacia complex isolated from cystic fibrosis patient by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID396501	Antibacterial activity against tetracycline-resistant Escherichia coli with single drug resistance determinant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID373038	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate NJ59 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID206304	In vitro antibacterial activity against Staphylococcus aureus UBMS 90-3 sensitive	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID548473	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID283394	Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID207660	Minimum inhibition concentration against Methicillin resistant Staphylococcus aureus	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Synthesis and biological evaluation of 9-substituted tetracycline derivatives.
AID558080	Inhibition of PAR2-mediated IL1-beta and SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM by ELISA	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID555513	Antibacterial activity against methicillin-resistant, Linezolid non-susceptible coagulase-negative Staphylococcus epidermidis 345 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID565328	Antibacterial activity against Mycoplasma genitalium M6282 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID562240	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1580096	Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID318670	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 in mouse dosed iv 1 hr after infection	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID555294	Antibacterial activity against Tmp-susceptible Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID1516023	Antibacterial activity against Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID548471	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID404901	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB41 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID562245	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID510508	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID562623	Antimicrobial activity against Coagulase-negative Staphylococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID558077	Inhibition of PAR2-mediated SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 5 uM after 24 hrs by ELISA	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID396500	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates without tet(B) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID1325294	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM after 24 hrs by Griess assay relative to control	2016	Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22	Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID544952	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID285156	Antimicrobial activity against Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID553490	AUBKC (24 hrs) in methicillin-resistant Staphylococcus aureus SMH 32985 infected in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID565317	Antibacterial activity against Mycoplasma genitalium M2282 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID373024	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID555304	Antibacterial activity against methicillin-resistant Staphylococcus aureus 507 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID548254	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID565320	Antibacterial activity against Mycoplasma genitalium M2341 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1863877	Inhibition of MMP-7 (unknown origin)	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID510506	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID285327	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID562620	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID565321	Antibacterial activity against Mycoplasma genitalium M6257 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID66587	In vitro antibacterial activity against Enterococcus ATCC 29212	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID544955	Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID562630	Antimicrobial activity against Group G Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID601184	Antimicrobial activity against tetracycline-resistant Escherichia coli isolate 155 harboring tetA gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID562618	Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID318646	Antibacterial activity against methicillin-resistant Staphylococcus aureus KT0116 clinical isolate by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID278742	Antimicrobial activity against Candida parapsilosis in silicone disk biofilm at 3 mg/ml after 60 mins	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID585744	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated yniDp gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID1303894	Antibacterial activity against multidrug resistant Acinetobacter baumannii 2208 (ATCC 19606) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID562243	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID373049	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate JN45 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1887586	Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs in presence of artocarpin by checkerboard method	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID520087	Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID544962	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555295	Antibacterial activity against Tmp-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID1210069	Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID396279	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(D), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID428290	Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID396265	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID562241	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID558081	Inhibition of PAR2-mediated TNFalpha and SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM by ELISA	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID565314	Antibacterial activity against Mycoplasma genitalium TW10-6G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1447574	Bactericidal activity against Pseudomonas aeruginosa PAO1 at 4 times antibacterial MIC after 6 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID544536	Antibacterial activity against colistin-resistant Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID283390	Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID285159	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID562242	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID520959	Antimicrobial activity against Corynebacterium pseudodiphtheriticum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID373047	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ4A18 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1447582	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as ratio of MIC after 25 serial passages to MIC before 25 serial passages by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID555502	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis 057 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID1516085	Antibacterial activity against ciprofloxacin-resistant Escherichia coli ATCC 25922 incubated for 18 to 24 hrs	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID320706	Inhibition of PAD4 by ABPP-based assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID587836	Antibacterial activity against tetracycline-resistant Escherichia coli isolate 155 harboring tet(A) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520957	Antimicrobial activity against Corynebacterium jeikeium isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID548472	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1241223	Inhibition of pre-miR-372 (unknown origin) cleavage at A42 at 1 to 100 uM after 2 hrs by denaturing gel electrophoresis in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID601178	Antimicrobial activity against tetracycline-resistant Staphylococcus aureus isolate 158 harboring tetK gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID520965	Antimicrobial activity against Listeria monocytogenes isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID557105	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 135 to 180 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID557094	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID553509	Ratio of AUC to MIC in methicillin-resistant Staphylococcus aureus infected in in vitro hollow-fiber PK model at 100 mg after 8 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID601181	Antimicrobial activity against tetracycline-susceptible Streptococcus pneumoniae isolate 106 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID396499	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID278682	Antibacterial activity against Enterococcus faecium isolate 5753	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1241205	Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID373034	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-9 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID555301	Antibacterial activity against methicillin-susceptible Staphylococcus aureus 505 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID585738	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated mhpT gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID373041	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ36 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID544552	Antibacterial activity against extensively drug-resistant Acinetobacter baumannii clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID557104	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 50 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID324862	Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID544534	Antibacterial activity against colistin-susceptible Acinetobacter baumannii clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID555499	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis 051 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID285328	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID70763	In vitro minimum inhibitory concentration against Escherichia coli PRP-1 (tet A efflux).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID587837	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID565319	Antibacterial activity against Mycoplasma genitalium M2321 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID285525	Antibacterial activity against Neisseria meningitidis after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID562622	Antimicrobial activity against Coagulase-negative Staphylococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID553491	AUBKC (24 hrs) in methicillin-resistant Staphylococcus aureus SMH 32024 infected in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID1241222	Inhibition of pre-miR-372 (unknown origin) cleavage at A24 at 1 to 100 uM after 2 hrs by denaturing gel electrophoresis in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID645482	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Microbial transformation of deoxyandrographolide and their inhibitory activity on LPS-induced NO production in RAW 264.7 macrophages.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID544820	Antimicrobial activity against Staphylococcus epidermidis Xen 43 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID278065	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID544951	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1540255	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay	2019	Journal of natural products, 08-23, Volume: 82, Issue:8	Isolation, Structural Elucidation, Optical Resolution, and Antineuroinflammatory Activity of Phenanthrene and 9,10-Dihydrophenanthrene Derivatives from
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562244	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID324874	Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID404899	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB34 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID555297	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID585747	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated pcnB gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID357118	Decrease in accumulation of CD11b+ cells in spinal cord of dark agouti rat experimental allergic encephalomyelitis model at 45 mg/kg, ip administered twice a day at the first day of clinical signs and once a day for 14 days by immunostaining	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID562636	Antimicrobial activity against Listeria monocytogenes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID562628	Antimicrobial activity against Group C Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID324854	Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID396273	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID553488	Antibacterial activity against Staphylococcus aureus SMH 31236 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg after 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID529830	Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolates by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID495516	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID285325	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29213	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID555498	Antibacterial activity against methicillin-resistant and vancomycin-resistant Staphylococcus aureus VRS1 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID1241213	Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of Escherichia coli tRNA to Kd for 5'-FAM-pre-miR-372 (unknown origin)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID553479	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMH 32024 after 24 hrs by Etest	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID585741	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated metV gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID585736	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated treC gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID373037	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate DL34 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID562624	Antimicrobial activity against Group A Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID283218	Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID601185	Antimicrobial activity against tetracycline-susceptible Acinetobacter baumannii isolate 110 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID553469	Cmax in simulated human serum in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID565327	Antibacterial activity against Mycoplasma genitalium M6151 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID585566	Antibacterial activity against wild-type Escherichia coli BW25113 after 20 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID509850	Antibacterial activity against Escherichia coli DH10B expressing Tn1721-tet(A) carrying plasmid SK2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID428293	Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID544957	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID562631	Antimicrobial activity against Group G Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID565810	Antimicrobial activity against Neisseria meningitidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
AID544953	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID562632	Antimicrobial activity against Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1303883	Antibacterial activity against methicillin resistant Staphylococcus aureus subsp. aureus HPV107 (ATCC BAA-44) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID1516086	Resistance index, ratio of MIC for antibacterial activity against ciprofloxacin-resistant Escherichia coli to MIC for Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID572150	Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID553508	Ratio of AUC to MIC in methicillin-resistant Staphylococcus aureus infected in in vitro hollow-fiber PK model at 100 mg after 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID678719	Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID70764	In vitro minimum inhibitory concentration against Escherichia coli UBMS 88-1 (tet B efflux).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID1651604	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay
AID1516026	Antibacterial activity against Acinetobacter baumannii AB1901 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID585746	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated cyaA gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID555315	Antibacterial activity against methicillin-susceptible, vancomycin-intermediate Staphylococcus aureus 505 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID509842	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID544966	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1447579	Bactericidal activity against Pseudomonas aeruginosa PAO1 at 0.125 times antibacterial MIC after 6 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID562633	Antimicrobial activity against Streptococcus pneumoniae assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID544550	Antibacterial activity against all antibiotic-resistant Acinetobacter baumannii clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID555316	Antibacterial activity against methicillin-susceptible, vancomycin-intermediate Staphylococcus aureus 505 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID278684	Antibacterial activity against Enterococcus faecalis isolate 5746	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID520956	Antimicrobial activity against Corynebacterium amycolatum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID318669	Antibacterial activity against methicillin-resistant Staphylococcus aureus KT0116 in mouse dosed iv 1 hr after infection	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID520960	Antimicrobial activity against Corynebacterium striatum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID318653	Antibacterial activity against vancomycin-susceptible Enterococcus faecium ATCC 19434 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID587834	Antibacterial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 harboring tet(M) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID373029	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA7 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID565330	Antibacterial activity against Mycoplasma genitalium M6284 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1516024	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1863879	Inhibition of MMP-9 (unknown origin)	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID572151	Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID544959	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID318667	Antibacterial activity against Mycoplasma pneumoniae Mac by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID562614	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID544964	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID557095	Binding affinity to first site on human serum albumin by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID396276	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID1447484	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 91433 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID555312	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID544949	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID396270	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(M) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID571766	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-N616 mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID585745	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated hns gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID555293	Antibacterial activity against methicillin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID495511	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID283398	Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID428292	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID318649	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1447593	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P262-101856 infected in Galleria mellonella assessed as mortality at 75 mg/kg after 24 hrs relative to control	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID544961	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID322985	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2063G mutant isolate 1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID575678	Antibacterial activity against Listeria monocytogenes isolated from humans harboring int-tn gene	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.
AID510504	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID318668	Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith in mouse dosed iv 1 hr after infection	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID534825	Antimicrobial activity against Campylobacter fetus subsp. fetus CA73 harboring pCA73 carrying tet(44) resistance gene of 1516477 in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID585742	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated yfdG gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1580091	Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID404900	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB40 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID1332258	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Biotransformation of isofraxetin-6-O-β-d-glucopyranoside by Angelica sinensis (Oliv.) Diels callus.
AID396504	Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID285329	Antimicrobial activity against Streptococcus pyogenes ATCC 19615	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID571767	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID562638	Antimicrobial activity against Streptococcus mitis by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID553487	Antibacterial activity against Staphylococcus aureus SMH 26910 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg administered every 12 hrs measured after 24 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID575677	Antibacterial activity against Listeria monocytogenes isolated from humans harboring tet(M) gene	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.
AID587835	Antibacterial activity against Escherichia coli ATCC 25922 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1303882	Antibacterial activity against multidrug resistant Staphylococcus aureus subsp. aureus Seattle 1945 (ATCC 25923) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID324856	Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID520963	Antimicrobial activity against Arcanobacterium haemolyticum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID544827	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 20 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID285161	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID553695	Bactericidal activity against methicillin-resistant Staphylococcus aureus infected in rabbit at 6 mg/kg of body weight administered every 8 hrs measured after 72 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID555307	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis 057 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID534827	Antimicrobial activity against Campylobacter fetus subsp. fetus CA75 harboring pCA75 carrying ant(6)-Ib resistant gene of 1516477 in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID396266	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID555292	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID67234	In vitro minimum inhibitory concentration against Enterococcus faecalis ATCC 29212.	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID555311	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 345 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID558078	Inhibition of PAR2-mediated SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes at 10 uM after 24 hrs by ELISA	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID206122	In vitro minimum inhibitory concentration against Staphylococcus aureus smith (sensitive).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID1067614	Antiamyloidogenic activity in R6/2 mouse Huntington's disease model assessed as increase in survival rate relative to control	2013	Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15	A new face for old antibiotics: tetracyclines in treatment of amyloidoses.
AID1596894	Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 18 hrs by broth microdilution assay
AID562220	Antimicrobial activity against Desulfovibrio sp. by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID555306	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis 051 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID373031	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A22 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID565325	Antibacterial activity against Mycoplasma genitalium M6328 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID553697	T>MIC in Staphylococcus aureus infected rabbit	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID320707	Inhibition of PAD4 measured by slope plot of Lineweaver-Burke analyses	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID357120	Decrease in IFN-gamma-induced MHC2 expression in Sprague-Dawley rat primary microglial cells at 100 uM	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID1447546	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AB030 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID555302	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID555737	Antibacterial activity against methicillin-resistant and vancomycin-resistant Staphylococcus aureus VRS1 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID544540	Antibacterial activity against colistin-resistant Acinetobacter baumannii clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID565308	Antibacterial activity against Mycoplasma genitalium by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID206121	In vitro minimum inhibitory concentration against Staphylococcus aureus UBMS 90-3 (sensitive).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID520964	Antimicrobial activity against Rhodococcus equi isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID373039	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ32 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID562626	Antimicrobial activity against Group B Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1516028	Antibacterial activity against Pseudomonas aeruginosa 25349 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1241201	Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID553492	AUBKC (24 hrs) in methicillin-resistant Staphylococcus aureus SMH 26910 infected in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID1303896	Antibacterial activity against multidrug resistant Enterobacter cloacae subsp. cloacae CDC 442-68 (ATCC 13047) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID565312	Antibacterial activity against Mycoplasma genitalium R32 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562616	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1303893	Antibacterial activity against multidrug resistant Klebsiella pneumoniae subsp. pneumoniae NCTC 9633 (ATCC 13883) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID278731	Antimicrobial activity against Candida parapsilosis embedded in MRD biofilm at 3 mg/ml after 15 mins in drug assessed as 24 hr regrowth	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID285326	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 43300	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID585570	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated cspGp gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID585750	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated tolC gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID357116	Decrease in number of MOG-induced inflammatory lesions in spinal cord of dark agouti rat experimental allergic encephalomyelitis model at 45 mg/kg, ip administered twice a day at the first day of clinical signs and once a day for 14 days by hematoxylin an	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID70921	In vitro antibacterial activity against Escherichia coli J3272 Tet C	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID587832	Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate 158 harboring tet(K) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID70922	In vitro antibacterial activity against Escherichia coli J3272 Tet D	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID548474	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID555298	Antibacterial activity against Tmp-susceptible coagulase-negative Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID730308	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Microbial transformation of acetyl-11-keto-β-boswellic acid and their inhibitory activity on LPS-induced NO production.
AID562223	Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID404903	Antibacterial activity against Streptococcus bovis ATCC 33317 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID283395	Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID318671	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KT2524 in mouse dosed iv 1 hr after infection	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID258275	Antibacterial activity against Escherichia coli UBMS 88-1 carrying tetB-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID318665	Antibacterial activity against Propionibacterium granulosum GAI 7414 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1638683	Antimicrobial activity against adult Brugia malayi L3 larvae stage infected in CB17 SCID mouse assessed as reduction in Wolbachia load at 25 mg/kg, po administered BID for 28 days starting 6 weeks post infection and measured 12 weeks post infection by QPC	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
AID520962	Antimicrobial activity against Corynebacterium xerosis isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID396271	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(B) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID322988	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2064G mutant isolate 4	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID373044	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY6 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID373035	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ55 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID520085	Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID510514	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID396502	Antibacterial activity against tetracycline-resistant Escherichia coli with multiple drug resistance determinant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID544824	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1516019	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID318657	Antibacterial activity against Staphylococcus saccharolyticus GAI 5520 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID373028	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU86 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID475504	Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID571925	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID318651	Antibacterial activity against Streptococcus pyogenes ATCC 12344 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1447478	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID373043	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY7 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID324858	Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID565313	Antibacterial activity against Mycoplasma genitalium TW10-5G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID510512	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-51	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID428294	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID324870	Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID530586	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae isolate 685 with A2603G mutation by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID357133	Inhibition of MHC2 expression in Sprague-Dawley rat peritoneal macrophages at 100 uM after 24 hrs by immunostaining	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID601187	Antimicrobial activity against tetracycline-susceptible Enterobacter cloacae isolate 108 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID585567	Antibacterial activity against MarA-deficient Escherichia coli CR2000 after 20 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID318658	Antibacterial activity against Streptococcus intermedius GAI 7416 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID575170	Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID534771	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID562634	Antimicrobial activity against Corynebacterium spp. by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID428291	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID555325	Antibacterial activity against methicillin-resistant Staphylococcus aureus 145 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID422944	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae harboring A2064G transition in domain V of 23S rRNA isolated from pediatric patients with community-acquired pneumonia after 10 to 14 days by microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
AID307122	Inhibition of HIV1 recombinant integrase strand transfer activity	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID529827	Antimicrobial activity against Acinetobacter baumannii by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID318647	Antibacterial activity against methicillin-resistant Staphylococcus aureus KMP9 clinical isolate by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID520086	Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID318656	Antibacterial activity against Haemophilus influenzae TH13 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID324860	Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID562627	Antimicrobial activity against Group B Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID562222	Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID396503	Antibacterial activity against tetracycline-susceptible Escherichia coli clinical isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID1303881	Antibacterial activity against multidrug resistant Enterococcus faecium NCTC 7171 (ATCC 19434) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID1447479	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID285157	Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID553481	Antibacterial activity against Staphylococcus aureus SMH 31236 after 24 hrs by Etest	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID285158	Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
AID283219	Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID1325295	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 50 uM after 24 hrs by Griess assay relative to control	2016	Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22	Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID320708	Inhibition of PAD4 measured by intercept plot of Lineweaver-Burke analyses	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID396269	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID404898	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB33 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID565316	Antibacterial activity against Mycoplasma genitalium UTMB-10G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID396277	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID571927	Ratio of MIC for Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene to MIC for Escherichia coli K-12 3-AG300	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID520961	Antimicrobial activity against Corynebacterium urealyticum isolates by CLSI M45-A protocol based microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.
AID562635	Antimicrobial activity against Corynebacterium spp. assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID283397	Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID1447480	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID555320	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID445445	Permeability at pH 6.5 by PAMPA method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID283391	Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID326277	Antibacterial activity against methicillin-resistant Staphylococcus aureus at 4 hrs daily exposure for 2 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
AID509848	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 expressing ACYC177 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID71156	Inhibition of [3H]tetracycline uptake into everted membrane vesicles, prepared from tetracycline resistant Escherichia coli D1-209	1993	Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3	Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines.
AID520083	Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID565323	Antibacterial activity against Mycoplasma genitalium M6285 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID558079	Inhibition of PAR2 gene expression in normal human epidermal keratinocytes at 10 uM after 48 hrs by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID1516025	Antibacterial activity against Escherichia coli 20411 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1447482	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P262-101856 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1447549	Antibacterial activity against multidrug-resistant Enterobacter cloacae 117029 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID509847	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 harboring ramR-5649 mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID555299	Antibacterial activity against Tmp-resistant coagulase-negative Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID562617	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID585749	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated acrB gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID679405	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, Minocycline: 500 uM) in OAT1-expressing S2 cells	2002	Japanese journal of pharmacology, Jan, Volume: 88, Issue:1	Human organic anion transporters mediate the transport of tetracycline.
AID324864	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1329015	Antibacterial activity against Streptococcus pneumoniae PBS1399	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID548256	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID571768	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-I626M mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1887539	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 16 to 18 hrs by broth microdilution method	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID206302	In vitro antibacterial activity against Staphylococcus aureus UBMS 88-7 Tet K	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID323254	Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID565310	Antibacterial activity against Mycoplasma genitalium G37 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1516020	Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1447545	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AB027 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID318645	Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID495509	Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID565318	Antibacterial activity against Mycoplasma genitalium M2300 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID373030	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU78 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1241204	Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1241225	Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) assessed as change in total free energy by thermodynamic assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID520081	Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1447548	Antibacterial activity against multidrug-resistant Acinetobacter baumannii 110193 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID283400	Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID530587	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae isolate 1006 with A2603G mutation by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID1325296	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 100 uM after 24 hrs by Griess assay relative to control	2016	Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22	Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID357123	Decrease in IFN-gamma-induced MHC2 mRNA levels in Sprague-Dawley rat primary microglial cells at 100 uM after 24 hrs by RT-PCR	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID1241203	Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1447550	Antibacterial activity against multidrug-resistant Klebsiella pneumoniae 116381 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID553486	Antibacterial activity against Staphylococcus aureus SMH 26910 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg after 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID520082	Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1387692	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay	2018	Journal of natural products, 10-26, Volume: 81, Issue:10	Coumarinolignoids and Taraxerane Triterpenoids from Sapium discolor and Their Inhibitory Potential on Microglial Nitric Oxide Production.
AID278743	Antimicrobial activity against Candida parapsilosis in silicone disk biofilm at 3 mg/ml after 60 mins in drug assessed as 24 hr regrowth	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID553467	Half life in human serum	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID396278	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(C), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID509846	Antibacterial activity against Salmonella enterica serovar Hadar VA5649 harboring wild type ramR-2313 gene by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID575168	Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric a	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID565329	Antibacterial activity against Mycoplasma genitalium M6283 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1241210	Binding affinity to 5'-FAM-pre-miR-17 (unknown origin) after 4 hrs by fluorescence assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID730307	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay relative to control	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Microbial transformation of acetyl-11-keto-β-boswellic acid and their inhibitory activity on LPS-induced NO production.
AID206120	In vitro minimum inhibitory concentration against Staphylococcus aureus UBMS 90-1 (tet M ribosomal protection).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID357136	Suppression of IFN-gamma-induced PKCalpha/beta2 nuclear translocation in Sprague-Dawley rat primary microglial cells at 100 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID1241220	Inhibition of pre-miR-372 (unknown origin) cleavage at 1 to 100 uM after 15 mins by RNase footprinting assay in presence of RNase-V1	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1241224	Inhibition of pre-miR-372 (unknown origin) cleavage at U28 at 1 to 100 uM after 2 hrs by denaturing gel electrophoresis in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID519833	Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID544960	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1329018	Antibacterial activity against Streptococcus pneumoniae PBS1399 infected in mouse assessed as protection against bacterial infection by measuring mouse survival administered intravenously as single dose after 2 hrs of infection measured on day 7	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID697853	Inhibition of horse BChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID530581	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae isolate 6 with A2604G mutation by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID585743	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated yibLp gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID373026	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID544538	Antibacterial activity against colistin-susceptible Acinetobacter baumannii clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
AID258273	Antibacterial activity against Staphylococcus aureus Smith	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID548257	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID510509	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1776041	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay
AID555309	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 197 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID1241214	Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of 15-mer DNA	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID530580	Antimicrobial activity against Mycoplasma pneumoniae isolate FH by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID318660	Antibacterial activity against Peptostreptococcus asaccharolyticus GAI 5534 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID557097	Protein binding in serum	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID510510	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID278680	Antibacterial activity against Enterococcus faecium isolate 5751	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID557096	Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID680949	TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2alpha: 0.005 uM, Minocycline: 5 uM) in OAT2-expressing S2 cells	2002	Japanese journal of pharmacology, Jan, Volume: 88, Issue:1	Human organic anion transporters mediate the transport of tetracycline.
AID530582	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae isolate 11 with A2604G mutation by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID422883	Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID534824	Antimicrobial activity against ciprofloxacin-resistant Campylobacter fetus subsp. fetus 1516477 human isolate harboring tet(44) and ant(6)-Ib resistance gene in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID555310	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 225 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID544965	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1316657	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID585752	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated crp gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID1887614	Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration incubated for 24 hrs in presence of artocarpin by checkerboard method	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID1566489	Inhibition of biotinylated pre-let-7d microRNA (unknown origin) maturation preincubated for 15 mins followed by Pre-let-7d addition and measured after 5 hrs by cat-ELCCA	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID553489	Antibacterial activity against Staphylococcus aureus SMH 31236 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg administered every 12 hrs measured after 24 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID530584	Antimicrobial activity against Mycoplasma pneumoniae isolate 18 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID510511	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID206119	In vitro minimum inhibitory concentration against Staphylococcus aureus UBMS 88-7 (tet K efflux).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID562637	Antimicrobial activity against Listeria monocytogenes assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID318650	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KT2524 clinical isolate by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID495510	Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID357124	Decrease in IFN-gamma-induced CIITA mRNA expression in Sprague-Dawley rat primary microglial cells at 100 uM after 24 hrs by RT-PCR	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID278683	Antibacterial activity against Enterococcus faecalis isolate 5745	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID557091	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID562615	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID601183	Antimicrobial activity against tetracycline-susceptible Escherichia coli isolate 107 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID475505	Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID396267	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(C) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID1869478	Anti-inflammartory activity against LPS-activated human BV-2 cells assessed as reduction in TNF-alpha levels at 50 uM pretreated with compound for 1 hr followed by co-incubation with LPS for 24 hrs by ELISA	2022	Journal of natural products, 07-22, Volume: 85, Issue:7	Batatasin III, a Constituent of
AID357126	Effect on IFN-gamma-induced IFN-gamma regulatory factor 1 expression in Sprague-Dawley rat primary microglial cells at 100 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID318644	Antibacterial activity against methicillin-susceptible Staphylococcus aureus FDA 209P by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID509843	Antibacterial activity against Escherichia coli DH10B by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID565331	Antibacterial activity against Mycoplasma genitalium M6287 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1869479	Anti-inflammartory activity against LPS-activated human BV-2 cells assessed as reduction in IL-6 levels at 50 uM pretreated with compound for 1 hr followed by co-incubation with LPS for 24 hrs by ELISA	2022	Journal of natural products, 07-22, Volume: 85, Issue:7	Batatasin III, a Constituent of
AID553478	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMH 32985 after 24 hrs by Etest	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID1241207	Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID422882	Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID509845	Antibacterial activity against wild type Salmonella enterica TY2313 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID510505	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID553468	Bactericidal activity against Staphylococcus aureus assessed as reduction log reduction in viable bacterial count at 0.5 to 1 times MIC	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID553466	fAUC in serum of human at 100 mg, po after 2 to 3 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID206301	In vitro antibacterial activity against Staphylococcus aureus Smith sensitive	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID428295	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID324866	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID307119	Cytotoxicity against CEM cells after 5 days by MTT method	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID70766	In vitro minimum inhibitory concentration against Escherichia coli UBMS 90-5 (sensitive).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID1241212	Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay in presence of 100-fold excess of Escherichia coli tRNA	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID555742	Antibacterial activity against methicillin-resistant, Linezolid non-susceptible coagulase-negative Staphylococcus epidermidis 345 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID495515	Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID258272	Antibacterial activity against Staphylococcus aureus UBMS 88-7 carrying the tetK-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID318663	Antibacterial activity against Clostridium perfringens GAI 5526 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318655	Antibacterial activity against Moraxella catarrhalis K1209 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID404896	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB28 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID534826	Antimicrobial activity against kanamycin-resistant Campylobacter fetus subsp. fetus CA74 harboring deletion in tet(44)::pCA64 resistant gene in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID1241209	Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID585740	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated alx gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID1325293	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 1 uM after 24 hrs by Griess assay relative to control	2016	Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22	Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID318661	Antibacterial activity against Peptostreptococcus anaerobius GAI 5506 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1580090	Antibacterial activity against novobiocin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1447483	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P264-104354 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID405455	Antibacterial activity against Escherichia coli 1540 isolate by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID681052	TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Minocycline: 50 uM) in OAT3-expressing S2 cells	2002	Japanese journal of pharmacology, Jan, Volume: 88, Issue:1	Human organic anion transporters mediate the transport of tetracycline.
AID1303895	Antibacterial activity against multidrug resistant Pseudomonas aeruginosa NCTC 10332 (ATCC 10145) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID1516027	Antibacterial activity against Acinetobacter baumannii AB1902 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID278675	Antibacterial activity against Enterococcus faecalis isolate 5743	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID534828	Antimicrobial activity against kanamycin-resistant Campylobacter fetus subsp. fetus CA76 harboring deletion in ant(6)-Ib::pCA76 in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID278678	Antibacterial activity against Enterococcus faecium isolate 5749	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID495512	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID697852	Inhibition of electric eel AChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID557093	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID601112	Antimicrobial activity against tetracycline-susceptible Staphylococcus aureus isolate 101 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID258276	Antibacterial activity against Minocycline sensitive Escherichia coli 88-2	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID510502	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID373046	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS5 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1241208	Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID555305	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID575167	Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID258274	Antibacterial activity against Enterococcus faecalis ATCC 29212	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID553472	Tmax in simulated human serum in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID396275	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(B), tet(C) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID1325290	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	2016	Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22	Antioxidant and anti-inflammatory neolignans from the seeds of hawthorn.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID548475	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID585571	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated ompR gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID307121	Inhibition of HIV1 recombinant integrase 3'-processing activity	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID283396	Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID326276	Antibacterial activity against methicillin-resistant Staphylococcus aureus after 24 hrs by silicone disk biofilm colonization method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
AID278674	Antibacterial activity against Enterococcus faecalis isolate 5744	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID283392	Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID373042	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ49 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID548255	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID571926	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-N623S-Q624S mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1657136	Ant-inflammatory LPS-induced mouse BV2 cells assessed as reduction in NO production after 24 hrs by Griess reagent based assay	2020	Journal of natural products, 04-24, Volume: 83, Issue:4	Amide-Iminoate Isomerism in Antineuroinflammatory Isoquinoline Alkaloids from
AID585573	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated degP gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID565326	Antibacterial activity against Mycoplasma genitalium M6090 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID357117	Decrease in size of MOG-induced inflammatory lesions in spinal cord of dark agouti rat experimental allergic encephalomyelitis model at 45 mg/kg, ip administered twice a day at the first day of clinical signs and once a day for 14 days by hematoxylin and	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID206786	Inhibitory activity against MRSA	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID278736	Antimicrobial activity against methicillin-resistant Staphylococcus aureus in silicone disk biofilm at 3 mg/ml after 60 mins	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID565811	Antimicrobial activity against Neisseria meningitidis assessed as susceptible isolate by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
AID357137	Suppression of IFN-gamma-induced IFN-gamma regulatory factor 1 nuclear translocation in Sprague-Dawley rat primary microglial cells at 100 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID601179	Antimicrobial activity against tetracycline-susceptible Enterococcus faecalis isolate 103 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID544967	Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID555509	Antibacterial activity against methicillin-resistant, vancomycin-intermediate coagulase-negative Staphylococcus epidermidis 225 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID258278	Antibacterial activity against Minocylcine sensitive Escherichia coli 89-2	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID645483	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Microbial transformation of deoxyandrographolide and their inhibitory activity on LPS-induced NO production in RAW 264.7 macrophages.
AID1241202	Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562625	Antimicrobial activity against Group A Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1767669	Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID562619	Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1464282	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	2017	Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20	Natural neuro-inflammatory inhibitors from Caragana turfanensis.
AID555300	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID534829	Antimicrobial activity against Campylobacter fetus subsp. fetus CA80 harboring ciprofloxacin-resistant gene and IMD523-06 pathogenicity island with tet(44) and ant(6)-Ib resistant marker gene in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID585735	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated recD gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID1434704	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Natural potential neuroinflammatory inhibitors from Alhagi sparsifolia Shap.
AID1450010	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as ratio of MIC after 25 serial passages at sub-MIC to MIC after 1 passage by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID373032	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FW-F1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID585568	Antibacterial activity against MarA-overexpressing Escherichia coli CR1000 after 20 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID530579	Antimicrobial activity against Mycoplasma pneumoniae isolate M129 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID585569	Ratio of MIC for marA-overproducing Escherichia coli CR1000 to MIC for MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID258270	Antibacterial activity against Staphylococcus aureus UBMS 90-2 carrying tetM-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID495513	Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID558082	Cytotoxicity against normal human epidermal keratinocytes at 5 uM after 72 hrs by MTT assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID283393	Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID495514	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID601177	Antimicrobial activity against methicillin-, tetracycline-resistant Staphylococcus aureus isolate 161 harboring tetM gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID553507	Ratio of AUC to MIC in methicillin-resistant Staphylococcus aureus infected in in vitro hollow-fiber PK model at 100 mg after 24 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID322984	Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae M129	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1497528	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS induced nitric oxide production preincubated for 2 hrs followed by LPS challenge measured after 24 hrs by Griess reagent based assay	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Hexahydrobenzophenanthridine alkaloids from Corydalis bungeana Turcz. and their anti-inflammatory activity.
AID70762	In vitro minimum inhibitory concentration against Escherichia coli J3272 (tet D efflux).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID278730	Antimicrobial activity against Candida parapsilosis embedded in MRD biofilm at 3 mg/ml after 15 mins	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID601182	Antimicrobial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 harboring tetM gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID520088	Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID258271	Antibacterial activity against Staphylococcus aureus UBMS 90-3	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID553483	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMH 32985 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg administered every 12 hrs measured after 24 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID322987	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2064G mutant isolate 2	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID258277	Antibacterial activity against Escherichia coli UBMS 89-1 carrying tetM-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID1566488	Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation preincubated for 15 mins followed by pre-miRNA-21 addition and measured after 5 hrs by cat-ELCCA	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID530585	Antimicrobial activity against Mycoplasma pneumoniae isolate 19 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
AID70928	In vitro antibacterial activity against Escherichia coli UBMS 88-1 Tet B	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID318648	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID206303	In vitro antibacterial activity against Staphylococcus aureus UBMS 90-1 Tet M	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID1447485	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 101243 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID572147	Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID1241211	Binding affinity to 5'-FAM-pre-miR-373 (unknown origin) after 4 hrs by fluorescence assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID553493	AUBKC (24 hrs) in methicillin-resistant Staphylococcus aureus SMH 31236 infected in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID357119	Decrease in accumulation of MHC 2+ cells in spinal cord of dark agouti rat experimental allergic encephalomyelitis model at 45 mg/kg, ip administered twice a day at the first day of clinical signs and once a day for 14 days by immunostaining	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID565322	Antibacterial activity against Mycoplasma genitalium M6280 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID587831	Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate 161 harboring tet(M) gene by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID575169	Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID520084	Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID318652	Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID519834	Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID562221	Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID534823	Antimicrobial activity against nalidixic acid-resistant Campylobacter fetus subsp. fetus IMD523-06 bovine isolate harboring tet(44) and ant(6)-Ib resistance gene in presence of 5% lacked horse blood	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.
AID373027	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA6 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID278737	Antimicrobial activity against methicillin-resistant Staphylococcus aureus in silicone disk biofilm at 3 mg/ml after 60 mins in drug assessed as 24 hr regrowth	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID302863	Antibacterial activity against Staphylococcus aureus Rosenbach after 14 hrs	2007	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23	Bactericidal activity of extended 9-glycyl-amido-minocyclines.
AID318659	Antibacterial activity against Atopobium parvulum GAI 5542 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID556349	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae ATCC 15531 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
AID1580092	Antibacterial activity against novobiocin and test compound-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages in presence of novobiocin by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID404895	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB10 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID278676	Antibacterial activity against Enterococcus faecalis isolate 5742	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID575165	Inhibition of acrAB AcrAB-TolC in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as [3H]TMG accumulation at 200 uM by scintillation counter method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID1447481	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P259-96918 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID562621	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID585737	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated ynfE gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID571764	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID571763	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-F628F mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID404897	Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB30 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID278677	Antibacterial activity against Enterococcus faecium isolate 2547	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID357129	Reduction in IFN-gamma-induced PKCalpha/beta2 phosphorylation in Sprague-Dawley rat primary microglial cells at 100 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID278724	Antimicrobial activity against methicillin-resistant Staphylococcus aureus embedded in MRD biofilm model at 3 mg/ml after 15 mins	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.
AID548253	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID557090	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID565324	Antibacterial activity against Mycoplasma genitalium M6286 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1055951	Antibacterial activity against Acinetobacter baumannii ATCC BAA-747 after 16 hrs	2013	Journal of natural products, Nov-22, Volume: 76, Issue:11	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
AID601189	Antimicrobial activity against tetracycline-resistant Klebsiella pneumoniae isolate 153 harboring tetA gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID601186	Antimicrobial activity against tetracycline-susceptible Pseudomonas aeruginosa isolate 111 by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID70929	In vitro antibacterial activity against Escherichia coli UBMS 90-4 Tet M	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID1767670	Antibacterial activity against Stenotrophomonas maltophilia EM 0104assessed as inhibition of bacterial growth incubated for 24 hrs by microdilution assay	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimicrobial, modulatory, and antibiofilm activity of tt-farnesol on bacterial and fungal strains of importance to human health.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID396498	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(B), tet(D), tet(E) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID278681	Antibacterial activity against Enterococcus faecium isolate 5752	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID555743	Antibacterial activity against methicillin-resistant, vancomycin-intermediate coagulase-negative Staphylococcus epidermidis 225 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID544963	Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID601180	Antimicrobial activity against tetracycline-resistant Enterococcus faecalis isolate 159 harboring teM gene by CLSI dilution method	2011	Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.
AID555308	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 074 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID357135	Decrease in PKCalpha phosphorylation in Sprague-Dawley rat peritoneal macrophages at 100 uM after 24 hrs	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID544636	Antimicrobial activity against Staphylococcus aureus Xen 30 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID373048	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ84 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID285160	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID562629	Antimicrobial activity against Group C Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1241215	Ratio of Kd for 5'-FAM-pre-miR-372 (unknown origin) in presence of 100-fold excess of 15-mer DNA to Kd for 5'-FAM-pre-miR-372 (unknown origin)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1447547	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AB031 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID357121	Decrease in IFN-gamma-induced MHC2 protein levels in Sprague-Dawley rat primary microglial cells at 100 uM by Western blotting	2007	The Journal of biological chemistry, May-18, Volume: 282, Issue:20	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
AID70761	In vitro minimum inhibitory concentration against Escherichia coli J3272 (tet C efflux).	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.
AID565311	Antibacterial activity against Mycoplasma genitalium M30 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID553482	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMH 32985 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg after 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID509844	Antibacterial activity against Escherichia coli DH10B harboring Tn1721-tet(A) carrying plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID318664	Antibacterial activity against Propionibacterium acnes GAI 5568 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID495518	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID585574	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated maoC gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID322982	Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae FH	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID1566490	Inhibition of Dicer mediated biotinylated pre-miRNA-21 (unknown origin) maturation at 1 mM measured after 15 mins by cat-ELCCA relative to control	2019	ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5	Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.
AID553484	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMH 32024 infected in in vitro hollow-fiber model assessed as log reduction in viable bacterial count at 100 mg after 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID404902	Antimicrobial activity against Enterococcus faecalis ATCC 29212 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID553475	Half life in simulated human serum in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID544828	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID555303	Antibacterial activity against methicillin-resistant Staphylococcus aureus 145 by broth macrodilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID318666	Antibacterial activity against Mycoplasma pneumoniae FH Liu by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID558075	Cytotoxicity against normal human epidermal keratinocytes at 100 uM after 72 hrs by MTT assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID307123	Antimycobacterial activity against Mycobacterium tuberculosis by agar dilution method	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID544950	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID510503	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID318662	Antibacterial activity against Peptostreptococcus magnus GAI 5528 by broth microdilution method	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1869477	Anti-inflammatory activity in human BV-2 cells assessed as inhibition of LPS-induced NO production at 50 uM pretreated with compound for 1 hr followed by coincubation with LPS for 24 hrs by Griess reagent based analysis	2022	Journal of natural products, 07-22, Volume: 85, Issue:7	Batatasin III, a Constituent of
AID373033	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-23 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID324868	Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID396274	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(M) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID258269	Antibacterial activity against Staphylococcus aureus UBMS 90-1 carrying tetM-resistant determinant	2006	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.
AID585572	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated appA gene assessed as MarA-mediated multidrug resistance level by measuring fold change in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID324872	Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID429057	Antimicrobial activity against tetracycline-resistant Mycoplasma hominis isolate overexpressing tet(M) gene	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracyclines.
AID1449965	Antibacterial activity against XDR Pseudomonas aeruginosa isolate P262-101856 infected in Galleria mellonella assessed as protection against bacterial infection by measuring larval death at 75 mg/kg up to 24 hrs relative to control	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID585751	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated damX gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID555507	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 197 after 50 passages by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.
AID1516022	Antibacterial activity against Escherichia coli UB1005 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID562224	Antimicrobial activity against Desulfovibrio piger by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID307118	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral-induced cytopathicity	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
AID510507	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID544830	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 200 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID373025	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU73 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID373045	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS15 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID585748	Antibacterial activity against marA-overproducing Escherichia coli CR1000 harboring inactivated acrA gene assessed as MarA-mediated multidrug resistance level by measuring fold decrease in MIC relative to MarA-deficient Escherichia coli CR2000	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.
AID396496	Antibacterial activity against tetracycline-resistant Escherichia coli clinical isolates expressing tet(A), tet(B), tet(D) gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
AID1516029	Antibacterial activity against Staphylococcus aureus 11011 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID70931	In vitro antibacterial activity against Escherichia coli UBMS 90-5 sensitive	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID207661	Minimum inhibition concentration against Staphylococcus aureus	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Synthesis and biological evaluation of 9-substituted tetracycline derivatives.
AID553694	Bactericidal activity against Staphylococcus aureus assessed as log reduction in bacterial count	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID70927	In vitro antibacterial activity against Escherichia coli PRP1 Tet A	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID278679	Antibacterial activity against Enterococcus faecium isolate 5750	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID324852	Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID283399	Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID1863876	Inhibition of MMP-3 (unknown origin)	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID322983	Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae Mac	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
AID553480	Antibacterial activity against Staphylococcus aureus SMH 26910 after 24 hrs by Etest	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.
AID1241206	Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID680189	TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Minocycline: 50 uM) in OAT4-expressing S2 cells	2002	Japanese journal of pharmacology, Jan, Volume: 88, Issue:1	Human organic anion transporters mediate the transport of tetracycline.
AID1516021	Antibacterial activity against Salmonella enterica serovar typhimurium C77-31 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID558076	Cytotoxicity against normal human epidermal keratinocytes at 10 uM after 72 hrs by MTT assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID587833	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by CLSI M07-A8 method	2011	Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID510513	Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	664 (10.60)	18.7374
1990's	738 (11.78)	18.2507
2000's	1642 (26.20)	29.6817
2010's	2638 (42.10)	24.3611
2020's	584 (9.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	502 (7.63%)	5.53%
Reviews	636 (9.67%)	6.00%
Case Studies	1,304 (19.82%)	4.05%
Observational	20 (0.30%)	0.25%
Other	4,117 (62.58%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (240)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Single Dose Two-Way Crossover Fed Bioequivalence Study of Minocycline 100 mg Capsules in Healthy Volunteers [NCT00777413]		24 participants (Actual)	Interventional	2002-11-30	Completed
A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease [NCT00277355]	Phase 2/Phase 3	114 participants (Actual)	Interventional	2006-04-30	Completed
Minocycline Augmentation in Early-Course Schizophrenia [NCT01561742]		120 participants (Anticipated)	Interventional	2012-02-29	Recruiting
Pilot, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Acne Vulgaris Patients [NCT01362010]	Phase 2	150 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-12) [NCT04608500]	Phase 3	771 participants (Actual)	Interventional	2017-06-01	Completed
Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) [NCT01073813]	Phase 2	6 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Lack of recruitment)
A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo [NCT01171326]	Phase 2	32 participants (Actual)	Interventional	2010-08-31	Completed
A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin [NCT01206348]	Phase 4	97 participants (Actual)	Interventional	2010-09-30	Completed
A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer [NCT01317550]		14 participants (Actual)	Interventional	2011-07-31	Completed
PRISM: A Double Blind, Randomized, Vehicle Controlled Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea [NCT03667222]	Phase 2	207 participants (Actual)	Interventional	2018-09-18	Active, not recruiting
Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial [NCT02297412]	Phase 2	47 participants (Actual)	Interventional	2014-11-30	Completed
A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11) [NCT03142451]	Phase 3	751 participants (Actual)	Interventional	2017-06-02	Completed
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial [NCT02533232]	Phase 1	60 participants (Anticipated)	Interventional	2022-08-30	Recruiting
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04 [NCT02815267]	Phase 3	466 participants (Actual)	Interventional	2016-05-31	Completed
Rescue Therapy for Helicobacter Pylori Eradication: A Randomized Non-Inferiority Trial of Minocycline or Tetracycline in Bismuth Quadruple Therapy [NCT04531059]	Phase 4	368 participants (Actual)	Interventional	2020-10-15	Completed
A Randomized, Evaluator-Blinded, Bilateral Comparison Study of Two Topicals in the Treatment of Subjects With Acne Vulgaris [NCT03743038]	Phase 1	12 participants (Actual)	Interventional	2018-11-20	Completed
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting [NCT03160040]		71 participants (Actual)	Observational	2017-10-11	Completed
Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery [NCT01297816]	Phase 2	0 participants	Interventional	2010-12-31	Recruiting
A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder [NCT01320982]	Phase 3	400 participants (Anticipated)	Interventional	2011-03-31	Not yet recruiting
The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial [NCT01083420]	Phase 3	30 participants (Anticipated)	Interventional	2010-03-31	Not yet recruiting
The Effect of Lycopene Antioxidant Gel Compared to Minocycline Hydrochloride Microspheres as Adjunctive to Non Surgical Periodontal Treatment by Measuring Matrix Metalloproteinase-9, Transforming Growth Factor-Beta 1, Interleukin-8, and Tissue Inhibitor o [NCT03964935]	Phase 2	30 participants (Actual)	Interventional	2018-12-01	Enrolling by invitation
The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization. A Phase I Study [NCT02178813]	Phase 1	6 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Study stopped prematurely because of multiple logistic difficulties)
Open-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment Benefit [NCT04291456]	Phase 3	9 participants (Actual)	Interventional	2020-01-31	Terminated(stopped due to Completion is not possible due to recruitment concerns)
A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder (MDD) [NCT02456948]	Phase 2	168 participants (Actual)	Interventional	2015-01-31	Completed
Development of Minocycline as a Neuroimmune Therapy for Alcohol Use Disorder [NCT03244592]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2018-01-15	Withdrawn(stopped due to Investigator left institution prior to enrollment of study participants)
Targeting Microglial Activation for Treatment of Autism Spectrum Disorder (ASD): A Proof-of-Concept, Target-Engagement Study [NCT03117530]	Phase 1	30 participants (Anticipated)	Interventional	2017-04-11	Suspended(stopped due to COVID)
Neurophysiological and Acute Pharmacological Studies in FXS Patients [NCT02998151]	Early Phase 1	29 participants (Actual)	Interventional	2016-01-31	Completed
A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma [NCT01283997]	Phase 2	79 participants (Actual)	Interventional	2011-01-25	Active, not recruiting
A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design [NCT04052711]	Phase 1	233 participants (Actual)	Interventional	2016-09-08	Completed
Phase 4 Study Into the Effect of Minocycline and Amoxicillin Administration of the Prevalence of Antibiotic Resistant Bacteria and on the Indigenous Oral, Faecal, Cutaneous and Nasal Microbiotas [NCT02030912]	Phase 4	42 participants (Actual)	Interventional	2009-12-31	Completed
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions [NCT01468831]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2012-03-28	Completed
[NCT02113176]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2010-01-31	Withdrawn(stopped due to Funding of minocycline)
Efficacy of 45mg Oral Minocycline (Solodyn) and 45mg Oral Minocycline (Solodyn) Plus 15% Azelaic Acid (Finacea) in the Treatment of Acne Rosacea [NCT05014906]	Phase 4	60 participants (Actual)	Interventional	2010-05-31	Completed
Depression, Obesity and Inflammatory Markers [NCT02765100]		21 participants (Actual)	Interventional	2014-10-31	Completed
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled Study of the Efficacy and Safety of HY02 Ointment in Subjects With Inflamed Meibomian Gland Dysfunction [NCT03888378]	Phase 2	270 participants (Actual)	Interventional	2019-04-02	Completed
An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05) [NCT03050086]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2017-03-29	Completed
Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome [NCT02056665]	Phase 2	32 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 3, Multi-center, Randomized, Double-Blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Topical Administration of Minocycline Hydrochloride Foam (4%) in the Treatment of Moderate-to-Severe Acne Vulgaris [NCT04960930]	Phase 3	372 participants (Actual)	Interventional	2021-09-17	Completed
Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial [NCT02263872]	Phase 4	41 participants (Actual)	Interventional	2014-10-31	Completed
The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis [NCT05474729]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Angiotensin and Neuroimmune Activation in Hypertension [NCT02133885]	Phase 1/Phase 2	56 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Effects of Antimicrobial Peptides Application After Non-surgical Periodontal Therapy on Treatment of Stage III and Grade B Periodontitis [NCT05530252]	Phase 4	51 participants (Anticipated)	Interventional	2022-09-05	Not yet recruiting
[NCT01133080]	Phase 4	50 participants (Anticipated)	Interventional	2010-06-30	Recruiting
Randomized Placebo Controlled Study of Minocycline for Amelioration of Chemotherapy Induced Affective Disorders [NCT02203552]	Phase 2	61 participants (Actual)	Interventional	2015-06-23	Active, not recruiting
Usability of Levodopa Cyclops™ Compared to INBRIJA® During an Off Episode in Parkinson's Disease Patients [NCT05499572]		16 participants (Anticipated)	Observational	2023-11-01	Not yet recruiting
Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Moderate to Severe Rosacea Patients [NCT01134991]	Phase 2	21 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Difficulty in recruitment)
The Regenerative Potential of Immature Necrotic Teeth With Apical Periodontitis Based on Clinical and Radiographic Assessments [NCT03507556]		40 participants (Anticipated)	Interventional	2010-06-28	Active, not recruiting
A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-05 [NCT02815280]	Phase 3	495 participants (Actual)	Interventional	2016-05-31	Completed
A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN) [NCT03369951]	Phase 4	58 participants (Actual)	Interventional	2018-03-28	Completed
Minocycline and Tobacco Craving in Smokers With Schizophrenia [NCT02968602]	Phase 4	32 participants (Actual)	Interventional	2017-03-31	Completed
The Effect of Acute Minocycline Administration on Emotional Processing and Cognition in Healthy Volunteers [NCT03768557]		40 participants (Actual)	Interventional	2017-04-26	Completed
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response [NCT03414502]	Phase 3	400 participants (Anticipated)	Interventional	2007-12-10	Recruiting
A 6-Week, Randomized Study to Evaluate the Potential of FMX-101, 4% And Vehicle to Induce a Photo Allergic Skin Reaction in Healthy Volunteers, Using a Controlled Photo Patch Test Design [NCT04070755]	Phase 1	56 participants (Actual)	Interventional	2016-09-21	Completed
A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of FMX-101 in Healthy Volunteers Using a Cumulative Irritant Patch Test Design [NCT04064125]	Phase 1	42 participants (Actual)	Interventional	2016-09-01	Completed
A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia [NCT00733057]	Phase 3	70 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, Double-blind Trial Evaluating the Effects of Treatment With DFD-29 Capsules 40 mg QD in Comparison to Placebo on Microbial Flora in Healthy Adult Human Subjects, When Administered Over a Period of 16 Weeks. [NCT05597462]	Phase 1	60 participants (Actual)	Interventional	2022-09-30	Completed
Efficacy of Locally Delivered Minocycline in Advanced Periodontitis. A Clinico-microbiological Study [NCT04076098]	Phase 4	40 participants (Actual)	Interventional	2018-06-25	Completed
A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris [NCT02815332]	Phase 2	225 participants (Actual)	Interventional	2016-08-31	Completed
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial [NCT05836740]	Phase 3	1,672 participants (Anticipated)	Interventional	2023-05-19	Recruiting
A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study F [NCT04104685]	Phase 2	446 participants (Actual)	Interventional	2019-09-18	Completed
Cognitive Effects of Minocycline in Humans [NCT02193269]	Phase 1	10 participants (Actual)	Interventional	2013-07-08	Completed
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics of Minocin® (Minocycline) for Injection in Healthy Adult Subjects [NCT02802631]	Phase 1	69 participants (Actual)	Interventional	2017-04-20	Completed
Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients [NCT02213575]	Phase 2	9 participants (Anticipated)	Interventional	2024-04-15	Not yet recruiting
Angiotensin and Neuroimmune Activation in Hypertension [NCT02133872]	Phase 4	35 participants (Anticipated)	Interventional	2014-10-31	Recruiting
The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study [NCT02060149]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2014-03-31	Not yet recruiting
An Open-label, Multiple Dose Study to Assess the Pharmacokinetic Profile of Minocycline From FMX-101 Foam (4%) in Male and Female Volunteers [NCT02250859]	Phase 1	12 participants (Actual)	Interventional	2014-09-30	Completed
An Open Label Study to Document the Treatment Effect of 1 and 2% BPX-01 Minocycline Topical Gel in Moderate to Severe Inflammatory Non-nodular Acne Vulgaris (Protocol Number BPX-01-C04) [NCT02946788]	Phase 2	20 participants (Actual)	Interventional	2017-03-13	Completed
Minocycline's Effects on Alcohol Responses in Humans [NCT02187211]	Phase 1	54 participants (Actual)	Interventional	2015-07-01	Completed
A Safety and Feasibility Study of Minocycline Therapy for Management of Adverse Radiation Effects After Brain Metastases Radiosurgery [NCT02201563]	Phase 1	1 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Very slow recruitment (only one patient was recruited))
Comparing the Efficacy of Metronidazole and Minocycline Gels for the Treatment of Diabetic Periodontitis Patients [NCT06027151]		380 participants (Actual)	Interventional	2022-10-06	Completed
Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots [NCT01976065]	Phase 1	125 participants (Actual)	Interventional	2014-09-30	Completed
A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States [NCT02569307]	Phase 2	326 participants (Actual)	Interventional	2015-10-31	Completed
Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial, A Double-Blind, Randomized, Placebo-controlled, Multi-center Study [NCT00930020]	Phase 4	139 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to interim analysis shows futility)
Effect of Oral Minocycline on Acute Stroke Outcome: A Randomized Open Label Prospective Study [NCT06107725]	Phase 2/Phase 3	1,120 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks [NCT00988026]	Phase 4	168 participants (Anticipated)	Interventional	2009-06-30	Recruiting
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive [NCT05644301]	Phase 3	240 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
Effect of Non-Surgical Periodontal Therapy With and Without Minocycline HCl Microspheres, 1 mg on Bacterial Load and Systemic Markers of Inflammation [NCT03762915]	Phase 4	64 participants (Actual)	Interventional	2019-05-20	Completed
A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Two Different Doses of a Topical Minocycline Foam Compared to Vehicle in the Treatment of Papulopustular Rosacea - Study FX2015-10 [NCT02601963]	Phase 2	233 participants (Actual)	Interventional	2015-09-30	Completed
A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression [NCT02719392]	Phase 4	40 participants (Anticipated)	Interventional	2017-08-09	Suspended(stopped due to Due to limited study staff and the COVID-19 pandemic, enrollment has been paused as staff hours for this project have been reduced and reallocated to other projects.)
A Randomised, Double Blind Pilot Study of Minocycline and Placebo Added to Treatment-as-Usual (TAU) in First-Episode Psychosis [NCT00916461]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2006-05-31	Completed
The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori [NCT06004401]		400 participants (Anticipated)	Interventional	2023-08-20	Not yet recruiting
A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection [NCT01064752]		7 participants (Actual)	Observational	2005-04-30	Completed
A Phase III, Multicenter, Randomized, Double Blind-Double Dummy Study, To Evaluate Efficacy And Safety Of Treatment With Azithromycin, Microspheres, Oral Powder For Suspension, 2 G, In One Administration A Week, For 8 Weeks, Compared With Treatment With M [NCT00392223]	Phase 3	118 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to See Detailed Description)
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer [NCT01048983]	Phase 1/Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to No accrual.)
The Efficacy of Prophylactic Administration of Minocycline in Reducing Chronic Intercostal Neuralgia Post-thoracotomy [NCT01314482]	Phase 2	116 participants (Anticipated)	Interventional	2010-11-30	Recruiting
A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX) [NCT02680379]	Phase 2	22 participants (Actual)	Interventional	2016-03-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended-Release Tablets on Spermatogenesis in Human Males [NCT00765336]	Phase 4	180 participants (Actual)	Interventional	2006-11-30	Completed
Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda [NCT00855062]	Phase 1/Phase 2	73 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended to terminate the study early due to futility on 11/6/2009.)
A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS) [NCT00666887]	Phase 3	142 participants (Actual)	Interventional	2009-01-31	Completed
The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients: an Open-label, One-arm Clinical Study [NCT05958069]		25 participants (Anticipated)	Interventional	2023-03-01	Enrolling by invitation
Long-term Safety Evaluation of Minocycline Resistance After Treatment With Minocycline HCl Microspheres, 1 mg in Subjects With Chronic Periodontitis [NCT00668746]	Phase 4	35 participants (Actual)	Interventional	2007-12-31	Completed
Single Dose Two-Way Crossover Fasted Bioequivalence Study of Minocycline 100 mg Capsules in Healthy Volunteers [NCT00776542]		28 participants (Actual)	Interventional	2002-10-31	Completed
A 4-Day, Randomized, Controlled Study to Evaluate the Phototoxicity Potential of FMX-101, 4% in Healthy Volunteers [NCT04070742]	Phase 1	32 participants (Actual)	Interventional	2016-08-17	Completed
Comparison of the Pharmacodynamic and Tolerability Profiles of Minocycline Versus Placebo in Autism Spectrum Disorder: a Double-blind, Placebo-controlled, Crossover, Proof-of-concept Study [NCT04031755]	Phase 1	53 participants (Actual)	Interventional	2019-04-19	Completed
Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS [NCT00409747]	Phase 4	11 participants (Actual)	Interventional	2006-11-30	Completed
Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis [NCT02618317]	Phase 4	75 participants (Actual)	Interventional	2013-07-31	Completed
A Phase 1/2,Open-Label Study to Evaluate the Safety and Efficacy of the International Brain Research Foundation (IBRF) Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Patients With Severe Disorders of Consciousness [NCT02696512]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2016-03-31	Recruiting
Intrapleural Minocycline After Manual Aspiration for the Prevention of Primary Spontaneous Pneumothorax. A Phase III Multicenter Prospective Randomized Controlled Trial [NCT00839553]		100 participants (Anticipated)	Interventional	2007-04-30	Recruiting
A Pilot Study to Assess Clinical Safety and Tolerance of Minocycline and Spinal Perfusion Pressure Augmentation in Acute Spinal Cord Injury [NCT00559494]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2004-06-30	Completed
A Pilot, Open-label, 8-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Minocycline for the Treatment of Bipolar Depression [NCT01403662]	Phase 3	29 participants (Actual)	Interventional	2011-07-31	Completed
An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS) [NCT02541500]	Phase 3	40 participants (Anticipated)	Interventional	2013-04-30	Recruiting
PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke [NCT02541032]	Phase 3	400 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis [NCT00662532]	Phase 3	44 participants (Actual)	Interventional	2008-04-30	Completed
A Randomised Controlled Trial Comparing the Effectiveness of Heparin Bonded or Antibiotic Impregnated Central Venous Catheters (CVCs) With Standard CVCs for the Prevention of Hospital Acquired Blood Stream Infection in Children [NCT01029717]	Phase 3	1,859 participants (Actual)	Interventional	2010-12-31	Completed
Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression: A Factorial Design Randomised Controlled Trial [NCT02703363]	Phase 3	265 participants (Actual)	Interventional	2016-08-31	Completed
Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone [NCT00579644]	Phase 3	91 participants (Actual)	Interventional	2001-03-28	Completed
Placebo-controlled, Randomized, Double-blind Study of Minocycline for Sporadic and Hereditary Cerebral Amyloid Angiopathy [NCT05680389]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-12-02	Recruiting
A Randomized, Single-Dose, Three-Way Crossover Comparative Bioavailability Study of DFD-29 (Minocycline Hydrochloride ER Capsules 40 mg) Versus SOLODYN® (Minocycline Hydrochloride ER Tablets 105 mg), Under Fasting and Fed Conditions in Healthy Adult Human [NCT05452785]	Phase 1	24 participants (Actual)	Interventional	2022-05-07	Completed
Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazor [NCT00145106]	Phase 4	189 participants	Interventional	2002-03-31	Completed
Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial [NCT02913118]	Phase 4	462 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Effects of Local Minocycline Adjunctive Application in Comparison to Instrumentation Alone, in Patients With Residual Pockets Under Supportive Periodontal Therapy: a Double-blinded Randomized Controlled Clinical Trial [NCT04036890]	Phase 4	68 participants (Actual)	Interventional	2016-06-03	Completed
The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [NCT00893724]		60 participants (Anticipated)	Interventional	2009-06-30	Active, not recruiting
Phase III Study of Additional Minocycline Pleurodesis After Video-Assisted Thoracoscopic Surgery for Primary Spontaneous Pneumothorax [NCT00154895]	Phase 3	200 participants	Interventional	2001-06-30	Recruiting
A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections [NCT01049438]		31 participants (Actual)	Interventional	2006-08-31	Completed
Intra-Arterial Administration of Neuroprotective Agents and Cold Saline at Time of Recanalization for Acute Ischemic Stroke Due to Large Vessel Occlusion [NCT05032781]	Phase 1	24 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer [NCT00473083]	Phase 2	150 participants (Actual)	Interventional	2009-01-31	Completed
Bioequivalence Study Between Two Medications for the Oral Administration of 100 mg of Minocycline in Oral Solids in Healthy Volunteers. [NCT01938508]	Phase 1	28 participants (Actual)	Interventional	2013-05-31	Completed
A Randomized Study to Compare the Acne Relapse Rate After a 3-mo Course of Oral Minocycline, to a 3-mo Course of Oral Minocycline in Combination With a Daily Dose of Topical Tretinoin 0.01% Followed by 3 mo of Topical Tretinoin Alone [NCT00240513]	Phase 4	38 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to Too much difficulty recruiting and retaining patients, PI decided to stop.)
Neuroinflammatory Mechanisms Linking Chronic Stress to Motivational Deficits [NCT06044090]	Phase 4	38 participants (Anticipated)	Interventional	2022-09-12	Recruiting
A Phase 1, Randomized, Open-Label Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Minocin (Minocylcine) for Injection [NCT03291158]	Phase 1	0 participants (Actual)	Interventional	2018-04-30	Withdrawn(stopped due to Sponsor Decision)
[NCT01600625]		46 participants (Actual)	Interventional	2011-11-30	Completed
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease [NCT05605366]	Phase 1	30 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema [NCT01120899]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2010-04-30	Completed
Minocycline Administration During Human Liver Transplantation [NCT02712775]	Phase 4	0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to Study logistics)
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion: a Randomized, Open-label, Proof of Concept Study [NCT05512910]	Phase 4	90 participants (Anticipated)	Interventional	2022-12-13	Recruiting
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma [NCT02770378]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2016-11-30	Completed
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. [NCT01173692]	Phase 2	47 participants (Actual)	Interventional	2010-07-22	Completed
A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA). [NCT00203112]	Phase 2	44 participants (Actual)	Interventional	2004-06-30	Completed
Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study [NCT00203697]	Phase 3	0 participants	Interventional		Active, not recruiting
Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) [NCT00630942]	Phase 1	16 participants (Actual)	Interventional	2003-02-28	Completed
An Investigation of the Effect of MMP-9 Inhibition With Minocycline on the Reconsolidation of Intrusive Trauma- or Cocaine-related Memories [NCT05902819]		180 participants (Anticipated)	Interventional	2023-05-10	Recruiting
Lipids of the Human Tear Film and Their Effect on Tear Stability [NCT00803452]	Phase 4	31 participants (Actual)	Interventional	2008-07-31	Completed
Effect of Minocycline on Neuropathic Pain [NCT01869907]	Phase 4	60 participants (Actual)	Interventional	2011-09-30	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Minocycline Hydrochloride 135 mg Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of OHM Laboratorie [NCT02312297]		28 participants (Actual)	Interventional	2008-09-30	Completed
A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia [NCT01493622]	Phase 4	78 participants (Actual)	Interventional	2010-06-30	Completed
CITI-100 EA - Intermediate-Size Expanded Access, Open-Label Study for Use of Mino-Lok Therapy (MLT) in Combination With Systemic Antibiotics in the Treatment of Central Line Associated Bloodstream Infection [NCT04513821]		0 participants	Expanded Access		Available
Open-Label Exploratory Investigation Of NPL-2003 In Adolescents With Obsessive Compulsive Disorder [NCT00515255]	Phase 2	6 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to Recruitment Goal of 20 Not Met)
Healing Rates After Single Versus Multiple Visits Endodontic Treatment of Necrotic Teeth With Apical Periodontitis: A Randomized Clinical Trial [NCT02947763]	Phase 1	44 participants (Actual)	Interventional	2016-11-30	Completed
Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma [NCT00536042]	Phase 2	14 participants (Actual)	Interventional	1997-10-31	Completed
Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA) [NCT01422148]	Phase 2	60 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
Minocycline as Adjunctive Treatment for Treatment Resistant Depression: a Double Blind, Placebo-controlled, Randomized Trial [NCT03947827]	Phase 3	100 participants (Anticipated)	Interventional	2020-02-01	Recruiting
Minocycline add-on Medication to Antipsychotics in the Treatment of Schizophrenia Patients: A Double- Blind Randomized Controlled Trial [NCT02907437]	Phase 3	40 participants (Anticipated)	Interventional	2015-01-31	Recruiting
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms [NCT02928965]	Phase 2	207 participants (Actual)	Interventional	2013-02-28	Completed
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail [NCT02928692]	Phase 3	750 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans [NCT03340350]	Phase 4	10 participants (Actual)	Interventional	2017-05-10	Completed
Comparison of Pleural Abrasion Plus Minocycline Pleurodesis Versus Apical Pleurectomy After Thoracoscopic Bullectomy for High Recurrent Risk Patients With Primary Spontaneous Pneumothorax: A Prospective Randomized Trial. [NCT00270751]	Phase 2/Phase 3	200 participants	Interventional	2005-04-30	Recruiting
[NCT00294502]	Phase 4	120 participants	Interventional	2003-09-30	Completed
Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans [NCT01058395]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2010-02-28	Completed
A Randomized, Placebo-Controlled Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy [NCT00401921]	Phase 2	0 participants (Actual)	Interventional	2006-10-31	Withdrawn(stopped due to PI moved to a new facility)
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22) [NCT03271021]	Phase 3	1,488 participants (Actual)	Interventional	2017-07-17	Completed
The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial [NCT04068207]	Phase 2	35 participants (Actual)	Interventional	2019-08-25	Completed
Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome [NCT01053156]		66 participants (Actual)	Interventional	2010-01-31	Completed
Minocycline and Aspirin in the Treatment of Bipolar Depression [NCT01429272]	Phase 3	99 participants (Actual)	Interventional	2011-09-30	Completed
A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remit [NCT01134627]	Phase 2	305 participants (Actual)	Interventional	2006-02-28	Terminated
Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma [NCT00456677]	Phase 2	20 participants (Actual)	Interventional	1996-06-30	Completed
Multi-Center Phase 3 Trial of Minocycline HCl 1 mg Microspheres for the Use in Subjects With Peri-Implantitis: Clinical and Microbiological Evaluations [NCT01517334]	Phase 3	208 participants (Actual)	Interventional	2012-05-31	Completed
Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis [NCT01539564]	Phase 3	215 participants (Actual)	Interventional	2012-04-30	Completed
Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions [NCT00378781]		0 participants (Actual)	Interventional		Withdrawn(stopped due to Study withdrawn.)
A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease [NCT00063193]	Phase 2	195 participants	Interventional	2003-05-31	Completed
Minocycline in Acute Cerebral Hemorrhage (MACH) Trial [NCT01805895]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2013-02-28	Completed
Minocycline Dosing and Safety in Huntington's Disease [NCT00029874]	Phase 1/Phase 2	63 participants	Interventional	2001-09-30	Completed
A Single Center, Open Label Study Assessing the Feasibility, Safety and Therapeutic Effect of Minocycline in Adult Patients With Diagnosis of Unipolar Depression. [NCT01574742]	Phase 1	30 participants (Anticipated)	Interventional	2012-06-30	Recruiting
[NCT00047723]	Phase 3	400 participants	Interventional	2003-01-31	Completed
A 9 Month,3-arm Multicenter Clinical Trial of Treatment With Periocline Gel (2.1% Minocycline HCl) for Adjunctive Use to Scaling and Root Planing (SRP) in Adults With Periodontal Disease. [NCT00529555]	Phase 3	602 participants (Actual)	Interventional	2006-01-31	Completed
Study of Minocycline Accelerated Intracerebral Hemorrhage Absorption (MACHA) [NCT05630534]	Phase 1	90 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
Efficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke [NCT05367362]	Phase 2	134 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
A Prospective, Multicenter, Randomized, Evaluator-Blinded, Study to Evaluate the Safety and Efficacy of AMZEEQ® Companion Treatment With Oral Isotretinoin Therapy in Patients With Moderate to Severe Acne Vulgaris [NCT04940767]	Phase 4	31 participants (Actual)	Interventional	2021-06-28	Completed
Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis [NCT04923113]		281 participants (Actual)	Interventional	2021-06-28	Completed
Add-on Pilot Trial of Minocycline in Fragile X Syndrome [NCT00858689]		20 participants (Actual)	Interventional	2007-10-31	Completed
[NCT00371332]	Phase 3	128 participants	Interventional	2004-01-31	Completed
Minocycline as a Neuroprotective Agent Against Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage [NCT04876638]	Phase 2	20 participants (Anticipated)	Interventional	2019-07-01	Active, not recruiting
Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline [NCT02695446]	Phase 4	12 participants (Actual)	Interventional	2016-03-31	Completed
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms [NCT00243893]	Phase 1	26 participants (Actual)	Interventional	2004-07-31	Completed
Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients [NCT01433055]		52 participants (Actual)	Interventional	2011-07-31	Completed
Phase 1 Trial in Newly Diagnosed High Grade Glioma With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide. (D-TERMINED) [NCT02272270]	Phase 1	25 participants (Actual)	Interventional	2014-10-27	Completed
Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax: A Randomized Trial [NCT00418392]	Phase 3	300 participants (Anticipated)	Interventional	2006-11-30	Recruiting
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury [NCT05826912]	Phase 2	672 participants (Anticipated)	Interventional	2024-03-29	Not yet recruiting
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivant [NCT06120140]	Phase 2	180 participants (Anticipated)	Interventional	2024-03-08	Not yet recruiting
Pilot Study of the Neuroprotective Effects of Hydrogen and Minocycline in Acute Ischemic Stroke [NCT03320018]	Phase 2/Phase 3	15 participants (Actual)	Interventional	2017-08-02	Completed
Bioequivalence Study Between Two Medications for Oral Administration of Minocycline in 100 mg Oral Solids in Healthy Volunteers [NCT01755611]	Phase 1	25 participants (Actual)	Interventional	2011-06-17	Completed
Randomized Double Blind Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting [NCT01765738]	Phase 2	0 participants (Actual)	Interventional	2013-02-28	Withdrawn(stopped due to Project never received funding.)
The Safety and Efficacy of Minocycline as an Anti-Proteinuric in Diabetic Nephropathy [NCT01779089]		30 participants (Actual)	Interventional	2009-02-28	Active, not recruiting
A Double-blind Randomized Placebo-controlled Trial of Adjuvant Therapy With Minocycline for Schizophrenia [NCT01809158]	Phase 4	150 participants (Actual)	Interventional	2013-04-30	Completed
An Exploratory, Blinded, Randomized, Placebo-controlled Study in Subjects With Depressive Disorder to Investigate the Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced (Partial) Symptoms Response [NCT01809340]	Phase 2	29 participants (Actual)	Interventional	2013-06-30	Terminated(stopped due to study team decision because of IP supply issue and necessary amendment to protocol)
[NCT01813240]	Phase 2/Phase 3	444 participants (Anticipated)	Interventional	2013-05-31	Not yet recruiting
Phase III Study of Minocycline in Acute Spinal Cord Injury [NCT01828203]	Phase 3	248 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis: Open-lable, Randomised, Proof of Concept Study [NCT06033846]	Phase 2	40 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Minocycline for Reduction of Symptom Burden After Surgery in Patients With Head and Neck Malignancy: A Randomized Study [NCT02055963]	Phase 2	30 participants (Actual)	Interventional	2014-05-06	Terminated(stopped due to Early termination due to the protocol lack of progress in improving accrual rate)
MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy [NCT01463384]	Phase 2	13 participants (Actual)	Interventional	2011-09-30	Completed
The Response of Periodontal Pathogens to the Respective or Combined Treatment of Scaling and Root Planning and Locally Delivered Minocycline in Patients With Chronic Periodontitis- a Short-term Randomized Clinical Trial [NCT02355977]	Phase 4	70 participants (Actual)	Interventional	2013-06-30	Completed
Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke [NCT00836355]		6 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Too few acute stroke patients available to meet enrollment requirements.)
Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients [NCT01647282]	Phase 4	60 participants (Actual)	Interventional	2012-10-01	Completed
Effect of Anti-inflammatory Treatments on the Symptoms, Cognition, and Functioning of Adolescents With Schizophrenia [NCT04020588]	Phase 4	90 participants (Anticipated)	Interventional	2019-02-25	Recruiting
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy as First-Line Regimen for Helicobacter Pylori Eradication [NCT04558502]	Phase 4	339 participants (Anticipated)	Interventional	2022-01-05	Not yet recruiting
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration [NCT02564978]	Phase 2	37 participants (Actual)	Interventional	2016-12-14	Active, not recruiting
Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Therapy of Carbapenem-Resistant Acinetobacter Baumannii Infection [NCT05586815]	Phase 4	94 participants (Anticipated)	Interventional	2023-01-10	Recruiting
Minocycline and Matrix Metalloproteinase Inhibition in Acute Intracerebral Hemorrhage: A Pilot Trial [NCT03040128]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-06-27	Completed
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions [NCT01468844]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2011-12-21	Completed
A Randomized, Placebo-controlled Trial of Minocycline Added to Serotonin Reuptake Inhibitors in Pediatric OCD: Examining the Effects on Clinical Symptoms and on Brain Glutamate Levels Using MRS Imaging [NCT01695291]	Phase 2	31 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in Patients With Recurrent gliOma (RAMBO) [NCT01580969]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2012-07-06	Completed
To Evaluate the Efficacy and Safety of Different Intense Pulsed Light Filters Combined With Oral Medication in the Treatment of Moderate to Severe Acne [NCT04433143]		60 participants (Anticipated)	Interventional	2020-05-15	Enrolling by invitation
Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections [NCT05575427]	Phase 4	112 participants (Anticipated)	Interventional	2022-11-24	Recruiting
Characterization of Neuroimmune Dysfunction in Alcohol Use Disorder [NCT04210713]	Phase 1	142 participants (Actual)	Interventional	2020-02-03	Completed
A Phase I, Open-Label, Single-Dose Trial To Determine The Safety And Pharmacokinetics Of Minocin (Minocycline) For Injection In Subjects With Renal Insufficiency [NCT02808052]	Phase 1	9 participants (Actual)	Interventional	2017-05-29	Terminated(stopped due to Sponsor decision due to change in strategy)
Minocycline to Improve Neurologic Outcome in Stroke (MINOS) [NCT00630396]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2008-05-31	Completed
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa [NCT02140164]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2014-05-31	Completed
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Head and Neck Cancer [NCT01219673]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to Low accrual.)
A Randomized Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer [NCT01746043]	Phase 2	22 participants (Actual)	Interventional	2013-02-28	Completed
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe) [NCT01349192]	Phase 2	47 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects)
Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment [NCT00361257]	Phase 2	107 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to This study was terminated early due to futility.)
Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery [NCT00556491]		40 participants (Actual)	Interventional	2007-12-31	Completed
Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy [NCT05487417]	Phase 4	180 participants (Anticipated)	Interventional	2022-11-01	Recruiting
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) [NCT03489629]	Phase 2	42 participants (Anticipated)	Interventional	2018-04-03	Recruiting
A Trial of Minocycline for Pain After Carpal Tunnel and Trigger Release [NCT02051296]	Phase 2	131 participants (Actual)	Interventional	2012-01-31	Completed
Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder [NCT02362529]	Early Phase 1	115 participants (Anticipated)	Interventional	2015-02-28	Completed
Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19 [NCT05077813]	Phase 2	250 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline [NCT04202263]	Phase 2	25 participants (Anticipated)	Interventional	2019-09-26	Recruiting
The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia: a Double-blind, Randomized, Crossover Pilot Study [NCT04594733]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2021-12-06	Completed
Open Treatment of Minocycline in Geriatric Depression [NCT01659320]		16 participants (Actual)	Interventional	2012-03-31	Completed
Kidney and Periodontal Disease Study [NCT01802216]		51 participants (Actual)	Interventional	2014-02-28	Completed
Locally Delivered Antibiotics for the Treatment of Periodontitis Topical Doxycycline Versus Minocycline Gels as an Adjunct to Mechanical Treatment [NCT04125706]		44 participants (Anticipated)	Interventional	2019-11-01	Not yet recruiting
Efficacy and Safety of the Treatment of Minocycline for Cystoid Macular Edema [NCT05474950]	Phase 1/Phase 2	5 participants (Anticipated)	Interventional	2019-01-01	Recruiting
The Efficacy of Minocycline in the Treatment of Angelman Syndrome [NCT01531582]		25 participants (Actual)	Interventional	2012-04-30	Completed
The Role of Neuroinflammation in Hypertension.Minocycline for Resistant Hypertension: a Randomized Double Blind Placebo-Controlled Trial [NCT04478500]	Phase 3	60 participants (Anticipated)	Interventional	2020-07-02	Recruiting
Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease [NCT05861258]	Phase 2	15 participants (Anticipated)	Interventional	2023-05-08	Recruiting
Phase II, Randomized, Placebo-Controlled Study of Minocycline for Reducing Symptom Burden in Patients With Colorectal Cancer [NCT01906008]	Phase 2	122 participants (Actual)	Interventional	2013-11-30	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Minocycline Hydrochloride 135 mg Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of OHM Laboratorie [NCT02312609]		18 participants (Actual)	Interventional	2008-09-30	Completed
A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden During Maintenance Therapy for Multiple Myeloma [NCT01793051]	Phase 2	88 participants (Actual)	Interventional	2013-03-22	Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 1% and 3% Topical MIinocycline Gel (HY01) in Patients With Papulopustular Rosacea [NCT03263273]	Phase 2	270 participants (Actual)	Interventional	2017-10-30	Completed
Effect of Minocycline on Delirium Incidence in Critically Ill Patients [NCT04219735]	Phase 2	160 participants (Actual)	Interventional	2020-01-30	Completed
Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections [NCT03378427]		35 participants (Actual)	Interventional	2018-08-28	Completed
A Randomized, Placebo- and Comparator-controlled, Double-blind, Multiple (Ascending) Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Subjects [NCT02515955]	Phase 1	76 participants (Actual)	Interventional	2015-08-31	Completed
The Effects of Minocycline on Opioid-induced Hyperalgesia in Opioid-Maintained Patients [NCT02359006]		27 participants (Actual)	Interventional	2015-03-12	Completed
Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis [NCT00355576]	Phase 2	86 participants (Actual)	Interventional	2006-07-31	Completed
Imaging Glia-mediated NeuroInflammation and Treatment Efficacy (the IGNITE Study) [NCT03106740]	Phase 2	145 participants (Anticipated)	Interventional	2017-10-10	Recruiting
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients [NCT01693523]	Phase 2	80 participants (Actual)	Interventional	2013-01-28	Completed
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer [NCT01636934]	Phase 2	51 participants (Actual)	Interventional	2012-07-31	Completed
A Pilot Study of Minocycline Augmentation to Clozapine in Individuals With Treatment Resistant Schizophrenia [NCT02124811]	Phase 4	10 participants (Actual)	Interventional	2015-02-28	Completed
Minocycline for Bipolar Disorder [NCT01514422]	Phase 4	20 participants (Actual)	Interventional	2011-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00277355 (2) [back to overview]	Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]
NCT00277355 (2) [back to overview]	Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]
NCT00361257 (24) [back to overview]	Change of HIV Plasma RiboNucleic Acid (RNA) Viral Load
NCT00361257 (24) [back to overview]	Change in Karnofsky Performance Score
NCT00361257 (24) [back to overview]	Change in Investigator's Clinical Global Impression Score (ICGIS)
NCT00361257 (24) [back to overview]	Changes in Medication Management Test (Modified)
NCT00361257 (24) [back to overview]	Changes in Markers of Oxidative Stress (Unit = Pixels/mm2 Only)
NCT00361257 (24) [back to overview]	Changes in Cluster of Differentiation 8 (CD8) Cell Counts (24 Weeks)
NCT00361257 (24) [back to overview]	Changes in Cluster of Differentiation 4 (CD4) Cell Counts (24 Weeks)
NCT00361257 (24) [back to overview]	Change in Verbal Memory Domain Z-Score
NCT00361257 (24) [back to overview]	Change in Psychomotor Function Domain Z-Score
NCT00361257 (24) [back to overview]	Number of Participants With Grade 2 or Higher Toxicity and/or Signs and Symptoms
NCT00361257 (24) [back to overview]	Changes in Alternate Frontal Systems Z-Score
NCT00361257 (24) [back to overview]	Changes in Neurotransmitter Levels (Unit = uM Only)
NCT00361257 (24) [back to overview]	Changes in Markers of Oxidative Stress and Immune Activation (Unit=pg/mL Only)
NCT00361257 (24) [back to overview]	Changes in Protein Markers of Oxidative Stress (Unit = Counts Per Second Only)
NCT00361257 (24) [back to overview]	Changes in Instrumental Activities of Daily Living Questionnaire
NCT00361257 (24) [back to overview]	Change in Information Processing Function Domain Z-Score
NCT00361257 (24) [back to overview]	Change in Cognitive Gross Motor Function Domain Z-Score
NCT00361257 (24) [back to overview]	Change in Cognitive Performance Compared to Baseline
NCT00361257 (24) [back to overview]	Change in Fine Motor Function Domain Z-Score
NCT00361257 (24) [back to overview]	Change in Fine Motor/Nonverbal Function Domain Z-Score
NCT00361257 (24) [back to overview]	Change in Frontal Systems Function Domain Z-Score
NCT00361257 (24) [back to overview]	Change in Global Deficit Z-Score (GDS)
NCT00361257 (24) [back to overview]	Changes in Alternate Verbal Memory Z-Score
NCT00361257 (24) [back to overview]	Changes in Alternate Psychomotor Function Z-Score
NCT00392223 (6) [back to overview]	Number of Subjects With Mild, Moderate, and Severe Acne
NCT00392223 (6) [back to overview]	Improvement of Global Acne Grading System (GAGS) Score
NCT00392223 (6) [back to overview]	Change From Baseline in Global Acne Grading System (GAGS) Score
NCT00392223 (6) [back to overview]	Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score
NCT00392223 (6) [back to overview]	Change From Baseline to End of Treatment (EOT) in Global Acne Grading System (GAGS) Score - Per Protocol Population
NCT00392223 (6) [back to overview]	Change From Baseline in Acne Graded by Leeds Technique
NCT00409747 (2) [back to overview]	z Score
NCT00409747 (2) [back to overview]	Clinical Global Impressions Scale-Severity (CGI). (Connors & Barkley, 1985)
NCT00473083 (7) [back to overview]	Severity of Rash Caused by Erlotinib
NCT00473083 (7) [back to overview]	Time Duration From Onset of Rash Until Resolution
NCT00473083 (7) [back to overview]	Duration of Treatment
NCT00473083 (7) [back to overview]	Overall Incidence of Grade 3 Rash
NCT00473083 (7) [back to overview]	Overall Incidence of Rash
NCT00473083 (7) [back to overview]	Overall Survival
NCT00473083 (7) [back to overview]	Time to First Presentation of Rash
NCT00529555 (1) [back to overview]	Change in Pocket Depth.
NCT00556491 (6) [back to overview]	On Vent >48 Hours
NCT00556491 (6) [back to overview]	Post Operative Hospital Days
NCT00556491 (6) [back to overview]	Re-operation
NCT00556491 (6) [back to overview]	Stroke Post Operative
NCT00556491 (6) [back to overview]	Development of Post-operative Acute Kidney Injury
NCT00556491 (6) [back to overview]	Infections Post Operative
NCT00630396 (3) [back to overview]	90 Day Modified Rankin Scale Score
NCT00630396 (3) [back to overview]	Maximally Tolerated Dose of IV Minocycline
NCT00630396 (3) [back to overview]	Half-life of IV Minocycline
NCT00662532 (3) [back to overview]	Initial PD Reduction
NCT00662532 (3) [back to overview]	Overall PD Reduction
NCT00662532 (3) [back to overview]	BOP Percent Reduction From Baseline
NCT00668746 (3) [back to overview]	Micocycline-Resistance From Saliva Sample
NCT00668746 (3) [back to overview]	Micocycline-Resistance From Plaque Samples
NCT00668746 (3) [back to overview]	Change in Percent of Minocycline-Resistant Bacteria Using Bacterial Culture
NCT00765336 (1) [back to overview]	Mean Percent Change From Screening in Sperm Concentration.
NCT00803452 (1) [back to overview]	Global Response to Therapy
NCT00855062 (10) [back to overview]	Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms.
NCT00855062 (10) [back to overview]	24-week Change of Instrumental Activities of Daily Living
NCT00855062 (10) [back to overview]	24-week Change of Uganda Neuropsychological Test Battery Summary Measure (U NP Sum)
NCT00855062 (10) [back to overview]	24-week Change of HIV RNA Plasma Viral Loads (Log10 Transformed)
NCT00855062 (10) [back to overview]	48-week Change of CD4 Cell Counts
NCT00855062 (10) [back to overview]	24-week Change of Karnofsky Performance Score
NCT00855062 (10) [back to overview]	24-week Change of Memorial Sloan Kettering (MSK) HIV Dementia Stage
NCT00855062 (10) [back to overview]	Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms
NCT00855062 (10) [back to overview]	24-week Change of Center for Epidemiologic Studies Depression (CES-D) Score
NCT00855062 (10) [back to overview]	24-week Change of CD4 Cell Counts
NCT00858689 (2) [back to overview]	Change From Baseline of ABC Irritability Subtest Score at 8 Weeks
NCT00858689 (2) [back to overview]	ABC Irritability Subtest Score
NCT01053156 (11) [back to overview]	VAS Categorized by Behavior:Language/ Cognition
NCT01053156 (11) [back to overview]	Vineland Adaptive Behavior Scale-II (VABS-II)Adaptive Behavior Composite Score
NCT01053156 (11) [back to overview]	Visual Analogue Scale Behavior 3- VAS3
NCT01053156 (11) [back to overview]	Visual Analogue Scale- Behaviors 2
NCT01053156 (11) [back to overview]	Visual Analogue Scale- Behavior 1
NCT01053156 (11) [back to overview]	Aberrant Behavior Checklist-Community Edition (ABC-C)Composite Score
NCT01053156 (11) [back to overview]	Clinical Global Impression Scale (CGI)
NCT01053156 (11) [back to overview]	Expressive Vocabulary Test-2
NCT01053156 (11) [back to overview]	VAS Categorized by Behavior: Aggression/ ADHD
NCT01053156 (11) [back to overview]	VAS Categorized by Behavior: Other
NCT01053156 (11) [back to overview]	VAS Categorized by Behavior:Anxiety/ Mood
NCT01058395 (3) [back to overview]	Disability Rating Scale
NCT01058395 (3) [back to overview]	Drug Levels
NCT01058395 (3) [back to overview]	Aspartate Aminotransferase (AST) Levels
NCT01120899 (17) [back to overview]	Change in BCVA in the Study Eye at 12 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Change in BCVA in the Study Eye at 18 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Change in BCVA in the Study Eye at 24 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Change in BCVA in the Study Eye at 6 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 12 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 18 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 24 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 6 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Study Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 12 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Study Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 24 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Study Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 6 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Percentage Change in Retinal Thickness in the Study Eye at 12 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Percentage Change in Retinal Thickness in the Study Eye at 18 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Percentage Change in Retinal Thickness in the Study Eye at 24 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 6 Months Compared to Baseline
NCT01120899 (17) [back to overview]	Number of Study Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 18 Months Compared to Baseline
NCT01134627 (9) [back to overview]	Changes in Brain Volume Measured on Magnetic Resonance Imaging (MRI)
NCT01134627 (9) [back to overview]	Number of New or Enlarging Lesions on Time Constant 2 (T2) Weighted Magnetic Resonance Imaging (MRI)
NCT01134627 (9) [back to overview]	Number of Relapse Free Participants Without Progression
NCT01134627 (9) [back to overview]	Number of Participants With Total Number of Reported Relapses (Documented and Undocumented Relapses)
NCT01134627 (9) [back to overview]	Number of Participants With Documented Relapses
NCT01134627 (9) [back to overview]	Burden of Disease
NCT01134627 (9) [back to overview]	Relapse Severity Based on Expanded Disability Status Scale (EDSS)
NCT01134627 (9) [back to overview]	Number of Participants Who Experienced First Documented Relapse
NCT01134627 (9) [back to overview]	Number of Participants With Onset of Disability Progression
NCT01173692 (1) [back to overview]	Combined AUC for Selected Patient Symptoms
NCT01317550 (1) [back to overview]	Primary Outcome Variable: Combined AUC of Selected Symptoms Fatigue, Pain, Disturbed Sleep, Lack of Appetite and Drowsiness
NCT01349192 (4) [back to overview]	Antibiotic Use (Days of Use Per Subject)
NCT01349192 (4) [back to overview]	Antibiotic Use (Proportion of Subjects)
NCT01349192 (4) [back to overview]	MRSA Culture Status
NCT01349192 (4) [back to overview]	Pulmonary Exacerbations
NCT01429272 (2) [back to overview]	Treatment Response
NCT01429272 (2) [back to overview]	Remission Rate
NCT01433055 (5) [back to overview]	Effect of Minocycline on Cognitive Symptoms as Measured by the MATRICS Consensus Cognitive Battery.
NCT01433055 (5) [back to overview]	The Effect of Adjunct Minocycline to Placebo on Global Clinical Improvement of Symptoms.
NCT01433055 (5) [back to overview]	The Effect of Adjunct Minocycline to Placebo to Improve Depressive Symptoms as Measured by the Calgary Depression Scale
NCT01433055 (5) [back to overview]	Brief Psychiatric Rating Scale (BPRS) Positive Symptom Domain Scores Between Minocycline and Placebo.
NCT01433055 (5) [back to overview]	The Effect of Minocycline Compared to Placebo to Improve Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS)
NCT01463384 (3) [back to overview]	Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).
NCT01463384 (3) [back to overview]	Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)
NCT01463384 (3) [back to overview]	Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
NCT01468831 (17) [back to overview]	Number of Participants Improving ≥ 1 logOCT Scale Step in the Study Eye at 24 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Number of Participants Experiencing Changes in Fluid Leakage in the Macula of the Study Eye as Demonstrated by Fluorescein Angiography at 12 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Number of Participants Experiencing Changes in Fluid Leakage in the Macula of the Study Eye as Demonstrated by Fluorescein Angiography at 24 Months Compared to Baseline.
NCT01468831 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 12 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 18 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 24 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 3 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 6 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 12 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 18 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 24 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 6 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline.
NCT01468831 (17) [back to overview]	Mean Change in the ETDRS BCVA in the Study Eye at 24 Months Compared to Baseline
NCT01468831 (17) [back to overview]	Number of Bevacizumab Injections From Baseline to 12 Months
NCT01468831 (17) [back to overview]	Number of Bevacizumab Injections From Baseline to 24 Months
NCT01468831 (17) [back to overview]	Number of Participants Improving ≥ 1 logOCT Scale Step in the Study Eye at 12 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 6 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 12 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 18 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 24 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 6 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Mean Change in the ETDRS BCVA in the Study Eye at 24 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Number of Bevacizumab Injections From Baseline to 12 Months
NCT01468844 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 24 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Number of Bevacizumab Injections From Baseline to 24 Months
NCT01468844 (17) [back to overview]	Number of Participants Improving ≥ 1 logOCT Scale Step in the Study Eye at 12 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Number of Participants Improving ≥ 1 logOCT Scale Step in the Study Eye at 24 Months Compared to Baseline
NCT01468844 (17) [back to overview]	The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline.
NCT01468844 (17) [back to overview]	Changes in Fluid Leakage in the Macula of the Study Eye as Demonstrated by Fluorescein Angiography at 12 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Fluid Leakage in the Macula of the Study Eye as Demonstrated by Fluorescein Angiography at 24 Months Compared to Baseline.
NCT01468844 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 18 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 12 Months Compared to Baseline
NCT01468844 (17) [back to overview]	Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 3 Months Compared to Baseline
NCT01514422 (3) [back to overview]	Change in N-acetylaspartate (NAA), as Measured by 1H-MRS Scan
NCT01514422 (3) [back to overview]	Changes in Young Mania Rating Scale (YMRS)
NCT01514422 (3) [back to overview]	Change in Scores on the Montgomery-Asberg Depression Rating Scale (MADRS)
NCT01531582 (5) [back to overview]	Vineland Adaptive Behavior Scale, 4th Edition (Vineland-II)Score at Baseline, 8 Weeks After Treatment, and at 16 Week Follow-up
NCT01531582 (5) [back to overview]	Clinical Global Impressions Severity Scale Score at Baseline, 8 Weeks After Treatment, and at 16 Week Follow-up
NCT01531582 (5) [back to overview]	Normalization of the EEG (Electroencephalogram) Signature
NCT01531582 (5) [back to overview]	Bayley Scales of Infant and Toddler Development, 2nd Edition (BSID-II) Score at Baseline, 8 Weeks After Treatment, and at 16 Week Follow-up
NCT01531582 (5) [back to overview]	Preschool Language Scale, Fourth Edition (PLS-4)Score at Baseline, 8 Weeks After Treatment, and at 16 Week Follow-up
NCT01580969 (8) [back to overview]	Cognitive Change Over Time - GMLT
NCT01580969 (8) [back to overview]	Cognitive Change Over Time - IDN
NCT01580969 (8) [back to overview]	Progression Free Survival (PFS) at 3 Months
NCT01580969 (8) [back to overview]	Cognitive Change Over Time - OCLT
NCT01580969 (8) [back to overview]	Number of Participants With Adverse Events
NCT01580969 (8) [back to overview]	Quality of Life Change Over Time
NCT01580969 (8) [back to overview]	Progression Free Survival (PFS) at 6 Months
NCT01580969 (8) [back to overview]	Cognitive Change Over Time - DET
NCT01636934 (1) [back to overview]	AUC Value Symptom Severity Differences
NCT01647282 (2) [back to overview]	Change in Interproximal Bone Height Loss, Probing Depth and Clinical Attachment Level Over 24 Months
NCT01647282 (2) [back to overview]	Inflammatory Biomarkers Found in Gingival Crevicular Fluid: IL-1.
NCT01659320 (1) [back to overview]	Montgomery Asberg Depression Rating Scale (MADRS)
NCT01693523 (1) [back to overview]	Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms
NCT01695291 (2) [back to overview]	Striatal Glutamate Level Measured by Magnetic Resonance Spectroscopy (MRS).
NCT01695291 (2) [back to overview]	Yale-Brown Obsessive Compulsive Scale, Child Version (CYBOCS)
NCT01746043 (1) [back to overview]	Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.
NCT01793051 (1) [back to overview]	Symptom Reduction
NCT01802216 (2) [back to overview]	Number of Participants Completing Study Protocol
NCT01802216 (2) [back to overview]	Change in Estimated Glomerular Filtration Rate
NCT01805895 (2) [back to overview]	Modified Rankin Scale
NCT01805895 (2) [back to overview]	Safety Assessment
NCT01906008 (2) [back to overview]	Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months
NCT01906008 (2) [back to overview]	Average Area Under the Curve (AUC) for Fatigue Over 4 Months
NCT02051296 (1) [back to overview]	Time to Pain Resolution
NCT02055963 (2) [back to overview]	Efficacy of Minocycline for Reducing Patient-Reported Symptoms
NCT02055963 (2) [back to overview]	Number of Participants Time-to-Symptom-Recovery
NCT02124811 (5) [back to overview]	Brief Assessment of Cognition in Schizophrenia (BACS) Score
NCT02124811 (5) [back to overview]	Positive Subscale Score of the Positive and Negative Syndrome Scale (PANSS)
NCT02124811 (5) [back to overview]	General Psychopathology Score of the Positive and Negative Syndrome Scale (PANSS)
NCT02124811 (5) [back to overview]	Negative Subscale Score of the Positive and Negative Syndrome Scale (PANSS)
NCT02124811 (5) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Score
NCT02140164 (10) [back to overview]	Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment Values.
NCT02140164 (10) [back to overview]	Number of Ocular Adverse Events
NCT02140164 (10) [back to overview]	Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 12 Months Compared to the Average of the Pre-treatment Values
NCT02140164 (10) [back to overview]	Change in Microperimetry at 12 Months as Compared to the Average of Pre-treatment Values
NCT02140164 (10) [back to overview]	Number of Study Eyes Achieving a 15-letter or More Worsening in Electronic Visual Acuity (EVA) at 12 Months as Compared to Baseline
NCT02140164 (10) [back to overview]	Number of Severe Adverse Events
NCT02140164 (10) [back to overview]	Number of Non-ocular Adverse Events
NCT02140164 (10) [back to overview]	Change in Visual Field as Measured by HVF 30-2 Visual Field Testing at 6 Months as Compared to the Average of Pre-treatment Values
NCT02140164 (10) [back to overview]	Change in Visual Field as Measured by HVF 30-2 Visual Field Testing at 12 Months as Compared to the Average of Pre-treatment Values
NCT02140164 (10) [back to overview]	Change in Microperimetry at 6 Months as Compared to the Average of Pre-treatment Values
NCT02297412 (3) [back to overview]	Area Under the Curve (AUC) Per Assessment (aAUCpa) of Fatigue (Item 10 on the Acute Pain Syndrome Summary Questionnaire)
NCT02297412 (3) [back to overview]	Area Under the Curve (AUC) Per Assessment (aAUCpa) of Average Pain (Item 3 on the Daily Post-Paclitaxel Questionnaire)
NCT02297412 (3) [back to overview]	Area Under the Curve (AUC) of EORTC CIPN20 Sensory Neuropathy Subscale
NCT02355977 (3) [back to overview]	Bleeding on Probing
NCT02355977 (3) [back to overview]	Pocket Depth
NCT02355977 (3) [back to overview]	Bacterial Load
NCT02359006 (18) [back to overview]	Sustained Attention to Response Test (SART): No-go Trials: Errors of Commission
NCT02359006 (18) [back to overview]	Tumor Necrosis Factor Alpha (TNF-α)
NCT02359006 (18) [back to overview]	Brief Pain Inventory - Short Form: Pain Severity
NCT02359006 (18) [back to overview]	Ecological Momentary Assessments (EMA) - Craving
NCT02359006 (18) [back to overview]	Ecological Momentary Assessments (EMA) - Pain
NCT02359006 (18) [back to overview]	Ecological Momentary Assessments (EMA): SOWS
NCT02359006 (18) [back to overview]	Brief Pain Inventory - Short Form: Interference
NCT02359006 (18) [back to overview]	Digit Symbol Substitution Test
NCT02359006 (18) [back to overview]	Interleukin-1 Beta (IL-1β)
NCT02359006 (18) [back to overview]	Interleukin-6 (IL-6)
NCT02359006 (18) [back to overview]	Opioid Withdrawal Symptom Checklist (OWSC): Back Pain Item
NCT02359006 (18) [back to overview]	Pain Threshold
NCT02359006 (18) [back to overview]	Pain Tolerance
NCT02359006 (18) [back to overview]	Profile of Mood States (POMS) - Total Mood Disturbance
NCT02359006 (18) [back to overview]	Profile of Mood States (POMS) Depression Subscale
NCT02359006 (18) [back to overview]	Short-Form McGill Pain Questionnaire (SF-MPQ): Affective Subscale
NCT02359006 (18) [back to overview]	Short-Form McGill Pain Questionnaire (SF-MPQ): Sensory Subscale
NCT02359006 (18) [back to overview]	Sustained Attention to Response Test (SART): Go Trials: Errors of Omission
NCT02695446 (2) [back to overview]	Plasma Minocycline Level
NCT02695446 (2) [back to overview]	Skin/Dermal Levels of Minocycline
NCT02765100 (1) [back to overview]	Change in Depression as Measured by the Hamilton Depression Scale Collected at Baseline and Week 8
NCT02802631 (13) [back to overview]	Assessment Of Percentage Of Drug Excreted In Urine After Multiple Intravenous Doses Of Minocin Using Serial Urine Samples On Day 11
NCT02802631 (13) [back to overview]	Assessment Of Apparent Terminal Elimination Half-life (T1/2) By Cohort For A Single Dose Of Minocin Using Plasma From Serial Blood Samples On Day 1
NCT02802631 (13) [back to overview]	Assessment Of AUC0-t By Cohort After Multiple Doses Of Minocin On Day 11
NCT02802631 (13) [back to overview]	Assessment Of Amount Of Drug Excreted In Urine After Multiple Intravenous Doses Of Minocin Using Serial Urine Samples On Day 11
NCT02802631 (13) [back to overview]	Assessment Of Maximum Plasma Concentration (Cmax) By Cohort For A Single Dose Of Minocin On Day 1
NCT02802631 (13) [back to overview]	Assessment Of Cmax By Cohort For Multiple Doses Of Minocin On Day 11
NCT02802631 (13) [back to overview]	Assessment of Cmax by Cohort for a Single Dose of Minocin on Day 4
NCT02802631 (13) [back to overview]	Assessment Of Amount Of Drug Excreted In Urine After A Single Dose Of Minocin Using Serial Urine Samples On Day 1
NCT02802631 (13) [back to overview]	Assessment Of Percent of Dose Excreted In Urine After A Single Dose Of Minocin Using Serial Urine Samples On Day 1
NCT02802631 (13) [back to overview]	Assessment Of AUC0-t By Cohort After A Single Dose Of Minocin On Day 4
NCT02802631 (13) [back to overview]	Assessment of Area Under The Concentration-time Curve From Zero Hours To The Last Measured Concentration (AUC0-t) After A Single Dose Of Minocin On Day 1
NCT02802631 (13) [back to overview]	Number Of Participants Experiencing Treatment-emergent Adverse Events
NCT02802631 (13) [back to overview]	Assessment Of T1/2 By Cohort After Multiple Doses Of Minocin Using Plasma From Serial Blood Samples On Day 11
NCT02808052 (1) [back to overview]	Safety and Tolerability of Intravenous Dose(s) of Minocin (Minocycline) for Injection Assessed by Number of Subjects With Adverse Events
NCT02815267 (6) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and and Treatment-emergent Serious Adverse Events (TESAEs)
NCT02815267 (6) [back to overview]	Percentage of Participants Achieving IGA Treatment Success at Week 6 and Week 9
NCT02815267 (6) [back to overview]	Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12
NCT02815267 (6) [back to overview]	Percent Change From Baseline in the Non-inflammatory Lesion Count at Week 12
NCT02815267 (6) [back to overview]	Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12
NCT02815267 (6) [back to overview]	Absolute Change From Baseline in the Inflammatory Lesion Count at Week 6 and Week 9
NCT02815280 (6) [back to overview]	Percentage of Participants Achieving IGA Treatment Success at Week 6 and Week 9
NCT02815280 (6) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
NCT02815280 (6) [back to overview]	Absolute Change From Baseline in the Inflammatory Lesion Count at Week 6 and Week 9
NCT02815280 (6) [back to overview]	Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 12
NCT02815280 (6) [back to overview]	Percent Change From Baseline in the Non-inflammatory Lesion Count at Week 12
NCT02815280 (6) [back to overview]	Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12
NCT02946788 (1) [back to overview]	Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT02968602 (1) [back to overview]	Questionnaire for Smoking Urges-Brief
NCT02998151 (5) [back to overview]	Test of Attentional Performance for Children (KiTAP) Test of Alertness
NCT02998151 (5) [back to overview]	Clinical Global Impressions-Improvement
NCT02998151 (5) [back to overview]	Change in EEG Relative Gamma Power
NCT02998151 (5) [back to overview]	Change From Pre-dose in the Repeatable Battery for the Assessment of Neuropsychological Status at 4 Hours Post Dose
NCT02998151 (5) [back to overview]	Woodcock Johnson Test of Cognitive Abilities - Auditory Attention Task
NCT03142451 (7) [back to overview]	The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12
NCT03142451 (7) [back to overview]	The Percent Change From Day 0/Baseline in Inflammatory Lesion Count at Week 12
NCT03142451 (7) [back to overview]	Percentage of Participants Achieving IGA Treatment Success at Week 4 and Week 8
NCT03142451 (7) [back to overview]	The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Counts at Week 4 and Week 8
NCT03142451 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03142451 (7) [back to overview]	Percentage of Participants Achieving IGA Treatment Success of at Least 2 Grades at Week 12
NCT03142451 (7) [back to overview]	Percentage of Participants Achieving Investigator Global Assessments (IGA) Treatment Success at Week 12
NCT03271021 (7) [back to overview]	Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline
NCT03271021 (7) [back to overview]	IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9
NCT03271021 (7) [back to overview]	IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 6
NCT03271021 (7) [back to overview]	The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 9
NCT03271021 (7) [back to overview]	The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12.
NCT03271021 (7) [back to overview]	The Absolute Change From Baseline in the Inflammatory Lesion Count at the Interim Visit at Week 6
NCT03271021 (7) [back to overview]	The Absolute Change From Baseline in the Non-inflammatory Lesion Count at Week 12
NCT03320018 (3) [back to overview]	Number of Participants With Favorable Outcome on the Simplified Modified Rankin Scale (sMRSq)
NCT03320018 (3) [back to overview]	NIH Stroke Scale (NIHSS)
NCT03320018 (3) [back to overview]	Simplified Modified Rankin Scale (sMRSq)
NCT03340350 (9) [back to overview]	PTSD Symptom Severity
NCT03340350 (9) [back to overview]	Executive Functioning (Verbal Fluency)
NCT03340350 (9) [back to overview]	Executive Functioning (Set Shifting)
NCT03340350 (9) [back to overview]	Depression Symptom Severity
NCT03340350 (9) [back to overview]	Clinical Status (Severity)
NCT03340350 (9) [back to overview]	Clinical Status (Improvement)
NCT03340350 (9) [back to overview]	Change in C-reactive Protein (CRP) Level
NCT03340350 (9) [back to overview]	Change in Interleukin 6 (IL-6) Level
NCT03340350 (9) [back to overview]	Change in Tumor Necrosis Factor Alpha (TNF-α) Level
NCT03369951 (15) [back to overview]	Population Mean PK Parameter Estimates for Distribution Clearance (CLd)
NCT03369951 (15) [back to overview]	Calculated Exposure Measures for Area Under the Curve 0 to 24 Hours After a Dose (AUC0-24)
NCT03369951 (15) [back to overview]	Calculated Exposure Measures for Area Under the Curve From 0 to Infinity (AUC0-inf) Using Free-drug Concentrations
NCT03369951 (15) [back to overview]	Calculated Exposure Measures for Area Under the Curve From 0 to Infinity (AUC0-inf) Using Total-drug Concentrations
NCT03369951 (15) [back to overview]	Calculated Exposure Measures for Area Under the Curve to the Last Quantifiable Sample (AUC0-last)
NCT03369951 (15) [back to overview]	Population Mean PK Parameter Estimates for Peripheral Volume of Distribution (Vp)
NCT03369951 (15) [back to overview]	Calculated Exposure Measures for Maximum Plasma Concentration (Cmax)
NCT03369951 (15) [back to overview]	Population Mean PK Parameter Estimates for Free-drug Clearance (CL)
NCT03369951 (15) [back to overview]	Magnitude of the Inter-individual Variability for Central Volume of Distribution (Vc)
NCT03369951 (15) [back to overview]	Population Mean PK Parameter Estimates for Central Volume of Distribution (Vc)
NCT03369951 (15) [back to overview]	Population Mean PK Parameter Estimates for Total-drug Clearance (CL)
NCT03369951 (15) [back to overview]	Calculated Exposure Measures for Plasma Concentration at 24 Hours After Dose (C24)
NCT03369951 (15) [back to overview]	Magnitude of the Inter-individual Variability for Total-drug Clearance (CL)
NCT03369951 (15) [back to overview]	Magnitude of the Inter-individual Variability for Distribution Clearance (CLd)
NCT03369951 (15) [back to overview]	Magnitude of the Inter-individual Variability for Peripheral Volume of Distribution (Vp)
NCT03743038 (10) [back to overview]	Absolute Change From Baseline to Week 6 in Non-Inflammatory Lesion Count
NCT03743038 (10) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
NCT03743038 (10) [back to overview]	Number of Participants With 0 to 4 Investigator's Global Assessment Score at Week 6
NCT03743038 (10) [back to overview]	Change in Transepidermal Water Loss Relative to Baseline Versus Weeks 2, 4, 6 and 7
NCT03743038 (10) [back to overview]	Change in Sebum Percentage Relative to Baseline Versus Weeks 2, 4, 6 and 7
NCT03743038 (10) [back to overview]	Percentage Change From Baseline to Week 6 in Non-Inflammatory Lesion Count
NCT03743038 (10) [back to overview]	Absolute Change From Baseline to Week 6 in Inflammatory Lesion Count
NCT03743038 (10) [back to overview]	Number of Participants Having Local Skin Reactions With Improved/Same Versus Worsened Severities Compared to Baseline
NCT03743038 (10) [back to overview]	Number of Participants Achieving Investigator's Global Assessments Treatment Success at Week 6
NCT03743038 (10) [back to overview]	Percentage Change From Baseline to Week 6 in Inflammatory Lesion Count
NCT04608500 (7) [back to overview]	Percentage of Participants Achieving IGA Treatment Success of at Least 2 Grades at Week 12
NCT04608500 (7) [back to overview]	Percentage of Participants Achieving Investigator Global Assessments (IGA) Treatment Success at Week 12
NCT04608500 (7) [back to overview]	The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Counts at Week 4 and Week 8
NCT04608500 (7) [back to overview]	Percentage of Participants Achieving IGA Treatment Success at Week 4 and Week 8
NCT04608500 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT04608500 (7) [back to overview]	The Percent Change From Day 0/Baseline in Inflammatory Lesion Count at Week 12
NCT04608500 (7) [back to overview]	The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12

Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]

Establish preliminary estimate of minocycline's impact on progression of HD (measured by the change in Total Functional Capacity (TFC) score of Unified Huntington's Disease Rating Scale [UHDRS] between baseline & Month 18), and to assess futility of further study of minocycline. TFC consists of five ordinally scaled items assessing a person's capacity with: 1. occupation 2. financial affairs 3. domestic responsibilities 4. activities of daily living and 5. independent living. Total score ranges from zero (worst) to 13 (best). (NCT00277355)
Timeframe: Baseline to 18 months

Intervention	units on a scale (Mean)
Minocycline 100 mg Twice Daily	1.55
Matching Placebo Twice Daily	1.15

Intervention	units on a scale (Mean)
Minocycline 100 mg Twice Daily	1.71
Matching Placebo Twice Daily	1.15

Intervention	participants (Number)
	>= 30 copies/mL at base, >= 30 at week 24	>= 30 copies/mL at base, < 30 at week 24	< 30 copies/mL at base, >= 30 at week 24	< 30 copies/mL at base, < 30 at week 24
Matching Placebo	0	2	0	19
Minocycline	1	0	2	17

Intervention	participants (Number)
	Worsened	No Change	Improved
Matching Placebo	2	31	12
Minocycline	4	28	9

Intervention	participants with an event (Number)
	0 - 4 weeks	4.01 - 12 weeks	12.01 - 24 weeks	24.01 - 48 weeks
Matching Placebo	32	3	1	2
Minocycline	29	5	2	1

Intervention	uM (Median)
	Glutamate (uM)	Tryptophan (uM)	Anthranilic Acid (uM)	Quinolinic Acid (uM)	Kynurenin (uM)	3-Hydroxykynurenine (uM)
Arm 1: Minocycline	5.09	-0.21	0.0	-0.55	6.85	-4.09
Arm 2: Matching Placebo	-1.08	0.07	0.0	0.0	6.97	-0.83

Intervention	pg/mL (Median)
	Protein carbonyls (pg/ml)	TNF-α (pg/mL)	IL-6 (pg/mL)	CXCL8 (pg/mL)	Hepatocyte growth factor (pg/mL)	Osteopontin (pg/mL)	sFAS (pg/mL)	sFAS ligand (pg/mL)	CXCL12 (pg/mL)
Arm 1: Minocycline	4.0	0.04	-0.29	0.34	16.09	-5208.94	0.68	-0.27	204.39
Arm 2: Matching Placebo	13.2	0.14	0.95	-6.13	90.48	673.55	134.1	0.11	1,071.84

Intervention	counts per second (Median)
	Ceramides (counts per second)	Monohexosylceramides (counts per second)	Dihydro Glycosyl Galceramides (counts per second)	Dihexosylceramides (counts per second)
Arm 1: Minocycline	0.0007	0.0013	0.0201	0.0005
Arm 2: Matching Placebo	-0.0051	-0.0066	-0.0048	-0.0043

Intervention	participants (Number)
	Baseline Mild acne	Baseline Moderate acne	Baseline Severe acne	Baseline Very severe acne	Baseline Missing	Week 8 EOT (LOCF) Mild acne	Week 8 EOT (LOCF) Moderate acne	Week 8 EOT (LOCF) Severe acne	Week 8 EOT (LOCF) Very severe acne	Week 8 EOT (LOCF) Missing
Azithromycin	0	49	3	1	0	31	19	1	0	2
Minocycline	1	52	5	1	0	41	16	0	1	1

Intervention	participants (Number)
	Week 4 Best Improvement	Week 4 Good Improvement	Week 4 Moderate Improvement	Week 4 Light Improvement	Week 4 No Change	Week 4 Worsening	Week 4 Missing	Week 8 EOT Best Improvement	Week 8 EOT Good Improvement	Week 8 EOT Moderate Improvement	Week 8 EOT Light Improvement	Week 8 EOT No Change	Week 8 EOT Worsening	Week 8 EOT Missing	Week 8 EOT LOCF Best Improvement	Week 8 EOT LOCF Good Improvement	Week 8 EOT LOCF Moderate Improvement	Week 8 EOT LOCF Light Improvement	Week 8 EOT LOCF No Change	Week 8 EOT LOCF Worsening	Week 8 EOT LOCF Missing	8 weeks after EOT Best Improvement	8 weeks after EOT Good Improvement	8 weeks after EOT Moderate Improvement	8 weeks after EOT Light Improvement	8 weeks after EOT No Change	8 weeks after EOT Worsening	8 weeks after EOT Missing
Azithromycin	1	4	19	23	2	1	3	4	11	21	11	2	3	1	4	11	21	11	3	3	0	7	15	13	6	3	5	4
Minocycline	1	2	25	24	2	2	3	3	16	20	15	2	0	3	3	16	20	17	2	1	0	6	17	18	8	0	0	10

Intervention	score on scale (Mean)
	Week 4 (n=50,56)	Week 8 EOT (End of Treatment) (n=52,56)	Week 8 EOT (LOCF) (n=53,59)	8 weeks after EOT (n=49,49)
Azithromycin	-7.0	-9.7	-9.5	-11.1
Minocycline	-6.5	-10.2	-9.8	-12.9

Intervention	score on scale (Mean)
	Face Week 4 (n=50, 56)	Face Week 8 EOT (n=52, 56)	Face Week 8 EOT (LOCF) (n=53,59)	Face 8 weeks after EOT (n=49,49)	Back Week 4 (n=50,56)	Back Week 8 EOT (n=52,56)	Back Week 8 EOT (LOCF) (n=53,59)	Back 8 weeks after EOT (n=49,49)	Chest Week 4 (n=50,56)	Chest Week 8 EOT (n=52,56)	Chest Week 8 EOT (LOCF) (n=53,59)	Chest 8 weeks after EOT (n=49,49)
Azithromycin	-1.5	-2.5	-2.5	-3.0	-1.1	-1.5	-1.5	-1.5	-0.8	-1.5	-1.5	-1.5
Minocycline	-1.3	-2.4	-2.3	-2.9	-0.9	-1.4	-1.4	-2.0	-0.7	-1.2	-1.1	-1.8

Intervention	Z-score (Number)
	TNFalpha	IL-6	CCL2(MCP-1)	CCL3(MIP-1alpha)	CCL5(Rantes)	CXCL8(IL-8)	BDNF	CD40L	GDNF	HGF	Leptin
Minocycline	-0.45	-0.36	-1.78	-0.18	-0.73	-0.45	-2.03	-0.89	-0.37	-2.19	-1.48

Intervention	percentage of participants (Number)
	Maximal Rash Grade 1	Maximal Rash Grade 2a	Maximal Rash Grade 2b	Maximal Rash Grade 3
Arm 1: Prophylactic Treatment	40.5	26.2	19.0	14.3
Arm 2: Reactive Treatment	47.6	33.3	9.5	9.5
Arm 3: No Treatment Unless Severe (Grade 3)	46.3	14.6	4.9	34.1

Intervention	days (Median)
	Patients With Max Severity of Rash Gr 1, 2a and 2b	Patients With Maximum Severity of Rash Grade 3
Arm 1: Prophylactic Treatment	133.0	201.0
Arm 2: Reactive Treatment	92.0	76.0
Arm 3: No Treatment Unless Severe (Grade 3)	98.0	54.0

Intervention	days (Mean)
Arm 1: Prophylactic Treatment	17.4
Arm 2: Reactive Treatment	13.3
Arm 3: No Treatment Unless Severe (Grade 3)	12.0

Intervention	mm (Least Squares Mean)
Scaling and Root Planing + SHAM TX	-1.4
Scaling and Root Planing + Periocline Gel	-1.6
Scaling and Root Planing + Vehicle	-1.4

Intervention	Participants (Number)
	90 day mRS score of 0 overall	90 day mRS score of 1 overall	90 day mRS score of 2 overall	90 day mRS score of 3 overall	90 day mRS score of 4 overall	90 day mRS score of 5 overall	90 day mRS score of 6 overall
Minocycline	15	15	9	11	2	3	5

Intervention	Percentage of Participants (Least Squares Mean)
	Day 90	Day 180
Minocycline HCl	42.17	60.75
No Intervention	22.53	32.86

Intervention	Percentage of Subjects (Number)
	A.naeslundii	S.constellatus	E.nodatum	P.gingivalis	A.actinomucetemcomitans	F.nucleatum vincentii	C.rectus	R.dentocariosa	E.saburreum	P.micra	V.parvula	A.oris	S.anginosus	S.anguinis	A.gerencseriae	S.oralis	C.ochraccea	A.israelli	S.intermedius	C.matruchotti	P.nigrescens	A.odontolyticus	F.nucleatum polymorphum	C.showae	F.periodonticum	N.mucosa	F.nucleatum	C.ginigivaluis	S.gordonii	T.forsythia	S.noxia	P.acnes	P.melaninogenica	S.mitis	E.corrodens	G.morbillorum	C.sputigena	L.bucallis	C.gracilis	P.intermedia
Control Group at Baseline	9.09	72.73	9.09	27.27	27.27	9.09	18.18	9.09	27.27	18.18	81.82	27.27	27.27	72.73	9.09	63.64	9.09	9.09	63.64	9.09	0.00	45.45	9.09	36.36	9.09	36.36	0.00	18.18	72.73	0.00	54.55	9.09	18.18	81.82	72.73	27.27	9.09	18.18	0.00	18.18
Control Group at Day 180	0.00	63.64	9.09	18.18	27.27	18.18	0.00	9.09	72.73	18.18	90.91	9.09	45.45	100.00	9.09	90.91	0.00	0.00	90.91	36.36	0.00	36.36	27.27	9.09	0.00	72.73	9.09	9.09	72.73	0.00	72.73	27.27	0.00	100.00	45.45	100.00	0.00	27.27	0.00	54.55
Control Group at Day 30	9.09	63.64	0.00	18.18	0.00	0.00	0.00	0.00	0.00	0.00	81.82	18.18	9.09	72.73	0.00	90.91	0.00	0.00	45.45	9.09	0.00	0.00	9.09	0.00	0.00	27.27	0.00	0.00	45.45	0.00	54.55	0.00	18.18	90.91	81.82	0.00	0.00	9.09	0.00	27.27
Minocycline Group at Baseline	4.76	47.62	4.76	23.81	19.05	9.52	9.52	4.76	19.05	14.29	61.90	14.29	14.29	61.90	4.76	66.67	0.00	0.00	42.86	9.52	9.52	23.81	19.05	19.05	4.76	47.62	0.00	23.81	71.43	0.00	52.38	9.52	0.00	61.90	57.14	38.10	9.52	33.33	0.00	23.81
Minocycline Group at Day 180	19.05	80.95	14.29	9.52	14.29	19.05	14.29	14.29	61.90	23.81	80.95	14.29	42.86	100.00	9.52	100.00	4.76	0.00	80.95	23.81	0.00	28.57	14.29	4.76	4.76	76.19	9.52	19.05	66.67	0.00	57.14	19.05	19.05	90.48	57.14	76.19	0.00	38.10	4.76	33.33
Minocycline Group at Day 30	0.00	42.86	0.00	19.05	9.52	0.00	9.52	0.00	14.29	9.52	90.48	14.29	14.29	85.71	14.29	71.43	0.00	0.00	38.10	9.52	4.76	19.05	19.05	9.52	4.76	28.57	0.00	9.52	85.71	0.00	52.38	9.52	0.00	71.43	47.62	14.29	4.76	23.81	0.00	19.05

Intervention	Percentage Change (Mean)
	Plaque Sample at Day 30	Saliva Sample at Day 30	Plaque Sample at Day 180	Saliva Sample at Day 180
Minocycline HCl Microspheres	13.15	37.65	8.09	12.06
No Drug Intervention	0.81	-2.25	1.58	-0.51

minocycline

Description

Cross-References

Synonyms (117)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Pathways (1)

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (87)

Molecular Functions (52)

Ceullar Components (22)

Bioassays (822)

Research

Studies (6,266)

Study Types

Clinical Trials (240)

Trial Overview

Trial Outcomes

Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]

Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]

Change of HIV Plasma RiboNucleic Acid (RNA) Viral Load

Change in Karnofsky Performance Score

Change in Investigator's Clinical Global Impression Score (ICGIS)

Changes in Medication Management Test (Modified)

Changes in Markers of Oxidative Stress (Unit = Pixels/mm2 Only)

Changes in Cluster of Differentiation 8 (CD8) Cell Counts (24 Weeks)

Changes in Cluster of Differentiation 4 (CD4) Cell Counts (24 Weeks)

Change in Verbal Memory Domain Z-Score

Change in Psychomotor Function Domain Z-Score

Number of Participants With Grade 2 or Higher Toxicity and/or Signs and Symptoms

Changes in Alternate Frontal Systems Z-Score

Changes in Neurotransmitter Levels (Unit = uM Only)

Changes in Markers of Oxidative Stress and Immune Activation (Unit=pg/mL Only)

Changes in Protein Markers of Oxidative Stress (Unit = Counts Per Second Only)

Changes in Instrumental Activities of Daily Living Questionnaire

Change in Information Processing Function Domain Z-Score

Change in Cognitive Gross Motor Function Domain Z-Score

Change in Cognitive Performance Compared to Baseline

Change in Fine Motor Function Domain Z-Score

Change in Fine Motor/Nonverbal Function Domain Z-Score

Change in Frontal Systems Function Domain Z-Score

Change in Global Deficit Z-Score (GDS)

Changes in Alternate Verbal Memory Z-Score

Changes in Alternate Psychomotor Function Z-Score

Number of Subjects With Mild, Moderate, and Severe Acne

Improvement of Global Acne Grading System (GAGS) Score

Change From Baseline in Global Acne Grading System (GAGS) Score

Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score

Change From Baseline to End of Treatment (EOT) in Global Acne Grading System (GAGS) Score - Per Protocol Population

Change From Baseline in Acne Graded by Leeds Technique

z Score

Clinical Global Impressions Scale-Severity (CGI). (Connors & Barkley, 1985)

Severity of Rash Caused by Erlotinib

Time Duration From Onset of Rash Until Resolution

Duration of Treatment

Overall Incidence of Grade 3 Rash

Overall Incidence of Rash

Overall Survival

Time to First Presentation of Rash

Change in Pocket Depth.

On Vent >48 Hours

Post Operative Hospital Days

Re-operation

Stroke Post Operative

Development of Post-operative Acute Kidney Injury

Infections Post Operative

90 Day Modified Rankin Scale Score

Maximally Tolerated Dose of IV Minocycline

Half-life of IV Minocycline

Initial PD Reduction

Overall PD Reduction

BOP Percent Reduction From Baseline

Micocycline-Resistance From Saliva Sample

Intervention	participants with an event (Number)
	0-4 weeks	4.01 - 12 weeks	12.01 - 24 weeks
Minocycline	12	6	3
Placebo	10	7	3

Intervention	participants with an event (Number)
	0-4 weeks	4.01-12 weeks	12.01-24 weeks	24.01-48 weeks
Minocycline	12	6	3	1
Placebo	10	7	3	1

Intervention	units on a scale (Mean)
	DRS at 4 weeks	DRS at 3 months
800 mg Loading Then 200 mg Q12	12.5	8.5
800 mg Loading Then 400 mg Q12	9.7	6.0

Intervention	U/L (Mean)
800 mg Loading Then 200 mg Q12	88.0
800 mg Loading Then 400 mg Q12	264

Intervention	participants (Number)
	Relapse free participants (documented relapse)	Relapse free participants (overall relapse)
Rebif® + Placebo	108	89
Rebif®+ Minocycline	105	96

Intervention	square millimeter (mm^2) (Mean)
	Total area of lesions on T1 weighted MRI	Total area of lesions on T2 weighted MRI
Rebif® + Placebo	1716.8	5717.3
Rebif®+ Minocycline	1599.4	4813.9

Intervention	Units on a scale week (Mean)
	Average AUC	Fatigue	Pain	Disturbed Sleep	Lack of appetite	Drowsiness
Armodafinil	157.4	259.3	145.8	109.2	133.3	139.3
Armodafinil+Minocycline	255.9	372	185.3	213.2	298.3	210.7
Matching Placebo	200.8	279.8	190	224.7	189	120.3
Minocycline	81.1	127.2	114.5	80	27.7	59.2

Intervention	Percentage of Participants (Number)
Placebo & Placebo	21
Minocycline & Aspirin	44
Placebo + Minocycline	25
Placebo + Aspirin	50

Intervention	units on a scale (Mean)
	Baseline	10 Weeks (Endpoint)
Minocycline	30.4	35.6
Sugar Pill	35.1	34.2

Intervention	cm^3 (Mean)
	Baseline Values	Averaged Values for Months 1-3	Averaged Values for Months 4-6
Minocycline AD	5.49	5.42	4.94
Minocycline MCI	6.35	6.30	7.60
Minocycline NC	6.98	6.92	6.82